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Abstract
Schizophrenia is a debilitating disease that affects about 1% of the population. Current
therapeutic interventions mostly target dopaminergic neurotransmission but are not effective
in treating all symptoms. There is growing evidence to support involvement of glutamatergic
neurotransmission, which may better account for the symptomatology of schizophrenia.
Glutamate concentrations can be measured in vivo using magnetic resonance spectroscopy
(MRS). Stronger magnetic field strengths provide benefits for MRS, but they also present
challenges. Simulations were designed to examine how MRI field strength influences
metabolite quantification. Glutamate and its metabolic precursor, glutamine, were more
reliably and independently quantified with higher MRI field strengths, showing a clear
benefit for MRS.
Using a 7 T MRI, voxels were placed within the dorsal anterior cingulate cortex (dACC) and
thalamus of volunteers with schizophrenia, a psychiatric control group of volunteers with
major depressive disorder (MDD), and healthy controls. Glutamine and glycine, both
involved in glutamate neurotransmission, were lower in the thalamus in schizophrenia
relative to healthy controls, whereas dACC glutamate concentrations were higher,
demonstrating glutamatergic abnormalities in schizophrenia at rest.
Prior MRS studies of schizophrenia have been in resting conditions. In a proof of concept
study with healthy controls, it was shown that the Stroop Task was able elicit a significant
glutamate increase in the dACC when in a functional state (glutamate fMRS) relative to
resting conditions using the 7 T MRI. This was then explored in the same schizophrenic and
MDD subjects as the resting MRS study. Glutamate significantly increased in the healthy
controls, but not in the schizophrenic and MDD groups. The schizophrenic group had a
slower glutamatergic response followed by a slower recovery, and, was the only group to
demonstrate significant glutamine increases when activated, indicating potential
abnormalities in glutamate dynamics.
Using a 7 T MRI, glutamate was explored in resting and activated conditions in
schizophrenia. Glycine was demonstrated to be lower in schizophrenia using MRS for the
first time, and the first functional MRS study was performed in a psychiatric population. The
ii

studies were made stronger by inclusion of a psychiatric control group. Future studies of
schizophrenia with glutamate fMRS should focus on the delayed glutamatergic response to
functional activation and abnormal recovery.

Keywords
Schizophrenia, major depressive disorder, glutamate, glutamine, glycine, 7 T, fMRS, MRS,
simulations, metabolite quantification, Stroop task, anterior cingulate cortex (ACC),
thalamus.

iii

Co-Authorship Statement
This thesis contains material from one manuscript that has been published in NeuroReport
(chapter 4), one manuscript that is currently in press in npj Schizophrenia (chapter 5), one
manuscript that has been submitted to Magnetic Resonance in Medicine and is currently
being edited for resubmission (chapter 2), and one manuscript in preparation to be submitted
to the British Journal of Psychiatry (chapter 3). Each of these manuscripts have had
contributions from multiple authors, which are listed for each chapter.
Chapter 2 – This manuscript has been submitted to Magnetic Resonance in Medicine and is
currently being edited for resubmission. The manuscript and the batch program for all the
simulations (creation, fitting, and analysis) were all written by Reggie Taylor. Dr. Jean
Théberge and Dr. Peter C. Williamson helped with the design of the study and the
interpretation of the results. Both have also reviewed the manuscript and made edits
Chapter 3 – This manuscript is currently in preparation to be submitted to the British Journal
of Psychiatry. All of the pulse sequence and protocol development, data acquisition, postprocessing, statistical analysis, and manuscript writing was done by Reggie Taylor. Subject
recruitment was performed Betsy Schaefer and Dr. Elizabeth A .Osuch. The Structured
Clinical Interview for DSM-IV (SCID) was performed on all subjects by Betsy Schaefer and
Dr. Peter C. Williamson. Anatomical landmarks for the voxel position were chosen by Dr.
Nagalingam Rajakumar. All statistical analyses were processed after consultation with Dr.
Richard W.J. Neufeld. Dr. Jean Théberge and Dr. Peter C. Williamson helped with the design
of the study and the interpretation of the results.
Chapter 4 – This manuscript has been published in NeuroReport (2015; 26:107-112) in open
access and requires no written permission letter to be reused in this dissertation. All of the
pulse sequence and protocol development, data acquisition, post-processing, statistical
analysis, and manuscript writing was done by Reggie Taylor. Subject recruitment was
performed by Betsy Schaefer. Maria Densmore helped with the voxel segmentations into
grey matter, white matter, and CSF. Dr. Richard W.J. Neufeld guided all statistical analyses
and contributed to the design of the Stoop protocol. Anatomical landmarks for the voxel

iv

position were chosen by Dr. Nagalingam Rajakumar. Dr. Jean Théberge and Dr. Peter C.
Williamson helped with the design of the study and the interpretation of the results.
Chapter 5 – This manuscript has been accepted and is currently in press at npj Schizophrenia
(NPJSCHZ#00068) for open access publication and requires no written permission letter to
be reused in this dissertation. All of the pulse sequence and protocol development, data
acquisition, post-processing, statistical analysis, and manuscript writing was done by Reggie
Taylor. Subject recruitment was performed Betsy Schaefer and Dr. Elizabeth A. Osuch. The
Structured Clinical Interview for DSM-IV (SCID) was performed on all subjects by Betsy
Schaefer and Dr. Peter C. Williamson. Anatomical landmarks for the voxel position were
guided by Dr. Nagalingam Rajakumar. Dr. Richard W.J. Neufeld guided all statistical
analyses and contributed to the design of the Stoop protocol. Dr. Jean Théberge and Dr. Peter
C. Williamson helped with the design of the study and the interpretation of the results.

v

Acknowledgments
The work presented in this thesis would not have been possible without the contributions and
support of the many people who have assisted me and been there for me throughout the
years. One of the biggest lessons I have learned in grad school is that sometimes you need to
ask others for help, and there’s nothing wrong with that. Below I have listed some of the
main people that need to be thanked, but the list is certainly not exhaustive.
First of all, my supervisors, Jean Théberge and Peter Williamson, have both guided me with
plenty of patience throughout this project and have been excellent mentors. My transition
from a naïve graduate student to a Ph.D. Candidate has largely been due to their support and
I can’t thank them enough for believing in me over the years.
The rest of my advisory committee, Jim Neufeld and Rob Bartha, have both provided
excellent insight and feedback into the design of these studies. Jim has been especially
influential in the development of the fMRI/fMRS protocol, and has been a very helpful
resource for any statistical questions that I’ve had.
To my former lab mate, Linden Barton, thanks for always being willing to be my human
guinea pig for protocol development with the 7 T (in exchange for my own services as a
guinea pig, of course). You’ve been a good friend and I look forward to many more good
times.
There was always an open door just down the hallway from my office where I could take a
break and have a talk with Maria Densmore. She has often been a voice of reason and has
often provided some very helpful advice. Thanks for always making time for me.
The many hours spent acquiring data on the scanners would not have been the same without
the upbeat presence of Betsy Schaefer to make the time go by. This thesis could not have
come to fruition without the hard work that Betsy put in to recruit and schedule so many
subjects. Thanks for everything.
Prior to scanning subjects, countless hours were spent taming the beast that was the 7 T.
Thanks to Joe Gati, Martyn Klassen, Ravi Menon, David Rudko, Andrew Curtis, Kyle
Gilbert, Igor Solovey and the rest of the CFMM for all the technical support provided. In
vi

addition, I would like to thank Jacob Penner, Jean-Guy Belliveau, Kathryn Manning, Kim
Krueger, Izabela Aleksanderek, Oksana Opalevych, John Drozd, and Trevor Szekeres for
discussions and support at the scanners as well.
There are many people that I have met at Lawson and Robarts that have grown to become my
friends, including many great officemates. Fang Liu, Udunna Anazodo, Harini Suraweera,
Karina Quiaoit, Anindita Sengupta, Andrea Mitchell, and all the others that had a brief stint
in that office, thanks for being so great. I really do hope that we’ll be able to keep in touch
going forward. I would also like to quickly thank all the administrative staff I have worked
with including Shelagh Ross, Michele Avon, and Brenda Dubois at Lawson, Wendy Hough
in the biophysics office on campus, and Sheri-Lee Bradshaw at University Hospital. Thanks
for all your hard work.
Throughout my time in London at Western, I have had many friends come and go. Although
it can be hard having friends move away to continue on with their lives, I’m thankful to all of
them for the memories we’ve made and the time that we’ve spent together. Matt Garton,
Frasor Pollard, Mike Besser, Mevan Perrera, Jesse Melo, Jacqui Hayworth, Aaron Parsons,
James Dusten and Yashaan Malvalvala have all been housemates in the past and have been
great friends. I specifically need to acknowledge Jesse Melo for much of his help with
introducing me to some of the more advanced aspects of computer programming, which
really improved my programming abilities for this thesis.
I’ve been involved with many sports teams to which I’ve enjoyed the company of my
teammates, including my hardball team (London Area Angels, formerly Forest City Barons),
my softball team (LAFS), and my old intramural Frisbee team. It was always nice to take my
mind off of school work and spend some time with friends having fun and getting exercise.
The Western Outdoors Club have been a huge component of my life away from school work
for about eight years now. This is where I have met some of my closest friends. When the
stress of school was becoming so great, the best remedy was a couple nights camping in the
middle of nowhere with some good friends and some new friends. Although it was hard to
see so many people come and go as they started and then finished school, I still cherish all of
their friendships. Thank you to everyone involved.
vii

Finally, my family, especially my mom and dad, deserve the biggest thanks, as they have
been so supportive the entire time. Always optimistic and ever encouraging, their support
has really made a big difference.
As I mentioned before, this list is far from exhaustive, and there are many more whom have
helped me get through this degree. To all of you, thanks.

viii

Table of Contents
Abstract ............................................................................................................................... ii
Co-Authorship Statement................................................................................................... iv
Acknowledgments.............................................................................................................. vi
Table of Contents ............................................................................................................... ix
List of Tables ................................................................................................................... xiii
List of Figures .................................................................................................................. xiv
List of Abbreviations and Symbols.................................................................................. xvi
List of Appendices ........................................................................................................... xix
Chapter 1 ............................................................................................................................. 1
1 Introduction .................................................................................................................... 1
1.1 Schizophrenia; background and physiology ........................................................... 1
1.1.1

From dementia praecox to schizophrenia ................................................... 1

1.1.2

Neural physiology of schizophrenia ........................................................... 2

1.1.3

The glutamate-glutamine cycle in a healthy state ....................................... 5

1.1.4

Measuring components of the GLU-GLN cycle in SZ ............................... 8

1.1.5

Summary of 1H-MRS in SZ ...................................................................... 14

1.2 Magnetic Resonance Spectroscopy....................................................................... 14
1.2.1

Origin of the signal ................................................................................... 15

1.2.2

Relaxation ................................................................................................. 16

1.2.3

Electron shielding and chemical shift ....................................................... 20

1.2.4

J-coupling.................................................................................................. 21

1.2.5

Ultra-High Field (≥ 7 T) Spectroscopy ..................................................... 23

1.2.6

Voxel localization ..................................................................................... 24

1.2.7

Water Saturation ....................................................................................... 27
ix

1.2.8

Post-processing ......................................................................................... 29

1.2.9

Spectral Fitting .......................................................................................... 32

1.3 Thesis Objectives .................................................................................................. 38
1.3.1

Demonstrate the benefits of ultra-high field for GLU and GLN 1H-MRS 38

1.3.2

Examine glutamate, glutamine, and glycine in schizophrenia .................. 39

1.3.3

Demonstrate glutamate changes with 1H-fMRS in the ACC using a
cognitive task ............................................................................................ 40

1.3.4

Examine 1H-fMRS in the ACC using a cognitive task in schizophrenia .. 41

1.4 References ............................................................................................................. 41
Chapter 2 ........................................................................................................................... 55
2 Sources of Variability in the quantification of short-echo time human brain 1H-MRS
spectra .......................................................................................................................... 55
2.1 Introduction ........................................................................................................... 55
2.1.1

Hypotheses ................................................................................................ 58

2.2 Methods................................................................................................................. 59
2.3 Results ................................................................................................................... 63
2.4 Discussion ............................................................................................................. 71
2.5 References ............................................................................................................. 77
Chapter 3 ........................................................................................................................... 80
3 Neurometabolic abnormalities observed with magnetic resonance spectroscopy at 7 T
in the anterior cingulate cortex and thalamus of patients with schizophrenia and Major
Depressive Disorder ..................................................................................................... 80
3.1 Introduction ........................................................................................................... 80
3.2 Methods................................................................................................................. 83
3.2.1

Participants ................................................................................................ 83

3.2.2

1

H-MRS Data Collection and Analysis..................................................... 84

3.3 Results:.................................................................................................................. 87
3.4 Discussion ............................................................................................................. 88
x

3.4.1

GLU and GLN .......................................................................................... 88

3.4.2

GLY as a potential therapeutic target ....................................................... 91

3.4.3

Inositol in MDD ........................................................................................ 93

3.4.4

Future studies ............................................................................................ 94

3.4.5

Conclusions ............................................................................................... 94

3.5 References: ............................................................................................................ 94
Chapter 4 ........................................................................................................................... 99
4 Increased glutamate levels observed upon functional activation in the anterior
cingulate cortex using the Stroop Task and functional spectroscopy. ......................... 99
4.1 Introduction ........................................................................................................... 99
4.2 Methods............................................................................................................... 101
4.3 Results ................................................................................................................. 104
4.4 Discussion ........................................................................................................... 107
4.5 Acknowledgements ............................................................................................. 110
4.6 Conflicts of Interest............................................................................................. 110
4.7 References ........................................................................................................... 110
Chapter 5 ......................................................................................................................... 114
5 Functional magnetic resonance spectroscopy of glutamate in schizophrenia and major
depressive disorder: Anterior cingulate activity during a color-word Stroop task. ... 114
5.1 Introduction ......................................................................................................... 114
5.2 Methods: ............................................................................................................. 116
5.2.1

Participants .............................................................................................. 116

5.2.2

Anterior cingulate activation paradigm .................................................. 117

5.2.3

1

H-fMRS Data Collection and Analysis ................................................. 118

5.3 Results:................................................................................................................ 120
5.4 Discussion: .......................................................................................................... 128
5.5 Conclusion: ......................................................................................................... 131
xi

5.5.1

Acknowledgements: ................................................................................ 132

5.5.2

Competing Interests: None to disclose .................................................. 132

5.5.3

Funding: .................................................................................................. 132

5.5.4

Contributions: ......................................................................................... 132

5.6 References: .......................................................................................................... 133
Chapter 6 ......................................................................................................................... 140
6 Summary, Future Work, and Conclusions ................................................................. 140
6.1 Summary of chapters .......................................................................................... 140
6.1.1

Simulations ............................................................................................. 140

6.1.2

Single-voxel 1H-MRS ............................................................................. 141

6.1.3

1

H-fMRS in healthy controls .................................................................. 144

6.1.4

1

H-fMRS in schizophrenia and major depressive disorder ..................... 147

6.2 Future Work ........................................................................................................ 149
6.2.1

Simulations ............................................................................................. 149

6.2.2

Single-voxel 1H-MRS in SZ and MDD .................................................. 151

6.2.3

1

H-fMRS ................................................................................................. 153

6.3 Closing remarks .................................................................................................. 155
6.4 References ........................................................................................................... 156
Appendices ...................................................................................................................... 161

xii

List of Tables
Table 2-1. Significant correlations between metabolite concentration estimates ................... 64
Table 2-2. Metabolite precision (CV; %) across B0 with the SNR=1024 and IE1 ................. 65
Table 2-3. The increase in CV due to doubling initial fit seeding offsets ......................... 67
Table 2-4. Metabolite precision (%) across B0 with nt=256 and IE1 ..................................... 68
Table 2-5. Metabolite omissions from the fitting template (nt=64, IE1) ................................ 69
Table 3-1. Participant demographics ...................................................................................... 84
Table 3-2. Metabolite concentrations (mmol/kgww ± standard deviations) with statistical
comparisons for each subject group for a voxel in the ACC .................................................. 89
Table 3-3. Metabolite concentrations (mmol/kgww ± standard deviations) with statistical
comparisons for each subject group for a voxel in the TH ..................................................... 90
Table 4-1. Quantified metabolites with their resting concentrations (µmol/g) and relative
changes (%) during the task completion and the recovery period presented as means ± SE 105
Table 5-1. Participant demographics .................................................................................... 117
Table 5-2. Pairwise comparisons for adjacent blocks of the 1H-fMRS paradigm for GLU,
GLN, and GLX concentrations ............................................................................................. 123
Table 5-3. Pairwise comparisons for adjacent blocks of the 1H-fMRS paradigm, normalized
to the resting concentration for GLU, GLN, and GLX ......................................................... 124
Table 5-4. Behavioural response times (correct-only) to the incongruent Stroop condition and
correlation to glutamate and glutamine concentrations and percent changes during those trials
............................................................................................................................................... 125
Table 5-5. Correlation values between behavioural response times for each Stroop condition
and GLU and GLN concentrations during Stroop1 .............................................................. 126
xiii

List of Figures
Figure 1-1. A few neurotransmitter pathways within the limbic basal ganglia thalamocortical
circuits. ...................................................................................................................................... 3
Figure 1-2. The chemical structure of (A) glutamate and (B) glutamine ................................. 4
Figure 1-3. A simplified diagram of the GLU-GLN cycle in a healthy state. .......................... 7
Figure 1-4. The precession of spin-1/2 nuclei in the presence of a magnetic field (B0) will
preferentially orient parallel to the applied field..................................................................... 17
Figure 1-5. Excitation and refocusing of the magnetization in a spin-echo sequence ............ 18
Figure 1-6. The splitting of peaks in coupled spin systems. ................................................... 22
Figure 1-7. Slice-selection frequency bandwidth for a slice thickness and position. ............. 26
Figure 1-8. The 1H-MRS STEAM pulse sequence with VAPOR water suppression. ........... 28
Figure 1-9. Resonance information as it would be listed in (A) .cst and (B) .ges files. ......... 34
Figure 1-10. datSub, a user interface for the HLSVD fitting of macromolecules. ................. 36
Figure 2-1. Simulated chemical signatures of GLU and GLN. .............................................. 56
Figure 2-2. The full simulated set (top) of metabolites (middle) and macromolecules
(bottom)................................................................................................................................... 61
Figure 2-3. Example spectra for each B0 with 256 averages .................................................. 62
Figure 2-4. Correlations between metabolite concentration estimates. .................................. 66
Figure 2-5. Metabolite spectra (top) with their fits overlaid along with the residual from the
fits (bottom) A) when MM has been omitted and B) with a complete template .................... 67
Figure 3-1. Sagittal and transverse cross-sections depicting the voxel locations. .................. 86
Figure 3-2. Example 64 average spectra from (A) the ACC and (B) the thalamus. ............... 88
xiv

Figure 4-1. A sagittal cross-section of the brain with the MRS voxel placed in the anterior
cingulate cortex. MRS = magnetic resonance spectroscopy................................................. 103
Figure 4-2. A time-course of the average glutamatergic response to the Stroop Task ......... 106
Figure 5-1. (A) Sagittal and (B) transverse cross-sections depicting the position of the 1HfMRS voxel located in the bilateral ACC of one participant. ............................................... 122
Figure 5-2. (A) An example resting 80 average water suppressed spectrum. ...................... 127
Figure 5-3. Four-minute moving average time courses of glutamate concentrations........... 128

xv

List of Abbreviations and Symbols

ω
γ



1
H
1
H-fMRS

frequency (rad/s)
gyromagnetic ratio
phase
shielding constant
ppm value
Hydrogen nuclei, proton
proton functional magnetic resonance spectroscopy

1

H-MRS
ACC
Ala
Asp
ATP
BGTHC
B0
B1
Ca2+

proton magnetic resonance spectroscopy
anterior cingulate cortex
alanine
aspartate
adenosine triphosphate
basal Ganglia thalamocortical
external magnetic field
applied magnetic field
calcium

CB
CHESS
Cho
COV(metA,metB)
Cr
CRLB
CO2
CSI
CV
d

cerebellum
chemical shift selective
choline
covariance between metabolite A and B
creatine
Cramer-Rao Lower Bounds
cardon dioxide
chemical shift imaging
coefficient of variation
delay time

EAAT
FGA
FID
fMRI
FOV
FWE
GABA

excitatory amino acid transporter
first-generation antipsychotic
free-induction decay
functional magnetic resonance imaging
field of view
Family-Wise Error
gamma-aminobutyric acid
xvi

Glc

glucose

GLN
GLU
GLX
GLY
GLYt1/2
GPCho
GS
GSH
G(x,y,z)

glutamine
glutamate
glutamate+glutamine
glycine
glycine transport inhibitors
glycerophosphorylcholine
glutamine synthetase
glutathione
gradient in direction x, y, or z

HIP

hippocampus

HLSVD
IE1/2
Lac
LW
MDD
mGluR(1-8)
MM
M0
MRI

Hankel-lanczos singular value decomposition
Inexact seeding type 1 or 2
lactose
linewidth
major depressive disorder
metabolic glutamate receptors
macromolecules

MYO
NA
NAA
NAAG
NAVG
NADH
NMDA
NMR
nt

myo-inositol
nucelus accumbens

OVS
PAG
PCho
PCP
PCr
PE
PFC
PRESS

outer volume suppression
phosphate-activated glutaminase
phosphorylcholine
phencyclidine
phosphocreatine
phosphorylethanolamine
prefrontal Cortex
point resolved spectroscopy

resting magnetization
Magnetic Resonance Imaging

N-acetylaspartate
N-acetylaspartyl-glutamate
number of averages
nicotinamide adenine dinucleotide
N-methyl-D-aspartate
nuclear magnetic resonance
number of transients

xvii

QUECC
RF
R(metA,metB)
SAR
Scy
Ser
SGA
SNR
STEAM
SZ
T

quality eddy current correction
radiofrequency
correlation between metabolite A and B
specific absorption rate
scyllo-inositol
serine
second-generation antipsychotic
signal to noise ratio
stimulated echo acquisition mode
schizophrenia

T1
T2
Tau
TE
TH
TM
TMS
TORO
TR

Tesla
spin-lattice relaxation
spin-spin relaxation
taurine
echo time
thalamus
mixing time
tetra-methylsilane
transmit-only receive-only
repetition time

VAPOR
VTA

variable power and optimized relaxation delays
ventral tegmental area

xviii

List of Appendices
Appendix A. Ethics approval to acquire 1H-fMRS in schizophrenia at 7 T ......................... 161
Appendix B. Ethics approval for 1H-MRS in schizophrenia at 7 T ...................................... 162
Appendix C. Curriculum Vitae for Reggie Taylor ............................................................... 164

xix

1

Chapter 1

1

Introduction

The ultimate objective of this thesis is to gain insight into the state of glutamate and its
metabolic affiliates in the brains of individuals with schizophrenia using advanced MRI
hardware and methodology. This is, of course, a very general statement, as a brief
overview of schizophrenia and MRI physics is necessary to fully appreciate the specific
intentions and methods of the works in this thesis. This chapter will serve as a thorough
tutorial towards the development of specific hypotheses outlined in this work, and will
provide additional background information for the otherwise self-contained chapters 2, 3,
4 and 5.

1.1 Schizophrenia; background and physiology
1.1.1

From dementia praecox to schizophrenia

Schizophrenia (SZ) was first separated from other psychoses by Emil Kraeplin in 1899,
who at the time called the disorder “dementia praecox”1. Krapelin’s descriptions of
dementia praecox were very similar to the modern classification of SZ in the Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IVTR)1. The term “dementia praecox” was eventually replaced by SZ in 19112. Although
the classification of SZ is relatively recent, the disease is believed to have been with
humans throughout civilization, given early descriptions of similar illnesses in historical
texts1,3,4.
The prevalence of SZ in the population is approximately 1%, with a similar incidence
among men and women5,6. The typical age of onset is in the adolescent phase of a
person’s life (usually early twenties), with the onset being 3-4 years earlier in men than in
women5. Although onset typically occurs beyond puberty, subtle symptoms have been
identified retrospectively in childhood prior to disease diagnosis7. The cause of SZ is still
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unknown, although there are convincing arguments pointing towards the idea that there is
both a genetic and an environmental component. One meta-analysis of 12 studies of twins
(both monozygotic and dizygotic) found an 81% heritability component due to genetics
and an 11% heritability component due to the environment, such as exposure to
infectious agents, dietary characteristics, etc8. It is probable that there are in fact multiple
factors that can lead to the final common pathway of SZ2,9. What is clear is that, at the
point when a diagnosis of SZ would be made, there is a substantial contribution of
neurotransmitter anomalies influencing the symptoms of SZ.

1.1.2

Neural physiology of schizophrenia

The symptoms of SZ are variable in each individual, but generally can be subdivided as
either positive (i.e. auditory hallucinations and delusions), negative (i.e. asociality,
avolition, anhedonia, affective flattening, and alogia) or cognitive (i.e. attention and
working memory deficits, visual and verbal learning memory, reasoning and problem
solving)7,10,11. Most current antipsychotics offer effective relief from positive symptoms
by targeting dopaminergic neurotransmission but most do little to offer relief from the
negative and cognitive symptoms7,12–14 and can actually worsen cognitive symptoms15.
The negative and cognitive symptoms are present in 40-80% of people with SZ10 and are
better indicators of functional outcome7,9,10,13,14. There are currently no approved
treatments that target negative and cognitive symptoms specifically. The drugs that can
treat both positive and negative symptoms typically come with heavy undesirable side
effects (e.g. clozapine increases risk for agranulocytosis and requires regular blood
tests)12,16, which can influence patient compliance with regularly taking their prescribed
medication. These poorly treated negative and cognitive symptoms lead to progressive
deterioration in functioning throughout their lives10,15.
Differences in the effectiveness of drug interventions are likely due to the underlying
differences in brain physiology between positive, negative, and cognitive symptoms.
Positive symptoms have been connected to dopaminergic pathways originating in the
ventral tegmental area and projecting to the nucleus accumbens2, and, as such, the current
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antipsychotics generally target the D2 dopamine receptors in this area15. It is believed that
different brain pathophysiology is implicated in the negative and cognitive symptoms7,
and it is likely that the physiology of positive, negative, and cognitive symptoms are
connected through neural circuits, known as the basal ganglia thalamo-cortical circuits
(BGTHC)2,12 (Fig 1-1).

Figure 1-1. A few neurotransmitter pathways within the limbic basal ganglia
thalamocortical circuits.
ACC=anterior cingulate cortex; PFC=prefrontal cortex; NA=nucleus accumbens;
HIP=hippocampus; VT=ventral tegmental area; TH=thalamus; CB=cerebellum.
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The BGTHC are essential links between motivation and action in the brain, and are
important when learning new behaviours2. As the name implies, these are circuits that
cycle from the cortex, to the basal ganglia, through to the thalamus, and then back out to
the cortex, creating a flow of cyclical communication through these brain areas2,17. The
communication throughout each circuit is largely mediated by the main excitatory
neurotransmitter, glutamate (GLU; Fig 1-2A), with contributions from both dopamine
and the inhibitory neurotransmitter, gamma-aminobutyric acid (GABA). One BGTHC of
particular interest in the pathophysiology of SZ, the limbic BGTHC, completes a circuit
through the dopaminergic pathway from the ventral tegmental area (VTA) to the nucleus
accumbens, a pathway central to explaining the positive symptoms of SZ. The anterior
cingulate cortex (ACC)2,13,18–25, and the thalamus2,22,24–30 are key nodes within circuits
that are repeatedly implicated through the negative symptoms of SZ. The thalamus,
being a central hub of each BGTHC, is an area of interest in studies of SZ that have
demonstrated structural abnormalities26,27, abnormal functional connectivity27,28 and
metabolic abnormalities22,24–26,31,32. The dorsal component of the ACC, believed to be
involved in selective encoding of stimulus properties33, attention34 , and organization of
conflicting stimuli35,36, is associated with negative and cognitive symptoms in SZ7,13 and
is another important structure within the limbic BGTHC. Functional MRI (fMRI) studies
have demonstrated hypofunction in the ACC upon completion of complex tasks such as a
word-fluency task20 and the color-word Stroop task19 in people with SZ compared to

Figure 1-2. The chemical structure of (A) glutamate and (B) glutamine
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healthy controls. The ACC is an area that is heavily innervated with GLU neurons that
mediate the communication with functionally connected brain regions. Therefore, it is
possible that the positive, negative, and cognitive symptoms of SZ are due to the actions
of impaired GLU neurotransmission within areas of the BGTHC, with the dopamine
levels causing the positive symptoms as a downstream effect. Much of the current
understanding of the neural physiology of SZ actually comes from studies involving
drugs that act on GLU receptors, such phencyclidine (PCP) and ketamine37–39. These
drugs are antagonist of the N-methyl-D-aspartate (NMDA) ionotropic GLU receptor37–40.
They have been shown to induce both positive and negative symptoms when
administered to healthy controls, but will exacerbate existing symptoms in people with
SZ41,42. The prevalent stance in the GLU theory of SZ postulates that the presence of
localized NMDA receptor hypofunction as a likely cause of reduced efficiency or
function of GLU neurotransmission in connected regions12,43. There is also some
evidence pointing towards the presence of glutamate excitotoxicity in SZ in a small
number of studies (n=7)44. The exact biochemical mechanism of GLU neurotransmission
deficiency in SZ is still unknown but it is likely located somewhere within the glutamateglutamine (GLU-GLN) cycle.

1.1.3

The glutamate-glutamine cycle in a healthy state

The efficient recycling of GLU is an essential component to neural function. It is
estimated that 60-80% of neuronal glucose consumption directly supports the GLU-GLN
cycle45 (Fig. 1-3). Neuronal GLU is first created when glucose enters the Kreb’s cycle
(Tricarboxylic acid cycle) in the neuronal mitochondria. After citrate reacts with NAD+
to form alpha-ketoglutarate, CO2, NADH+ and H+, the alpha-ketoglutarate exits the
Kreb’s cycle and binds with an alpha-amino acid using aminotransferase to facilitate the
reaction46–48. This creates the amino acid GLU. Approximately 4000 GLU molecules are
then packaged into a vesicle for exocytosis into the synapse at a rate of 1.2 vesicles per
second, or 4800 GLU molecules per second49. After release into the synapse, GLU binds
with ionotropic receptors (NMDA, kainate, AMPA) or metabotropic receptors (mGluR1-
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on the post-synaptic membrane, an event modulated by certain agonists7,40,48,49. For

example, there is a glycine (GLY)/D-serine site on the NMDA receptor that needs to be
filled for GLU neurotransmission to be possible on that receptor50. With both GLU and
GLY sites bound, the NMDA channel opens and results in a Ca2+ influx into postsynaptic
neuron. The GLU molecule is eventually released from the receptor. A small percentage
will be reabsorbed into the presynaptic neuron, but the majority will be rapidly taken up
into the adjacent glial cell (astrocyte) by excitatory amino acid transporters (EAAT),
primarily EAAT2, to avoid excitotoxicity49,51. Each EAAT2 can transport a GLU
molecule once every 70 ms, so hundreds of them need to be present49. This is an active
transport of GLU which requires ATP45. In the glial cell, GLU can either be oxidized or
can undergo an amination reaction via glutamine synthetase (GS), an enzyme located
exclusively in the glial cell46,47,52, that will convert the GLU to glutamine (GLN; Fig 12B)45–47,49,53. The GLN can then be passively transported back into the neuron where the
phosphate activated enzyme glutaminase (PAG) can convert it to GLU through
hydrolysis for re-use in neurotransmission46,47. Approximately ¾ of the GLU will
undergo the amination reaction to GLN in the glial cell, and the remaining ¼ will be
oxidized using glutamate dehydrogenase46,47 to convert it to alpha-ketoglutarate54, which
can be fully degraded to CO2 and water within the glial cell for energy purposes55.
Therefore, each GLU molecule is only used a few times before it is ultimately oxidized
for energy46,47,49. This process of recycling GLU after it has been used for
neurotransmission is the GLU-GLN cycle, a process that is tightly coupled to neuronal
energy consumption from glucose45. Without glucose to resupply the loss of GLU
through oxidation, the GLU supply will be depleted in approximately 1 minute49. There
are, therefore, many metabolic processes within the GLU-GLN cycle that could
ultimately lead to hypofunction of GLU neurotransmission if they are not operating
efficiently (e.g. reduction in enzymatic levels, reduction in transporters, reduction in
number of receptors, dysfunctional receptors, etc). If there is a dysfunction somewhere in
the GLU-GLN cycle, one would expect an offset in the equilibrium concentration of
GLU and/or GLN. SZ does not spontaneously occur in animals other than humans and
laboratory animal models of SZ tend to only mimic a very specific feature of SZ (i.e.
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dopamine hyperresponsivity). Fortunately, there are methods by which GLU and GLN
can be measured non-invasively in human brains affected by SZ.

Figure 1-3. A simplified diagram of the GLU-GLN cycle in a healthy state.
GLU is created in the mitochondria, packaged into vesicles to be released in the
synaptic cleft where it binds with receptors on the post-synaptic membrane. This
reaction is mediated by local GLY. GLU is then actively transported into the
adjacent glial cell (via EAAT), where it is converted to GLN via GS. GLN is then
passively transported back into the neuron, where it can be converted back into
GLU via PAG. GLU = glutamate; GLN = glutamine; GLY = glycine; NMDA = Nmethyl-d-Aspartate; EAAT = excitatory amino acid transporters; GS = glutamine
synthetase; PAG = phosphate-activated glutaminase
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1.1.4
1.1.4.1

Measuring components of the GLU-GLN cycle in SZ
Glutamate/Glutamine

Since the first lines of evidence for the GLU theory of SZ emerged, there have been
many studies examining GLU and GLN in SZ. Although the GLU theory has evolved
throughout the years56, there has been relatively little progression given the number of
studies and the massive efforts put forth by researchers, demonstrating that it is a
complex disorder and there are still many obstacles to overcome. There have been useful
post-mortem studies of brain tissues from people with SZ that have found abnormalities
in the expression of proteins related to synaptic activity and GLU
neurotransmission32,51,57,58. However, post-mortem studies have limited results because
the tissues are typically from people with chronic SZ who have been heavily medicated
throughout the duration of their illness. This is a problem because there has been
substantial evidence showing that the GLU and GLN concentrations likely change
throughout the course of the disorder18,25 and that medications can influence their
concentrations in the human brain59,60. Another challenge of GLU and GLN studies in SZ
is that it appears to be a uniquely human disorder2 and although symptom analogs have
been well documented and studied in animal models (i.e. ketamine administrations61),
this fact still limits the translational potential of animal studies. Genetic studies have
identified some gene variants that affect the NMDA pathway and the susceptibility for
SZ7 but, so far, there has not been a “schizophrenia gene” identified. Therefore, it is
desirable to be able to non-invasively detect GLU and GLN concentrations in the brains
of humans with SZ in vivo. One method that has been extensively used for this is proton
magnetic resonance spectroscopy (1H-MRS).
There have been many 1H-MRS studies of SZ to date in various areas of the
brain12,18,62,63. Unfortunately, many of the studies are difficult to compare considering all
the possible factors that influence the results. As mentioned already, whether the SZ
subjects are first-episode, anti-psychotic naïve or chronic patients will influence the
results18,25,59,60. Studies are performed on different magnetic field strength scanners (1.5 T
-7 T), using different 1H-MRS acquisition pulse sequences and parameters, with different
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post-processing methods and different fitting algorithms63. Some studies use water to
determine the metabolite concentration (explained below) and others simply examine
ratios of metabolites to creatine, another metabolite detectable with 1H-MRS. Different
voxel sizes are used, and the placement of a voxel can be very different from one study to
the next. For example, the ACC is a structure that is much larger than a typical 1H-MRS
voxel size (1.5cm3 – 8cm3) with very different functions from one location to another2.
Not all studies specify all the metabolites that they fit, and, specifically, many studies do
not explain what metabolites are included in their GLU definition. At lower magnetic
field strengths, it can be necessary to combine GLU and GLN into one unitary
concentration, as the metabolites cannot be reliably separated for quantification. It is
then common to define “GLX” as GLU+GLN, but this is not always made clear, leading
one to assume that GLX could actually be a combination of GLU, GLN, and any other
metabolites (GABA, glutathione) or macromolecules that overlap their spectra. Even with
all these limitations in comparing studies, GLU, GLN, or GLX concentrations are
consistently implicated in voxels throughout the brain in SZ.
A recent meta-analysis was completed of 28 1H-MRS studies with 647 subjects with SZ
and 608 healthy controls at various voxel sizes and field strengths18, of which 9 studies
were completed in the medial frontal lobe (including the ACC and medial prefrontal
cortex)22,24,64–71. The study determined that GLU concentrations are typically lower than
controls at the onset of the disease, whereas GLN is typically higher than controls. Both
GLU and GLN decreased in concentration faster as the SZ subjects aged than in the
healthy controls. The same meta-analysis has examined GLU concentrations in 3 studies
in the thalamus, but determined no significant difference in SZ from healthy controls.
There were not enough studies in the meta-analysis to determine an effect of GLN in the
thalamus, but it has previously been demonstrated that there is increased GLN in firstepisode, antipsychotic naïve subjects with SZ22 and chronic SZ24 relative to controls, with
the GLN concentration decreasing after 30 months of antipsychotic treatment25.
One particularly interesting 1H-MRS study of the ACC involved healthy controls being
challenged with a sub-anesthetic dose of the NMDA antagonist ketamine72. This study
observed an increase in ACC GLN after the healthy controls had been exposed to
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ketamine, which returned to normal ten minutes later. This observation is consistent with
the GLU theory of NMDA hypofunction in SZ, as it has been observed that when the
NMDA receptor is in a condition of hypofunction there is an increase in the activity of
GLN synthetase leading to higher GLN concentrations synthesized73. Therefore,
increased GLN observed in people with SZ provides strong support for the GLU theory
of SZ.

1.1.4.2

Dynamic measurements of GLU and GLN

Static measurements of 1H-MRS have been paramount in moving research forward into
the possibility of GLU dysfunction in SZ, but a limitation of these studies is that all were
acquired in a resting condition, at only one time point. This is based on the assumptions
that the metabolite concentrations are not dynamic, and that the brain at rest is truly at
rest. It has since been demonstrated that the concentrations of some metabolites will
change when the tissue within the voxel is stimulated74–85. This technique is called
functional 1H-MRS (1H-fMRS). The first 1H-fMRS studies were largely looking at lactate
concentrations in the occipital lobe after visual stimulation in dyslexic children84, and in
subjects with migraines83. Since then, there have been reports that show that local GLU
(or GLX) concentrations will increase when an area of the brain is stimulated using a
visual task in the occipital lobe75–77,81, a finger tapping paradigm in the motor cortex80,
pain paradigms in the ACC78 and inferior parietal cortex79, and a sexual arousal task in
the ACC82. It is likely that the GLU increase is related to the creation of new GLU for
neurotransmission de novo from glucose, while the remaining GLU undergoes recycling
via the GLU-GLN cycle. In a dynamic state while the GLU-GLN cycle is being
challenged, it is possible that a dysfunction somewhere in the GLU-GLN cycle would
manifest itself as a significantly different response of GLU than in healthy controls, or
possibly even a change in GLN.
The previously mentioned 1H-fMRS studies of the brain have been pivotal in
demonstrating that metabolic changes can be observed as a result of functional activation.
A limitation of past studies is that no study has yet demonstrated that GLU increases can
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be seen using a cognitive behavioural task or in a psychiatric disorder. A behavioural task
is desirable if the technique is going to be extended to the study of psychiatric disorders
featuring impaired cognitive processing, such as SZ.
There are many possible cognitive tasks that could be chosen as the functional paradigm
for 1H-fMRS but there are also multiple considerations. First, the task needs to stimulate
a specific area of the brain, much like the visual tasks stimulate the occipital lobe75–77,81
and the motor tasks stimulate the motor cortex80. The first decision, then, needs to be in
what area of the brain is the voxel going to be placed. For a 1H-fMRS study of SZ, it
would be interesting to observe metabolic changes in an area implicated through the
negative symptoms. The task must also be able to actively engage the participant for an
extended period of time. If the participant loses interest or is not finding the task
particularly challenging anymore it is likely that the area of interest will also not be
stimulated as strongly, potentially biasing the results to any attentional impairment. This
is an important aspect to consider given that behavioural tasks already do not illicit as
strong of a neural response (according to measurements of the blood-oxygen level
dependent (BOLD) effect) as the visual and motor tasks86. It has been postulated that the
deficiencies in SZ may arise from an increased number of subprocesses that are involved
in the encoding of cognitive stimuli into task facilitative formats33,87. The color-word
Stroop Task88–92 is one such cognitive task that requires encoding operations in the
presence of interfering information that activates the ACC19,35,36,93–95.
The color-word Stroop Task is a common psychiatric battery that people in SZ find more
challenging (lower time efficiency) than healthy controls, although with a similar rate of
correct answers19,67,96. It involves the presentation of a color-word written in a certain
color of ink in a congruent condition (i.e. the word “red” written in red ink), incongruent
condition (i.e. the word “green” written in red ink), color-only condition (i.e. letters
(“XXXX”), or a nonsense word written in red ink) or word-only condition (the word
“red” written in white ink). The color of the ink is the expected correct response in all but
the word-only condition, where the word is the expected correct response (i.e. “Red”
would be the correct response in each of the previous examples). The organization of
conflicting or complex stimuli is often attributed to activity in the dorsal ACC20,35,36,
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which the color-word Stroop Task robustly and reproducibly activates19,35,93,95,97.
Therefore, due to the implication of ACC in negative and cognitive symptoms, the Stroop
Task appears to be a good cognitive paradigm for a 1H-fMRS study of SZ.
In a neuropsychiatric disorder like SZ, where one of the leading hypotheses is related to
hypofunction of the GLU-GLN cycle, 1H-fMRS has the potential to utilize the added
dimension of time to identify possible metabolic steps within the GLU-GLN cycle that
are functionally deficient, based on GLU or GLN accumulations (or lack thereof ). While
1

H-fMRS in SZ should provide valuable information on the glutamatergic system, there

is certainly still a role for static 1H-MRS measurements of brain tissue in a controlled
resting state. As technology has improved, so has the quality of 1H-MRS spectra. This
can translate to improved measurements of metabolites that are of low concentration and
have been traditionally difficult to quantify. One such metabolite that plays a pivotal role
in GLU neurotransmission is GLY.

1.1.4.3

Glycine

One of the growing ideas for potential pharmaceutical interventions of the NMDA
hypofunction is to try to increase GLY concentrations in glutamatergic neurons. There is
a GLU site and a GLY/D-serine site on the NMDA receptor (the NR2 and NR1 subunits,
respectively) that needs to be filled for successful GLU neurotransmission7,12,40,50,98.
Without an adequate supply of GLY (or D-serine) present in the synaptic cleft the
NMDA receptor will not operate optimally. This could be a target for pharmacological
intervention to increase the local concentrations. However, there are some obstacles to
overcome. First, GLY is also an inhibitory neurotransmitter, so increasing the
concentration throughout the brain may have some adverse effects. Another issue is that
GLY crosses the blood brain barrier very poorly99 so to increase concentrations in the
synaptic cleft just from the diet, there needs to be a large dose of GLY ingested, although
one study has demonstrated that increased GLY concentrations can be detected in the
brain using 1H-MRS after 2 weeks of ingesting it100. A molecule that is similar to GLY
but can cross the blood-brain barrier could be ingested, but GLY has such a small
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chemical structure that there is really not much leeway in creating a similar molecule50.
Alternatively, there could be a way to redirect more GLY into the synaptic cleft. One
such method lies in targeting GLY transport inhibitors.
There are two GLY transport inhibitors in the brain, GLYt1 and GLYt2, and they both
have very different functional mechanisms50. GLYt2 is located at the GLY inhibitory
neurons, and GLYt1 is located on glial and neuronal membranes and controls the GLY
concentration within the synaptic cleft50. It is possible to selectively target the GLYt1
receptor with 99% specificity over the GLYt250. Therefore, GLY and its transport
inhibitors are an exciting possibility for future drug interventions to improve NMDA
efficiency, but so far there has only been limited success40,50,98,101.
To date, there have only been limited studies of GLY in SZ. One study examined the
serum of people with SZ receiving either first-generation antipsychotics (FGA), second
generation antipsychotics (SGA), or the atypical antipsychotic clozapine102 and found the
patients receiving clozapine had lower serum GLY levels than patients taking FGA or
SGA. This is interesting because clozapine is one of the few currently approved
antipsychotics that has some effectiveness in treating negative symptoms2. Another study
examined GLY levels in the plasma of people with treatment-resistant SZ before and
after clozapine treatment103. This study found significantly increased plasma GLY levels
after clozapine treatment in the SZ group, which was also significantly higher after
treatment when compared to controls. Although the results of this study are somewhat
contradictory, they do both implicate GLY in the pathophysiology of SZ. It is also
important to note that treatment-resistant SZ may operate under different mechanisms
than SZ that can be successfully treated with FGA or SGA, going back to the notion that
SZ may be a final common pathway of multiple sub-disorders. However, a number of
other plasma/serum studies of GLY have shown increased, neutral, or decreased levels of
GLY, meaning that the results have been fairly inconsistent103. One of the limitations of
plasma/serum studies is that it is not necessarily an indication of tissue GLY levels, and
the results are not specific to one area of the brain. It would be ideal if GLY could be
measured accurately in vivo in a localized area of the brain. One possible technique to do
this would be 1H-MRS.
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The spectral signature of GLY consists of a single resonance at 3.548 ppm104. It is a
challenging metabolite to quantify reliably with 1H-MRS due to its low concentration and
the proximity of its spectral peak with the spectral signature of myo-inositol (MYO), a
high concentration metabolite with a complicated spectral signature (strong J-coupling).
Two studies have been able to detect GLY reliably on 4 T MRI scanners by using a
special pulse sequence called echo-time averaging sequence100,105. One of these studies
examined GLY concentrations in the occipital cortex before and after a 2 week period of
oral GLY supplementation and found that they were able to detect a significant increase
in GLY concentration after the 2 week period100. Another study used a 7 T MRI to detect
GLY reliably, again in the occipital lobe106. All these 1H-MRS studies have been in
healthy controls, and, to date, there have been no published studies on GLY
measurements in vivo in SZ using 1H-MRS63.

1.1.5

Summary of 1H-MRS in SZ

As technology has improved, so has the potential to achieve higher quality 1H-MRS
spectra. To advance the understanding of SZ it is necessary to utilize these advances and
push the limits of what can be achieved. Reliable measurements of GLY concentrations
along with static and dynamic measurements of GLU and GLN in SZ in implicated areas
within the brain would provide some critical information concerning the health of GLU
neurotransmission in SZ. Optimizing 1H-MRS spectra is critical to be able to reliably
make these measurements. This will require basic understandings of MRI and 1H-MRS
principles.

1.2 Magnetic Resonance Spectroscopy
This will be a brief introduction to concepts and processes involved in acquiring,
processing and quantifying 1H-MRS data. For a more thorough review of these topics,
please see references107–113.
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1.2.1

Origin of the signal

To understand the mechanisms of 1H-MRS and 1H-fMRS, it is important to first
understand some basic principles of nuclear magnetic resonance (NMR). The first
requirement for any signal in NMR is a nucleus with a magnetic moment. The magnetic
moment comes from a particle’s spin, which is a basic property of any nucleus, along
with mass, magnetism, and electric charge. Generally, all nuclei with an even mass are
bosons and will have full integer spin (i.e. -1, 0, 1), and all nuclei with an odd mass are
fermions and will have a half-integer spin (i.e. -½, ½). For any nucleus, there are |2*Spin|
+ 1 stable spin states. In the absence of an external magnetic field (B0), every one of these
stable rotational states are considered degenerate, meaning they will have the same
potential energy. When a B0 is applied, the degeneracy is removed and there will be an
energy separation between the quantum rotational states. This is called the Zeeman effect,
or Zeeman splitting, which underlies every observation in NMR spectroscopy.
A 1H nucleus has a ½ spin. It, therefore, has |2*(½)| + 1 = 2 stable spin states. When a B0
is applied, the magnetic moment of the 1H will precess about the B0 in one of its two
stable energy states, which is either parallel or anti-parallel to the B0 (Fig 1-4). The
parallel alignment is the lower energy state, so, at body temperatures, there will be a
small excess of nuclei in the parallel state relative to the anti-parallel. The interaction of
B0 with the particle’s magnetic moment results in a torque that will cause the precession
of the nuclei about the B0, and the speed of this precession is proportional to the strength
of the B0. This relationship between the precession frequency (ω) and the B0 is the
Larmor equation:
𝜔0 = 𝛾 ∗ 𝐵0

1.1

where γ is the gyromagnetic ratio, a nucleus specific value for the ratio between the
magnetic moment and the spin angular momentum. In a 1H nucleus, γ is equal to
267.52*106 rad/(s*T). Due to the excess number of 1H nuclei in the parallel orientation,
there is an accumulation of magnetic moments that leads to a bulk magnetization (M0z) in
the longitudinal axis (z-axis). By applying an additional magnetic field (B1)
perpendicularly to B0 and at the resonant frequency ω0 it is possible to tip M0 out of
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alignment with B0 and into the transverse (xy) plane (M0xy) (Fig. 1-5). Figure 1.5 assumes
that the axes are precessing about B0 at ω0. This is called the rotating frame of reference.
By choosing to view the magnetization with this rotating frame of reference, it is easy to
visualize the magnetization being tipped by the B1 pulse:
𝜃 = 𝜔1 ∗ 𝑇

1.2

where θ is the nutation angle, T is the pulse duration, and ω1 is the frequency in the
rotating frame:
𝜔1 = 𝛾 ∗ 𝐵1

1.3

The transfer of M0z to M0xy is known as an “excitation pulse”, and it enables the detection
of the precessing magnetization via an electromotive force induced into a nearby
radiofrequency (RF) coil. The electromotive force can be measured as a voltage using a
digital voltmeter with a high sampling rate (~1GHz). This voltage is what is typically
known as the NMR signal.

1.2.2

Relaxation

After Mz has been transferred to Mxy, the magnetization will gradually return back to Mz.
This process is called spin-lattice relaxation, or T1 relaxation:
𝑀𝑧 (𝑡) = 𝑀0 ∗ (1 − 𝑒

−

𝑡
𝑇1 )

1.4

where Mz(t) is Mz with respect to time, M0 is the magnitude of the equilibrium
magnetization vector, t is time, and T1 is the time required for the signal to recover (1-e-1)
of Mz. The greatest amount of signal is induced into the RF coils when Mz = 0, and all the
magnetization is in the Mxy plane (Mxy=M0). In this case, the excitation pulse is known as
a 90° flip angle. The T1 relaxation is an important factor in determining the time between
successive excitations. If Mz has not recovered sufficiently there will be less
magnetization transferred into Mxy in the following acquisition. The most basic NMR
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Figure 1-4. The precession of spin-1/2 nuclei in the presence of a magnetic field (B0)
will preferentially orient parallel to the applied field

18

Figure 1-5. Excitation and refocusing of the magnetization in a spin-echo sequence
(A) In the presence of an external magnetic field, B0, the magnetization in the z-axis,
Mz, is initially equivalent to the resting magnetization, M0. (B) After a 90° excitation,
the Mz component is fully transferred to the transverse magnetization, Mxy and (C)
will immediately begin to dephase. (D) After applying a 180° pulse, the Mxy is flipped
and begins to rephase. (E) This can be visualized by examining the signal in the time
domain.
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pulse sequence, the “pulse-acquire” sequence, consists of one 90° excitation RF pulse
tipping Mz into Mxy immediately followed by a signal recording the induced
electromotive force into the RF coil. This signal is recorded as a free-induction decay
(FID), which is heavily influenced by another form of relaxation called spin-spin
relaxation or T2 relaxation.
To reiterate, the ω0 is determined by the γ and the B0. Although efforts are made to make
the local magnetic field over the volume of interest as homogenous as possible, the B0
produced by the MRI and the magnetic characteristics of local environments at the
microscopic scale (i.e. local sources of magnetic field distortions, such as blood vessels
and interaction between intra- and extra-molecular spins) are still going to be
heterogeneous (static dephasing) and fluctuate randomly in time (dynamic dephasing).
The relaxation of the Mxy in the xy-plane due to the presence of fluctuations in the local
magnetic environments of individual spins at the microscopic level is the cause of T2
relaxation. The Mxy will eventually decay to 0 due to this relaxation. The overall effective
decay rate observed during as FID, T2*, has two components:
1
1
1
=
+
∗
𝑇2
𝑇2 𝑇2′

1.5

where T2 represents the irreversible decay, T2’ represents a reversible component. The
Mxy decay is an exponential decay:
𝑡

𝑀𝑥𝑦 (𝑡) = 𝑀0 ∗ 𝑒 −𝑇2∗

1.6

where Mxy(t) is the magnitude of the transverse magnetization changing in time, and T2* is
the observed time for Mxy to decay to e-1 of its original value. T2 relaxation is specific to
the transverse magnetization, while T1 relaxation is specific to the longitudinal
magnetization. During T2 decay, the bulk magnetization is still in Mxy, it is just out of
phase. Within a voxel, there are many pockets of spins that experience the same local and
relatively unchanging magnetic field called isochromats. These isochromats will accrue
phase differences relative to each other. By applying a 180° pulse, the Mxy will flip and
the isochromats will rephase forming an “echo” (Fig 1-5). Most 1H-MRS pulse sequences
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utilize some echo formation method to refocus some of the reversible decay. As the rate
of T2 decay is slower than the rate of T2*, echo formation allows for a significant delay
between the excitation pulse and the sampling of the signal. This delay is required to
implement the essential step of spatial encoding of the MR signal allowing the selection
of signals from a given volume of interest rather than from the entire sample.

1.2.3

Electron shielding and chemical shift

If all 1H nuclei experienced the same magnetic field, they would all resonate at the same
ω0. Fortunately for 1H-MRS, the local magnetic field differs from B0 due to the
weakening of B0 from the electron spins surrounding adjacent nuclei within the chemical
structure of a molecule. This phenomenon is called electron shielding. 1H-MRS would
not yield useful information without the frequency difference that results from electron
shielding as each 1H will resonate at a specific frequency determined by both B0 and its
local magnetic environment. The contributions to the local magnetic environment from
surrounding nuclei is much smaller than the contribution of the B0. It translates to a
difference in frequency on the order of Hz, which is considerably smaller than
frequencies in the MHz range from the main B0. This shift in frequency is called the
chemical shift:
𝜔𝑠ℎ𝑖𝑒𝑙𝑑 = 𝛾 ∗ 𝐵0 (1 − )

1.7

where ωshield is the resonant frequency of the shielded resonance, and  is the shielding
constant. It is common to refer to the chemical shift in a parts per million (ppm) scale:

 =

𝜔0 −𝜔𝑠ℎ𝑖𝑒𝑙𝑑
𝜔0

𝑥 106

1.8

with  as the resonance frequency in ppm and 𝜔0 as the frequency of a resonance at B0.
In 1H NMR, 0 ppm is represented by tetramethylsilane (TMS). TMS contains 4 CH3
groups attached to one Si. Each of the 1H nuclei are maximally shielded by surrounding
electrons. As shielding decreases, the ppm value increases. The ppm scale is convenient
because there are multiple common B0 utilized in MRI studies and the  of each 1H nuclei
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does not change with B0. For example, creatine resonates at 191.6 Hz relative to TMS at
1.5 T, 383.2 Hz on a 3 T and 894.1 Hz on a 7 T. Using ppm values, creatine resonates at
3.02 ppm relative to TMS at all fields. Electron shielding determines the ω, but the
shapes of spectra originating from molecules with more than one proton are complicated
by the intra-molecular interaction of spins (via their electron spin), an effect known as Jcoupling.

1.2.4

J-coupling

Also known as peak-splitting, J-coupling refers to the possibility that multiple local
magnetic field environments are possible within a molecule, which can reduce one strong
singlet peak into multiple smaller peaks (Fig 1-6). This can best be understood with an
example. The molecular structure of GLU is shown in Figure 1-2A, featuring five protons
(hydrogen nuclei). Each 1H nuclei attached to the C4 (carbon atom number 4) can align
itself with or against B0. They both can be up, they both can be down, or one can be up
and one can be down with the latter option having twice the probability. This means
there are three different local magnetic fields possible that the 1H nuclei on the C3 can
experience due to the 1H nuclei on the C4, splitting a singlet from a 1H on the C3 into a
triplet. The triplet is then further split into a complicated multiplet due to significant
interaction with the 1H nuclei on the C2, which can also align themselves with or against
the magnetic field. Peak splitting reduces the amplitude of the signal from resonances
closer to the level of noise, and widens the spectral signature for a given metabolite,
further complicating quantification.
Spin pairs can be strongly coupled (AB) or weakly coupled (AX). J-coupling leads to
phase cancellation within a multiplet, called J-dephasing. Stronger coupling accentuates
these effects and further complicates the relative amplitudes of the peaks that are being
split. Weak coupling will perform in very predictable ratios according to Pascal’s
triangle, while strong coupling will skew the proportions based on how strongly they are
coupled (Fig. 1-6). The coupling strength is determined by the relative magnitude of the
J-coupling constant to the differences in resonance frequency. For example, heteronuclear
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coupling (i.e. between a 1H spin and a 13C spin) would be very weakly coupled due to the
large differences in their resonant frequencies (i.e. MHz). GLU and GLN are examples of
two metabolites that experience strong J-coupling resulting in broader spectral patterns.
Due to the similar chemical structures between GLU and GLN, this broadening of the
spectral patterns leads to much overlap and can make them very hard to differentiate in
1

H-MRS. Fortunately, it is possible to reduce the influence of J-dephasing. The local

Figure 1-6. The splitting of peaks in coupled spin systems.
When the J-constant between two resonances, JAB, is comparable to the relative
difference between the centers of the two resonant frequencies, ωA and ωB, the pair
is deemed to be strongly coupled (i.e. AB). When JAB is not comparable to the
difference between ωA and ωB, as in heteronuclear systems, for example, the pair is
considered to be weakly coupled (i.e. AX).
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magnetic field differences due to the multiple possible spin orientations that cause Jcoupling are not influenced by B0. Therefore, on a ppm scale, as B0 increases, the shape
of the multiplets slowly begin to converge towards being a single peak (unresolved
multiplet). This increases the peaks’ signal above the noise, and reduces the peaks’
overlap with other spectral signatures. This effect will be described in greater detail in
chapter 2.

1.2.5

Ultra-High Field (≥ 7 T) Spectroscopy

One of the biggest determinants of spectral quality is the B0 strength of the MRI.
Although stronger B0 MRI scanners can be expensive, there are many potential benefits.
As mentioned in the above section, strong B0 reduces the influence of strong J-coupling
on the spectral lineshape on a ppm scale. By a similar argument, the spectral dispersion
of the spectra also improves. That is, the ratio of the distance between peaks of two
different 1H nuclei and their Lorentzian linewidths is increased, which results in sharper
peaks and less spectral overlap between metabolites. Some of the improvements in
spectral dispersion are countered by increased Lorentzian linewidths (decreased T2*) at
stronger B0 that increase in vivo at a rate of 1.35 Hz/T114. The linewidths are a measure of
the exponential T2* decay of the signal, such that slowly decaying signals (i.e. long T2*)
will have sharper spectral peaks than fast decaying signals (i.e. short T2*). Even with this
broadening of the resonance, there is still a net reduction in spectral overlap when B0
increases (assuming similar conditions).
A stronger B0 causes more 1H nuclei to align themselves parallel to the field. It also
induces more torque on the spin, leading to a faster ω (in accordance with the Larmor
frequency, Eq 1.1). All together, the SNR improves as B0 strengthens with an
approximately linear relationship when scanning humans115. 1H-MRS is a traditionally
low SNR technique and requires many signal averages (addition of repeated
measurements). In NMR, SNR is essentially a currency that can be traded for smaller
voxels to reduce partial volume effect on small brain structures, faster scan times (by
reducing averages) to reduce patient motion during the scan (and perhaps scan more
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voxels), or it can simply be used for improved quantification of the data. Therefore, there
are huge potential improvements that can be realized using ultra-high field B0, but there
are also challenges to overcome.
As the main B0 increases, so do the technical limitations. For example, the wavelength of
a B1 pulse in human brain tissue at 3 T is approximately 30cm. At 7 T, this wavelength is
approximately 13cm, which is also approximately the width of the human head. This is a
problem in imaging because there will be bright and dark spots throughout the volume
due to the nodes of the electromagnetic B1 pulse. Fortunately for spectroscopy, the phase
of the B1 pulse does not change substantially over a typically sized voxel. This problem
can effectively be mitigated in 1H-MRS by using an increased number of transmitters and
B1 shimming116.
A limitation of ultra-high field B0 1H-MRS is that the power required for a B1 pulse to
achieve a given ω1 increases with B0117. Although B1 shimming can help this issue,
hardware limitations and increased thermal energy deposition, or specific absorption rate
(SAR), are real problems at high B0. This needs to be considered during sequence
development.

1.2.6

Voxel localization

In vivo 1H-MRS is generally divided into single-voxel 1H-MRS (SVS) techniques and
chemical shift imaging (CSI) techniques. CSI outputs spectra from a slab or volume of
voxels, while SVS generally only outputs a spectrum from one or two voxels. There are
advantages and disadvantages to both techniques. With CSI it is obviously a benefit to
have multiple spectra from throughout the volume. This is especially good for observing
the three strongest singlet signals in 1H-MRS, namely N-acetylaspartate (NAA), creatine
(Cr), and choline (Cho). The disadvantages to CSI include the potentially very long
acquisition times, the contamination of the spectra from signals outside each voxel (point
spread function), and the increased linewidths from poorer B0 shims throughout the brain
that lead to reduced spectral quality111. SVS has superior spectral quality to CSI. It is
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much easier to shim over one localized voxel than it is to shim over the entire brain, the
SVS spectra can be acquired individually then easily frequency and phase corrected,
signals from outside the voxel can be suppressed using outer volume suppression (OVS)
techniques and there is usually sufficient time to acquire a water unsuppressed spectrum
and a metabolite suppressed spectrum (discussed below) to strongly improve overall
quantification of metabolites. Only SVS spectra were acquired for this thesis due to the
superior spectral quality required for quantification of glutamate and glutamine. For the
remainder of the thesis, 1H-MRS will refer to SVS.
As previously mentioned, most 1H-MRS pulse sequences utilize some method to refocus
Mxy. This is more of a necessity because 1H-MRS pulse sequences require voxel
localization. Voxel localization is the process by which the tissue within a specific
volume becomes excited while leaving the area around it in a relaxed or un-refocused
state. This is typically done using three slice-selective B1 pulses and orthogonal magnetic
field gradients. Magnetic field gradient pulses create magnetic field intensity distributions
throughout the volume that vary linearly along a selected direction. A slice-selective RF
pulse with a specific carrier frequency, excitation bandwidth, and gradient amplitude
alters B0 (and, therefore, ω0) along the axis of the gradient pulse and will excite a specific
slab within the volume (Fig 1-7). If this is done along all three axes then there will be a
rectangular volume at the intersection of all three slabs, the 1H-MRS voxel, from which
1

H-MRS signal will be refocused (generation of an echo signal). This process allows

selection of voxel position, shape, and volume. The two most common 1H-MRS
techniques for voxel localization are Stimulated Echo Acquisition Mode (STEAM)118 and
Point-Resolved Spectroscopy (PRESS)119, both of which have their advantages and
disadvantages120.
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Figure 1-7. Slice-selection frequency bandwidth for a slice thickness and position.
A slice-select gradient, given by the equation ω= γ * (B0+Gz*z), can create a
difference in the local magnetic field in one direction across a volume. Therefore, a
specific excitation bandwidth, Δω, can be used to excite a specific slice, Δz, while
leaving the remaining volume unexcited.
PRESS is a powerful technique that utilizes a slice-selective 90° pulse followed by two
slice selective 180° pulses. The initial 90° pulse will excite a slab by flipping the signal
from the longitudinal axis into the transverse axis (Mz to Mxy). The first 180° pulse will
excite another slab along a different axis, which will effectively flip the Mxy
magnetization about the z-axis in the voxel of interest. The final 180° pulse excites the
final slab that flips the magnetization within the voxel one more time about the z-axis and
leads to a spin echo from the voxel at a certain echo time (TE).
STEAM (Fig 1-8) utilizes three 90° pulses instead of the 90°, 180°, 180° combination for
PRESS. The first 90° pulse excites a slab similar to the first pulse in PRESS. The
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second 90° pulse then flips the signal from the voxel into the longitudinal axis for a
duration known as the mixing time (TM), before the final 90° pulse flips the signal back
into the transverse plane to form a stimulated echo. The 90° pulses require less power and
deposit less thermal energy, or SAR, into the volume. At high B0, power and SAR
become serious limitations during sequence development. The 90° pulses also have better
slice profiles, which means that the spectra will have less contributions from signals
outside the nominal voxel volume (the theoretical rectangular prism defining the desired
voxel boundaries). The TM can be much longer than the TE, which means that additional
saturation pulses and crusher gradients can be played out during this time without
reducing the signal (with the exception of some T1 relaxation). In addition, due to the
temporary storage of the magnetization into the longitudinal axis during the TM, the
sequence can have a shorter TE than a PRESS sequence. Lower TE reduce the amount of
signal decay from T2 relaxation and reduce the signal lost to J-dephasing in J-coupled
metabolites. Due to the strong coupling of GLU and GLN signals, lower TE are
desirable. A downside to the STEAM sequence is that only half of the magnetization gets
restored into the transverse plane, leading to half of the measured signal from the voxel
and reduces the SNR. However, this is partially compensated by the reduced achievable
TE. There are many benefits to STEAM at high B0, so it will be used for all 1H-MRS
measurements in this thesis and has been used by our lab previously22,24

1.2.7

Water Saturation

One of the obstacles to overcome with 1H-MRS is the overwhelming signal from the two
1

H nuclei in water molecules. In the human brain, the concentration of water is

approximately 37 mol/L121. This is huge in comparison to the concentrations of
metabolites of interest that are generally in the 1-10mmol/L range, approximately four
orders of magnitude smaller. It would not be possible to reliably measure metabolites in
vivo 1H-MRS without an effective means to remove the water signal peak located at 4.7
ppm. The typical method to do this involves a hard narrowband B1 pulse centered on 4.7
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Figure 1-8. The 1H-MRS STEAM pulse sequence with VAPOR water suppression.
The sequence begins with VAPOR water suppression, which has 8 radiofrequency
(RF) pulses that are chemical shift selective (CHESS) and 1 block of outer volume
suppression (OVS) interleaved between the 7 Th and 8th pulses. Voxel selection is
then performed by a STEAM sequence that has three slice-selective pulses one in
each axis. An additional water suppression pulse has been added in-between the 2nd
and 3rd slice-selective pulses. Gx, Gy and Gz represent gradients that are played out
in each of the x, y, and z axis, respectively.
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ppm that selectively excites the water signal into Mxy prior to the start of the voxel
localization sequence. The water signal is then sufficiently crushed using magnetic field
gradients, eliminating the detectable component of the water signal. It is common
practice to use multiple B1 pulses to provide more efficient suppression. One such
sequence, Variable Power and Optimized Relaxation Delays (VAPOR)122, involves eight
B1 pulses separated by crusher gradients and timing intervals is particularly insensitive to
small variations in B1 pulse power, which typically needs to be optimized at the start of
each acquisition. An example of a VAPOR water suppression sequence that could be
played out prior to a STEAM sequence is in Fig. 1-8.

1.2.8

Post-processing

After the FID for the spectra have been recorded there are multiple processing steps
necessary before the data is ready to be quantified.

1.2.8.1

Receiver combination

Most head coils have a multiple-receiver setup, especially if the brain area of interest is
not located on the periphery. Each coil will record a FID for every 1H-MRS acquisition.
Some of these coils will be close to the signal source, while others may be far away and
acquiring lower signal (mostly noise). Most resulting FIDs will be out of phase with each
other. For these reasons, spectra should not simply all be added together. This could add
noise unnecessarily, and the out of phase components will add at least somewhat
destructively. A method has been developed for optimal receiver combination that uses
the phases and amplitudes of the unsuppressed water peaks123. The phase of the water
signal from each coil is recorded and adjusted relative to the signal in the first coil. The
spectra can then be added constructively. The amplitudes of the water signal determine
the relative weighting of each spectrum so that the water suppressed spectra that are
acquiring mostly noise will contribute much less than spectra with lots of signal. After
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the receivers have been combined, the spectra are ready for frequency and phase
correction.

1.2.8.2
1

Frequency and phase correction

H-MRS acquisitions often require the combination of many spectra to acquire a

spectrum with adequate SNR. During long acquisitions, some frequency drift may occur
due to the heating up of the gradients and some phase shifts may occur due to subject
motion. That’s why it is important to collect the spectra individually and correct the
frequency and phase prior to averaging the spectra together. If left uncorrected, the
frequency shift between successive spectra will blur the resulting combined spectrum and
the phase offset between successive spectra will cause destructive addition. To correct the
frequency of each individual spectrum, one simply tracks the frequency of a prominent
spectral peak (i.e. Cr, Cho, NAA) and adjusts the frequency to each spectrum relative to
that of the first spectrum. To correct the phase, examine the phase of the first few points
of the FID and adjust the phase of each spectrum relative to that of the first spectrum.
This will ensure the optimal combination of the data (i.e. frequency- and phase-coherent
averaging).

1.2.8.3

Averaging

Now that the spectra from each of the receive channels have been combined and the data
have been frequency and phase corrected, the individually acquired spectra may now be
combined into one higher quality spectrum. With all the preprocessing complete, all that
is necessary is to add the spectra together. This will improve the SNR of the spectra at a
rate proportional to the root of the number of averages:
𝑆𝑁𝑅 α √𝑁𝐴𝑉𝐺

1.9

where NAVG is the number of averages. This is another reason why stronger B0 is important
for increasing the SNR, as it takes four times as many averages to double the SNR from an

31

acquisition. For example, it would take 3 minutes 12 seconds to acquire a 64 average
spectrum at 7 T. To acquire a spectrum with the same SNR at 3 T, this would take 17
minutes 25 seconds (5.4 times as long), assuming similar voxel conditions (i.e. volume,
location, etc) and the main source of the noise is the sample.

1.2.8.4

Lineshape correction

When a FID is acquired it typically does not decay with the perfect lineshape that would
be predicted from Eq 1.4. The main contributions to lineshape imperfections come from
magnetic field inhomogeneities and eddy-current artifacts. The magnetic field
inhomogeneities are often unavoidable but can be minimized by using a good B0
shimming algorithm. The eddy-current artifacts come from ramping magnetic field
gradients pulses shortly prior to signal acquisitions. This induces currents into the
cryostat of the scanner, which induces temporally decaying B0 offsets. These eddy
currents tend to be more pronounced in short-TE spectra because the last crusher gradient
is played out right before the acquisition of the FID (A longer TE would allow the eddycurrents to dissipate). These can greatly distort the lineshapes of spectral peaks and
ultimately make it difficult to predict the lineshape to use for fitting. Through a process
called Quality Eddy Current Correction (QUECC), it is possible to remove the eddy
current artifacts and remove the majority of the lineshape imperfections due to magnetic
field inhomogeneities124. QUECC requires a reference lineshape to deconvolve form the
spectrum. This lineshape reference is typically the water peak obtained from a waterunsuppressed spectrum. It is, therefore, necessary to acquire a water-unsuppressed
spectrum that produces the same eddy-current artifacts as those observed in the watersuppressed acquisition (matched gradient waveforms, i.e. only RF off). Essentially, the
water suppressed data is divided (complex division) by the water unsuppressed data and
convolved with a Lorentzian function to make all peaks in the spectrum Lorentzian. This
is done only until the water signal approaches 0 else there will be a characteristic artifact
in the data. The remainder of the signal undergoes phase corrections only (no division by
amplitude of reference, only its phase term). QUECC allows one to use the working
assumption that the spectral lineshapes are Lorentzian for the purpose of data modelling.
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1.2.9

Spectral Fitting

Now that the post-processing is complete, the next step is to quantify the data. Every
peak (excluding spectral noise) represents signal from the 1H of a particular metabolite
and the area underneath the peak will be proportional to the concentration of that
metabolite in the volume of interest. There are usually contributions from 1H nuclei of
many metabolites that often overlap and can make the spectrum very complicated. To
isolate a metabolite’s contribution to the signal, it is first necessary to know their unique
spectral signatures.

1.2.9.1

A priori information

Fitting a 1H-MRS spectrum requires a priori information (prior knowledge) about the
relative distribution of resonances from each metabolite’s 1H nuclei. Each metabolite has
a characteristic pattern of resonances with predictable relative amplitudes and chemical
shifts known as a spectral signature. Every resonance from a metabolite varies in
amplitude together so it is possible to model the spectral signatures by constraining the
predictable information together. There are multiple methods to determine the relative
resonances for each metabolite with a specific 1H-MRS pulse sequence and B0 (because
both will influence the fit). First, in vitro metabolite solutions (i.e. phantoms) containing
only one metabolite and a reference (TMS for reference at 0 ppm) can be scanned and
modelled. This will provide a spectrum with the predictable resonance pattern that can be
modelled iteratively with the relative amplitudes, chemical shifts, phases, and linewidths
of each resonance of the pattern appropriately constrained. This information would be
located in two files known as a .ges or a .cst files. The .cst file or “constraint” file, holds
all the set relationships between the properties of individual peaks within the metabolite’s
spectral signature (Fig 1-9A), while the spectrum specific initial parameter estimates for
each metabolite (not each resonance) are located in the .ges files (i.e. “guess” file; Fig 19B). The information in the .ges file is used to seed the iterative fitting algorithm that will
provide an estimate of each metabolite’s concentration.

33

Another method to determine the spectral signatures for each metabolite is to simulate
responses of a given spin system with known chemical shifts and coupling constants104,125
to a particular pulse sequence using density operator calculations or product operator
formalism. The advantage to the simulation method is that it can quickly produce exact
representations of the spectral signatures for a given TE and TM of the STEAM sequence
that can readily be incorporated into .ges and .cst files. Of course, the development of the
simulation package for a specific pulse sequence is a specific scientific effort and was not
part of this thesis (more details provided in chapter 2)125.
A full template that can be used for metabolite quantification of in vivo spectra can be
made by combining .ges and .cst files from each metabolite into one pair of large .ges and
.cst files. This works well if a complete list of metabolites contained in the spectrum is
known. This is not always the case. For example, the exact molecules producing the
broad, so called macromolecular, resonances part of short-TE human brain spectra are
typically not known.

1.2.9.2

Macromolecular fitting

One of the biggest challenges in quantification of short-echo 1H-MRS spectra is the issue
of modeling the broad, fast-relaxing macromolecular components that overlap metabolite
signals throughout the spectrum. This macromolecular baseline is composed of DNA,
RNA, proteins and phospholipids. The signal is most prominent at low TE, so one way to
reduce their influence in the spectrum is by using very long TE. However, this is not a
practical approach for quantifying strongly coupled metabolites such as GLU and GLN
that have highest signal at low TE63. Another way to account for the macromolecules is to
acquire a separate metabolite- (and water-) suppressed spectrum that will leave only
signal from the macromolecules remaining. One method to go about this is to use
multiple well-timed inversion recovery pulses that effectively saturate the metabolite
signal prior to the STEAM acquisition. This macromolecular signal can then be modeled
using a Hankel-Lanczos Singular Value Decomposition (HLSVD; Fig.1-10)126,127 fit,
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Figure 1-9. Resonance information as it would be listed in (A) .cst and (B) .ges files.
The .cst file contains the fitting parameters denoted by the { and } brackets, which
contain individual modifications for each resonance. The parameters that would be
constrained include the chemical shift (i.e. {shift}), the Lorentzian linewidth (i.e.
{lw}), the metabolite specific amplitude parameter (i.e. {glu} for glutamate), the
phase (i.e. {ph}), the delay time (i.e. {DT}), and the Gaussian linewidth (i.e. {WG}).
The “@” symbol indicates that the final value for the fit should be taken directly
from the .ges file. The .ges file includes the initial “guesses” for each parameter.
Values are only needed the first time a fitting parameter is used (or if there is an
“@” in the .cst file), which is why in this example only peak 1 has any values. The
*glu value is a variable that would be specific for modifying glutamate
concentrations, located for convenience at the top of the file. Due to the QUECC
lineshape correction employed in our lab, all Gaussian widths are set to 0.
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which will output a list of resonances that fit the data. These resonances can be
constrained together into a macromolecular spectral signature, and then added to the
quantification template.

1.2.9.3

fitMAN

Now that a template has been built with the resonances of each metabolite (and the
macromolecules) modelled and constrained, it is time to fit the spectrum using the timedomain iterative fitting algorithm, fitMAN128. The fitting algorithm takes the initial
estimate of the fit (constructed from the information in the .ges and .cst files) and
iteratively modifies the model parameters, within the given set of constraints, until the
difference between the data (from a .dat file) and the model (i.e. the residuals) is
minimized (i.e. the residuals are below a pre-defined acceptable level or after a
predefined maximum number of iterations has been reached as indicated in the header of
the .cst file). Upon completion, fitMAN will output the final fit parameters for every
resonance into a separate .out file to be used in determining the metabolite
concentrations.

1.2.9.4

Quantification

The amplitude of each resonance represents the signal contribution at t=0 in the time
domain. The total area occupied by the resonances of each metabolite can be determined
by adding up the amplitudes of each metabolite’s resonances from the .out file. This
estimate of the metabolite’s area can be used to estimate the metabolite’s concentration,
[Met], by using the area of the water signal as a reference of known concentration129:
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Figure 1-10. datSub, a user interface for the HLSVD fitting of macromolecules.
This program allows a user to overlay the (A) water suppressed spectrum with the
(B) macromolecular (metabolite and water suppressed) spectrum and (C) perform
an HLSVD fit of the macromolecules. (D) The residuals between the HLSVD fit and
the macromolecular spectrum can be viewed amplified by a factor of 10.
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where AM and AW is the spectral area of the metabolite and water, respectively, NAVG_M
and NAVG_W is the number of averages of the water suppressed spectrum and water
unsuppressed spectrum, respectively, GM and GW is the gain used in the water suppressed
acquisition and water unsuppressed spectrum, respectively, ScaleM and ScaleW is a
metabolite and water scaling factor (used for scaling the real and imaginary points of the
data spectrum), respectively, that can be found in the header of the original .dat files, 36.9
mol/L is the concentration of water in the brain, #protons is the number of protons
contributing to the metabolite’s spectral area, and %W is the percentage of tissue that is
water from that voxel. The %W is determined based on the amount of gray matter, white
matter, and CSF in the tissue129:
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where fgray, fwhite, and fCSF are the fractions of gray matter, white matter, and CSF in the
voxel, waterdensity is the density of water at body temperature (0.99299g/cm3),
watermolecularWeight is the molecular weight of water at body temperature (18.0152 g/mol),
0.81 is the fraction of water content in grey matter and 0.71 is the fraction of water
content in white matter129. Using this formula, it is possible to determine the
concentrations of metabolite spectra acquired in vivo. The typical concentration range of
detectable metabolites in vivo is 0.5-15 mmol/l for realistic acquisition times and voxel
sizes.
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1.3 Thesis Objectives
The ultimate purpose of this thesis is to learn more about the health of the glutamatergic
system in SZ using advanced hardware and methodology. Outlined below are specific
objectives with their associated hypothesis for chapters 2-5 of this thesis, respectively.

1.3.1

Demonstrate the benefits of ultra-high field for GLU and GLN
1
H-MRS

Prior to embarking on a challenging study using the new, advanced brain imaging
infrastructure that is the 7 T MRI scanner, it is wise to first demonstrate that the resulting
benefits are worth the significant effort involved. The first objective is to determine what
improvements in quantification can be expected as the B0 increases. One approach
consists in using a spectral simulation framework, such as the one previously mentioned
while describing the fitting process, to create metabolite quantification templates. These
simulations can generate spectra with known concentrations of a known list of
metabolites for a range of B0 and SNR, then use a Monte Carlo approach to repeatedly fit
noisy realizations of the simulated spectrum. With such large simulated datasets, one can
evaluate the factors affecting the precision and accuracy of the quantification procedure.
It is hypothesized that improvements in B0 and SNR will generally improve the
coefficients of variation of metabolite concentration estimates with the greatest
improvements being in J-coupled metabolites (i.e. GLU and GLN), while decreasing the
correlations between different metabolite concentration estimates due to the reduced
spectral overlap at higher B0 and reduced influence of noise on the variability of the fit
with higher SNR.
As B0 increases so do the number of metabolite peaks that rise above the level of the
noise and should be accounted for in the quantification template. Forming a complete list
of the metabolites that should be part of the quantification template is not a simple task.
There is currently no data-driven method to determine which metabolite should be
included versus omitted. The addition of extraneous metabolite signatures in the
quantification template increases the dimensionality of the spectral modelling problem
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and negatively affects the precision of all metabolites. If metabolites that should be
included are omitted, the spectral fitting algorithm will attempt to minimize residuals by
over- or under-estimating other metabolite considerations. This raises the question as to
which metabolites absorb the residual signal from these unaccounted metabolites, and
how could an incomplete quantification template influence the interpretation of the
existing large body of human brain MRS literature. It is hypothesized that metabolites
that overlap with each other will be influenced the most by an omitted metabolite, and
this will be more pronounced at lower B0 due to decreased spectral dispersion.
This thesis objective is explored in greater details in the article presented in chapter 2,
which was submitted for publication in Magnetic Resonance in Medicine. Revisions have
been requested by the reviewers prior to resubmission. These have been addressed in
chapter 6 of this thesis.

1.3.2

Examine glutamate, glutamine, and glycine in schizophrenia

The ACC and the thalamus are key nodes implicated in the symptoms of SZ, with
NMDA hypofunction as one of the leading theories. Past studies have implicated GLU
and GLN in SZ using 1H-MRS at lower B018,22,24. These studies should be replicated and
validated using the expected improvements in metabolite quantification of a 7 T MRI.
One limitation of previous studies is that the comparison is only of SZ to healthy
controls. The reality is that many of the symptoms of SZ are overlapped with other
disorders as well, such as in major depressive disorder (MDD). The inclusion of a
psychiatric control group would benefit the study and help improve the specificity of the
results. Therefore, metabolite concentrations will be assessed in the SZ group relative to
healthy controls and also to a psychiatric control group of MDD. It is possible that
NMDA hypofunction could be due abnormalities in GLU and GLN or to the
unavailability of GLY (lower glycine concentrations) in the synaptic cleft. It is
hypothesized that there will be increases in GLN and decreases in GLU in the SZ group
relative to the control groups based on the literature18,22,24. In addition, no study to date
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has examined GLY in SZ with 1H-MRS. It is hypothesized that there will be abnormal
GLY concentration in the SZ group relative to the control groups.
Our exploration of “resting” levels of GLU, GLN, and GLY in SZ compared to healthy
and MDD control groups is presented in chapter 3. This article has been prepared for
submission to The British Journal of Psychiatry.

1.3.3

Demonstrate glutamate changes with 1H-fMRS in the ACC
using a cognitive task

There have been many 1H-MRS studies that have demonstrated GLU and GLN
dysfunction in SZ. A limitation of these studies is that the concentrations have all been
measured in an uncontrolled “resting” state and at one time point. Of course, glutamate
concentrations are adjusted dynamically, at the microscopic level, when transitioning
from periods of rest (lower neuronal spiking activity) and periods of activity (higher
neuronal firing rates) in glutamatergic neurons. One way to assess the health of the GLUGLN cycle is to perform 1H-fMRS and assess GLU and GLN concentrations dynamically
during prolonged periods of controlled rest (visual fixation) versus periods of prolonged
functional activation (i.e. a cognitive task). There are no studies to date using 1H-fMRS
at 7 T to show GLU changes during a cognitive task, so the ability of 1H-fMRS to detect
such dynamic regulation of glutamate will first need to be demonstrated in healthy
controls. Based on other 1H-fMRS studies that have demonstrated GLU changes after
visual or motor stimulation75–77,80,81, it is hypothesized that a color-word Stroop task will
stimulate the ACC and increase GLU concentrations upon functional activation.
The results of the study conducted based on these scientific questions have been
published in NeuroReport and form the contents of chapter 4.
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1.3.4

Examine 1H-fMRS in the ACC using a cognitive task in
schizophrenia

Once the 1H-fMRS in the ACC has been established in healthy controls, the next step is
to implement this in individuals with SZ and MDD (psychiatric control group). Due to
the abnormal GLU and GLN concentrations that have been reported in “resting” 1H-MRS
studies in SZ, it is hypothesized that dysfunctions of the GLU-GLN cycle will manifest
themselves as abnormal modulation of either GLU or GLN concentrations in response to
functional activation.
The results of this study have been accepted for publication in npj Schizophrenia and
form the contents of chapter 5.
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Chapter 2

2

Sources of Variability in the quantification of short-echo
time human brain 1H-MRS spectra

The work presented in this chapter was done to learn more about how specific sources of
variability can influence metabolite quantification, with a focus on J-coupled metabolites
and magnetic field strength. A version of this work is currently being edited for a
resubmission to publish in Magnetic Resonance in Medicine. The reviewers’ comments
to the initial submission are addressed in chapter 6.

2.1 Introduction
Proton MR Spectroscopy (1H-MRS) is a useful technique for non-invasively determining
in-vivo metabolite concentrations of the human brain. Brain disorders, such as
neuropsychiatric illnesses, have been studied extensively with 1H-MRS1. Detection of
Glutamate (GLU) and glutamine (GLN) with 1H-MRS is of particular interest in
neuropsychiatric disorders thought to feature abnormalities of neurotransmitter
metabolism2. GLU and GLN have only slightly different molecular structures and, as
such, the protons have similar electromagnetic environments. In a 1H-MRS spectrum,
this translates to overlapping spectral signatures and makes independent estimates of their
concentration more challenging. Quantitative estimates of metabolite concentrations are
also influenced by 1H-MRS data quality, modeling method and model completeness.
Low signal-to-noise ratios (SNR) are an inherent feature of 1H-MRS spectra, often
making it difficult to differentiate metabolite signals from background noise. Previous
publications have used simulations to study how SNR influences 1H-MRS quantitation of
metabolites3–5. It was shown that the SNR had an effect on the standard deviation of
metabolite concentrations estimates. Therefore, SNR is an important variable to control
for in any simulation study.

56

It is often difficult to observe metabolite spectral peaks independently due to strong
spectral overlap. It is believed that as peak overlap is reduced there is less covariation in
metabolite concentration estimates. Mitigation of overlap can be achieved through
various strategies. One strategy, increasing the external magnetic field strength (B0),
leads to increased spectral dispersion, reduced influence of J-dephasing for metabolites
with strongly coupled spin (higher-order J-coupling) and a linear SNR increase
(assuming body noise dominance). Particularly, higher B0 reduces overlap in GLU and
GLN signals (C4 protons) and reduces signal loss through J-dephasing (Fig. 2-1).
However, even at B0 as high as 7.0T, there is still much overlap as some of the gain in
peak separation from spectral dispersion is offset by shortening of T2*(increased peak
linewidths (LW)). It is expected that spectral dispersion linewidths and J-coupling will
affect the quantification precision (modeling) of data from coupled metabolites.

Figure 2-1. Simulated chemical signatures of GLU and GLN.
GLU and GLN are two strongly coupled and overlapping metabolites in 1H-MRS
spectra. They are simulated across four B0, demonstrating apparent decreased
overlap as B0 increases.
Metabolite peak separation will influence the quantification algorithm’s ability to
converge to correct metabolite concentrations. Many metabolite quantification algorithms
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utilize a priori information for the metabolites’ spectral signatures6–8, which are
determined individually by acquiring the signal from a metabolite phantom or through the
use of simulation software. Fitting parameters for a metabolite’s peaks need to be
constrained to have specific, pre-determined amplitude ratios, 0th order phase offsets,
chemical shift offsets and LW offsets. Iterative fitting algorithms will require initial
values (seed values) for these parameters in order to compute the residual between the
data and the model. The algorithm will perform repeated trials of parameter changes
until convergence toward minimum residuals is achieved. When searching a vast
multidimensional minimization space for a global minimum, the final solution returned
by the fitting algorithm can become sensitive to the accuracy of the initialization
parameters and converge toward a local minimum. If it were possible to initialize the
algorithm with the known correct answer, the only source of metabolite concentration
variability would be random noise. Of course, this is not possible with in vivo data as the
correct answer is not known with certainty. Therefore, for in vivo 1H-MRS data,
variability due to noise cannot be separated from variability due to intra- and interindividual variability.
The 1H-MRS spectrum is composed of contributions from the protons of many
metabolites. Many of these are often not included in basis sets for quantification because
they are not represented by prominent peaks in human brain 1H-MRS spectra. This can
be due to low concentrations or because their peaks have been split into too broad of a
multiplet and as a result are on the order of the spectral noise. The inclusion of such
contributions is thought to unnecessarily complicate fits and increase overall variability
of concentration estimates. Either way, a metabolite that is not accounted for by the basis
set will leave additional spectral area that the fitting algorithm will still try to minimize
given the basis set provided. This can lead to errors in the estimates of metabolite
concentrations and it is not well known how these areas will propagate (only nearby
metabolites or remote metabolites). Therefore, if a basis set is not complete,
measurements of metabolite concentrations may actually represent contributions from a
number of metabolites and may decrease the quantification accuracy.
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The goal of this paper is to study factors influencing the quantification precision of brain
metabolites in controlled conditions similar to those encountered in vivo. Specifically,
simulations were conducted in this study to isolate and examine the effects of spectral
dispersion, weakened J-coupling versus changes in B0, the effect of noise, the effect of
inaccurate seeding values and the effect of template incompleteness on the variability of
metabolite concentration estimates.

2.1.1

Hypotheses

Due to the increased metabolite separation as B0 increases, the correlations between
metabolite concentration estimates in metabolites that experience strong coupling at low
B0 should generally decrease as B0 increases. This should also increase the precision of
metabolite concentration quantification.
It is hypothesized that higher SNR will result in higher inter-metabolite correlation
coefficient (r(METa,METb)) between the concentration estimates of two metabolite (a and b)
due to the decreasing interference of noise with the iterative modelling of the spectrum.
While fitting algorithms blindly perform the mathematical act of minimizing residuals,
spectral area from a metabolite not included in the quantification template can be
incorrectly assigned to another metabolite part of the template. It is hypothesized that
any metabolite omitted from a spectral basis set will result in corresponding
quantification errors in overlapping metabolites and that omitted metabolites will have
greater influence at lower B0 as there is greater spectral overlap between metabolites.We
hypothesize that the more inaccurate seed values of the fitting algorithm will result in
poorer precision of metabolite concentration estimates and greater amplitudes of intermetabolite correlations coefficients.
Finally, it is expected that the accuracy (measured mean concentrations minus expected
mean concentrations) will be generally unaffected by variations in B0, SNR, and initial
seed values of the fitting algorithm, whereas omitted metabolites will translate to reduced
accuracy of metabolites overlapping the omitted metabolite.
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2.2 Methods
Two sets of simulations were designed for this study. The first set thoroughly analyzed
the influences of B0, SNR, and the initial seeding of the quantification template. The
second set examined completeness of the basis set for quantification. They were all made
to be representative of in vivo human brain spectra at four common B0 (1.5 T, 3 T, 4 T, 7
T) that would be acquired with an ultra-short echo STEAM sequence (TE=6ms,
TM=32ms)9 and two SNR representative of what could be acquired with the averages
(nt) set to 64 and 256. TE values within 2ms have been used previously at all these B09–12.
The metabolite spectra included spectral signatures from 22 metabolites (glutamate
(GLU), glutamine (GLN), N-acetylaspartate (NAA), N-acetylaspartylglutamate (NAAG),
creatine (Cr), phosphocreatine (PCr), myo-inositol (Myo), choline (Cho),
Phosphorylcholine (PCho), glycerophosphorylcholine (GPCho), gamma aminobutyric
acid (GABA), serine (Ser), glycine (GLY), scyllo-inositol (Scy), phosphorylethanolamine
(PE), α-glucose (α-glc), β-glucose (β-glc), aspartate (Asp), alanine (Ala), glutathione
(GSH), lactate (Lac), taurine (Tau)). To provide an amplitude reference for calibration of
the SNR of simulated spectra that would be comparable to that commonly used in SNR
measurements of in vivo spectra, a singlet equivalent in concentration to the CH3 singlet
of NAA (10.3mmol/kgww)13 was added to the simulation, set upfield at 0.0 ppm so as to
not interfere with quantification. SNR was determined using the peak area definition of
SNR, which comes from the relative amplitude of the signal in the time-domain at t=0
compared to the standard deviation of the noise. The peak area definition is advantageous
because it is not influenced by the T2* changes with B0. Reference values from the
literature14 along with the assumption of linear SNR change with B0 and the common
SNR-to-nt (averages) relationship SNR1/SNR2=(nt1/nt2)0.5 were used to determine
representative SNR for nt=256 and nt=64. The resulting SNR for each B0 were 117 and
58.5 (7 T), 67 and 33.5 (4 T), 50 and 25 (3 T), 25 and 12.5 (1.5 T), for nt of 256 and 64,
respectively. Figure 2-2 shows example spectra for each B0 with nt=256. Additional
simulations were created for each B0 at an SNR of 1024 to minimize the variability
associated with the random distribution of noise. Each spectral signature was simulated
using GAVAgui, an in-house program designed by a medical physicist (J.T.). The
program is an interface to code designed by Brian Soher that uses the GAMMA
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simulations package to predict the response of spin systems to the STEAM pulse
sequence15. The interface allows the selection of a given echo time (TE), mixing time
(TM), B0 and spin system and transforms the output of the GAMMA simulation in a list
of the predicted resonances and their relative parameters compatible with the file format
of the Lawson Fitman Spectral Analysis Suite7,16. J-coupling constants and chemical
shifts used were derived from the literature13,17. A macromolecule (MM) signature was
added as well, composed of 15 resonances with combinations of Gaussian and Lorentzian
lineshapes, empirically determined to match a typical MM spectra (Fig. 2-3).
To model a spectrum containing MR signals from more than one metabolite, the
superposition of metabolites’ respective resonances must be constrained in order to
preserve their natural relative chemical shift (), LW, amplitude (An), 0th order phase (0)
and 1st order phase (d). Model constraints reduce the degrees of freedom of the
minimization problem submitted to the iterative fitting algorithm. Specifically, , LW,
0, and d of each resonance were linked within and between metabolites, whereas the
amplitudes of each resonance were linked within metabolites only (AMET(1-22)) and within
MM resonances (AMM). An additional chemical shift constraint was placed on the MM
signals, leading to a total of 28 fitting parameters (, MM, LW, 0, d, Amet (1-22), AMM). 0
and d order phases were initialized to 0. The LW has been shown to influence the
standard deviation of metabolite concentration estimates3,5 so, it will be set to 1.35 Hz/T
for each B0 based on work by Deelchand et al18.
To evaluate precision, 200 noisy realizations were produced and fit (in the time domain)
using fitMAN analysis software7 for each B0 and fitting template. The quantification
algorithm was seeded with the correct parameter values (exact seeding) and again with
two inexact metabolite templates that randomly varied the initial estimates of all fitting
parameters (inexact seeding). These inexact seeds more realistically represent the
variability associated with the manual iterative algorithm seeding step used to provide the
starting point of in vivo data modelling. Seed values for parameters 0, LW, , MM, Amet
(1-22),

AMM varied with a Gaussian distribution around 0.05 rad, 5%, 0.0025 ppm, 0.0025

ppm, 10% and 10%, respectively, for the first inexact seeding (IE1) and double these
values for the second inexact seeding (IE2) approach. Pseudo-random noise with
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Figure 2-2. The full simulated set (top) of metabolites (middle) and macromolecules
(bottom).

Gaussian distribution was added to each simulated spectra using Datsim, a program
developed in-house (J.T.) and part of the Lawson Fitman Spectral Analysis Suite7,16
Once all 200 noisy realizations have been fit for each B0, SNR, and template seeding
combination, the mean concentration (µ) of each metabolite is computed along with its
standard deviation () to get the Coefficient of Variation (CV):

CV 


 100%


2.1

The CV is taken to represent the quantification precision of a given metabolite’s
concentration. CV was chosen instead of Cramer-Rao Lower Bounds (CRLB)19 because
CV is a measure of the observed amount of variability including all sources, whereas
CRLBs are related to the minimum amount of variability observable given a specific
spectral quantification model. The interaction of the metabolite models during
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Figure 2-3. Example spectra for each B0 with 256 averages
quantification can be assessed using the following formula describing the inter-metabolite
correlation coefficient of metabolite ‘a’ (METa) and metabolite ‘b’ (METb):
r( METa , METb ) 

cov ( METa , METb,)

 METa  METb

2.2

where σMETa and σMETb are the standard deviations and cov(METa,METb) is the covariation,
represented by:

cov ( METa , METb) 

2
2
 (2METa  METb )   METa
  METb

2

where σ2(METa+METb) represents the variance of the sum of the two metabolites’
amplitudes.

2.3
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The accuracy will be assessed by comparing the mean concentration estimates for each
metabolite over all 200 noisy realizations relative to the actual known concentration.
Together, the CV, accuracy, and r(METa,METb) allow for a quantitative assessment of the
variability of concentration estimates of metabolite pairs and their interactions. Pearson’s
correlation were calculated and Sidak’s adjustment for multiple correlations corrected the
alpha value accordingly (p<0.00004 from p<0.01).
The same experimental design was used to evaluate the influence of a metabolite’s
omission from the basis set with IE1 seeding for 3 T and 7 T, with nt=64. Individual
metabolites were removed from the full quantification template, and 200 noisy
realizations of the complete spectra were then fit with the metabolite omitted. Omission
of the MM baseline was similarly explored. The correct concentration of each metabolite
is known, making it possible to determine which metabolites assume the remaining
spectral area of an omitted metabolite. The total spectral quantification error is defined to
be the resultant cumulative error in the remaining metabolites' concentration estimates
(measured-expected, µmol/g) when a metabolite is removed from the fitting template. In
total, 16800 simulated spectra were fit.

2.3 Results
Quantification precision (CV), accuracy, and r(METa,METb) were analyzed for every set of
simulations, excluding the metabolite omission simulations, which only looked at
accuracy of metabolite concentration estimates. Correlation tables were created for each
B0, SNR, and template seeding combination, with 253 possible correlations per table.
Significant r(METa,METb) are summarized in Table 2-1. The SNR had little impact on the
total significant r(METa,METb) (positive or negative) when the template was seeded with the
correct final answer. When seeded using IE1 or IE2, the total number of significant
r(METa,METb) increased with SNR. IE2 generally had more significant r(METa,METb) than IE1.
The magnitude of r(METa,METb) decreases with B0 when GLU and other coupled
metabolites (GLN, GABA, NAAG) are part of the metabolite pairs (Fig.2-4b). Metabolite
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pairs that make up the three largest singlet peaks in the spectrum at 2.01 ppm (NAANAAG), 3.03 ppm (Cr-PCr), and 3.21 ppm (GPCho-PCho) all still had strong r(METa,METb)
that did not seem to fluctuate with B0 (Fig 2-4c). Some metabolite pairs with GSH
seemed to initially decrease the magnitude of r(METa,METb) to a level below the significance
level, but eventually reached significance with opposite polarity from 1.5 T to 7 T (Fig.
2-4a).

Table 2-1. Significant correlations between metabolite concentration estimates
EXa
SNR

B0
7 T7 T
4T
1024
3T
1.5 T
7 T7 T
4T
ntf=256
3T
1.5 T
7 T7 T
4T
nt=64
3T
1.5 T
a
Exact seeding
b, c

+d
2
6
6
7
3
7
5
8
2
8
8
7

-e
4
3
4
3
6
4
6
3
7
6
4
4

Total
6
9
10
10
9
11
11
11
9
14
12
11

+
57
56
61
62
37
35
33
29
26
23
22
18

IE1b
Total
59
116
61
117
66
127
70
132
44
81
45
80
48
81
37
66
37
63
35
58
22
44
27
45

+
58
56
65
72
44
49
46
41
31
32
29
21

IE2c
59
60
75
67
45
53
59
45
42
45
45
33

Total
117
116
140
139
89
102
105
86
73
77
74
54

Inexact seeding 1 and inexact seeding 2, as described in the "Methods" section

d, e

Number of significant positive or negative correlations (p<0.01, Bonferroni corrected to
p<0.00004)
f

Number of averages
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Table 2-2. Metabolite precision (CV; %) across B0 with the SNR=1024 and IE1

GLN
GLU
NAAG
GABA
GSH
Tau
Ser
Cho
PCho
GPCho
Cr
PCr
Asp
α-Glc
β-Glc
NAA
Ala
Myo
PE
Lac
GLY
Scy

1.5 T
0.50
0.56
1.82
4.18
0.38
4.14
17.23
9.75
8.55
4.40
3.56
5.89
2.09
2.72
2.31
0.72
3.53
0.88
3.37
3.10
4.71
2.57

3T
0.44
0.34
2.38
2.14
0.50
4.08
27.42
10.63
8.24
4.28
4.04
5.59
3.91
5.39
3.48
0.84
3.76
0.85
4.79
4.92
4.32
1.37

4T
0.35
0.29
2.54
2.29
0.46
3.18
20.38
9.82
9.69
4.78
4.60
7.14
5.65
4.71
3.98
0.94
4.01
0.66
1.85
4.75
3.52
1.33

7T
0.30
0.23
2.35
1.98
0.29
2.57
19.35
9.75
8.45
4.10
4.35
6.58
6.79
2.85
4.14
0.97
2.81
0.39
2.35
4.27
1.39
1.06
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Figure 2-4. Correlations between metabolite concentration estimates.
Some of the main correlations found between metabolite concentration estimates as a
function of B0 with the IE1 template are displayed with linear lines of best fit.
Interacting metabolites are shown together in the legend. The dashed line in each
figure represents the significance threshold. A) Coupled metabolites are paired with
other coupled metabolites. B) Overlapping metabolites that make up the tallest
spectral peaks are paired. C) Metabolites paired with GSH that seemed to reverse
the polarity of the correlation strength
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Table 2-3. The increase in CV due to doubling initial fit seeding offsets

SNR

IE2/IE1a

12.5
1.36
1.5 T
25
1.40
1024
1.60
25
1.42
3T
50
1.41
1024
1.80
33.5
1.47
4T
67
1.31
1024
1.90
58.5
1.45
7T
117
1.37
1024
1.88
a
Inexact seeding 1 and 2, as defined in the "Methods" section

.

Figure 2-5. Metabolite spectra (top) with their fits overlaid along with the residual
from the fits (bottom) A) when MM has been omitted and B) with a complete
template
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Table 2-4. Metabolite precision (%) across B0 with nt=256 and IE1

GLN
GLU
NAAG
GABA
GSH
Tau
Ser
Cho
PCho
GPCho
Cr
PCr
Asp
α-Glc
β-Glc
NAA
Ala
Myo
PE
Lac
GLY
Scy

1.5 T
5.18
3.37
13.30
20.29
4.64
17.79
52.29
13.25
9.45
6.26
6.76
8.57
20.17
20.69
19.69
4.81
18.44
3.57
14.06
24.47
10.24
8.56

3T
3.07
1.67
13.13
10.27
2.88
15.62
42.59
13.17
9.44
5.74
6.37
6.97
18.60
13.56
17.07
4.43
13.48
2.40
10.78
18.57
10.24
5.65

4T
1.82
1.12
10.47
8.23
2.22
13.67
29.70
14.46
8.85
5.63
6.26
8.81
18.05
11.30
16.96
3.83
10.07
1.87
7.75
16.77
9.41
5.87

7T
0.97
0.68
5.43
4.26
1.17
7.22
31.38
14.41
9.18
4.67
5.70
8.05
12.69
8.52
11.25
2.26
7.19
1.04
6.52
9.37
5.21
4.01
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Table 2-5. Metabolite omissions from the fitting template (nt=64, IE1)

7T
Met
removeda
Noned
GLN
GLU
NAAG
Cr
Myo
Tau
Ser
Cho
PCho
GABA
GSH
Lac
Asp
α-Glc
β-Glc
NAA
Ala
PCr
PE
GPCho
MM
GLY
Scy

Total Spectral
Quantification
errorb (µmol/g)
0.13
4.62
10.02
3.09
8.39
4.79
1.84
0.77
0.71
1.93
2.63
4.79
0.28
1.13
1.39
0.90
19.94
0.48
5.82
2.16
4.89
24.92
1.17
0.93

3T
Largest
Errorc (Met,
µmol/g)
Cr
0.03
GLU
1.81
GLN
3.34
GLU
0.69
PCr
4.04
α-Glc
0.60
β-Glc
0.57
PE
0.28
PE
0.21
GPCho 0.49
GLU
0.42
GLN
1.20
Ser
-0.05
Ser
0.25
Ser
0.36
Tau
0.32
NAAG 7.13
α-Glc
0.09
Cr
2.31
Ser
0.89
PE
1.72
NAAG 2.80
Myo
0.49
Cho
-0.14

Total Spectral
Quantification
error (µmol/g)
0.30
6.30
13.37
3.16
9.92
7.04
1.75
1.05
1.03
5.56
3.27
10.18
0.46
0.92
1.54
1.40
19.37
0.45
7.24
2.57
4.82
23.16
1.30
1.67

Largest Error
(Met, µmol/g)
NAA
-0.05
GLU
2.61
GLN
5.05
GLU
0.79
PCr
3.80
GLY
2.52
β-Glc
0.45
PCr
0.26
PCr
0.35
NAA
-1.33
GLU
1.01
α-Glc
2.11
NAA
0.06
Tau
0.33
Ser
0.23
Tau
0.45
NAAG 8.23
α-Glc
0.08
Cr
1.79
Ser
0.76
PE
2.00
Lac
3.18
Myo
0.67
Tau
0.68

a

200 noisy realizations of the same data were fit with one (or zero) metabolites removed from the
fitting template
b

The resultant cumulative error in the remaining metabolites' concentration estimates (measuredexpected, µmol/g) when a metabolite is removed from the fitting template
c

The metabolite that had the largest spectral quantification error

d

No metabolites were removed from the fitting template
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The SNR, B0, and the seeding of the template all had important influences on the CV of
concentration estimates. When SNR doubled (from nt=64 to nt=256) the CV improved by
a factor of 1.96 on average over all metabolites and over all B0 using exact seeding of the
fitting algorithm. Using the IE1 and IE2 seeds, doubling SNR improved the CV by 1.52
and 1.47, respectively. Table 2-2 shows that there is lower CV at low B0 and high SNR
(1024) when exact seeding is used, but this is not consistent with the inexact seeding
models. There were improvements in some metabolites, namely GLU, GLN, GABA,
Myo, Tau, Scy, and GLY, while the remaining metabolites showed little variation, with
the exception of Asp and β-Glc, which seemed to get worse as B0 increased. There is also
a reduction in precision observed over all metabolite concentration estimates when going
from IE1 to IE2 (Table 2-3). This reduction factor increases at very high SNR
To isolate the influences on the CV specifically due to the changes in spectral signatures
of metabolites when the B0 changes, the SNR had to be equated. This was achieved by
running simulations with the SNR set to 1024 for all B0. The CV increased for every
metabolite as the B0 increased from 1.5 T to 7 T when using the exact seeding. However,
using the inexact seeding approach, GLU, GABA, GLN, Myo, Scy, GLY, and Tau all
exhibited decreased CV’s going from 1.5 T to 7 T for both the IE1 (Table 2-2) and IE2
(not shown) seeding techniques. All the remaining metabolites either had no change or
increased CV’s when B0 increased. Table 2-4 demonstrates improved CV’s at higher B0
when nt=256 at realistic SNR for each B0.
An additional evaluation of the influence of spectral lineshape changes due to B0 on CV
comes from the 1.5 T spectra with nt=256 and the 3 T spectra with nt=64 that both have
an SNR of 25. The quantity of significant r(METa,METb) were similar for exact seeding, but
were reduced in both the IE1 and IE2 seeding templates (Table 2-1) at 3 T compared to
1.5 T. The CV’s for GLU and GABA improved by factors of 1.34 and 1.35, respectively,
for 3 T using IE1, but, on average, all metabolite CV’s were 8% lower at 1.5 T.
The accuracy of the metabolites did not seem to be affected by the SNR, B0, nor the type
of seeding used. It was only the metabolite omissions that affected accuracy.
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The total spectral quantification error increased when any metabolite was excluded from
the basis set (Table 2-5). For comparison, the typical error that would be expected from
the full spectrum (i.e. no metabolite omissions) is also included in Table 2-5. As would
be expected, excluding the MM from the template created the largest errors in the fit as
its spectral area is broad and extends across all metabolites.

The fitting algorithm was able to efficiently account for the MM spectral area using the
remaining metabolites when the MM were not included in the basis set (Fig. 2-5). Where
there is little overlap between MM and other metabolites, the residual spectral area
resembles the corresponding portion of the MM spectrum with the exception of the
enlarged Lac doublet. However, where metabolites and MM overlap there is little
residual remaining. Omitting MM decreased total fitted spectral area by 10.10% and
8.82% at 3 T and 7 T, respectively. The only metabolite (with MM not considered to be a
metabolite) to alter the total spectral area of fitted metabolites by more than 1% when
omitted was NAA. The omission of NAA lead to total increases of 2.70% at 3 T and
2.56% at 7 T. Serine concentration estimates were the most susceptible to fitting errors
from incomplete fitting templates and were not within 10% of the correct concentration
when any metabolite was omitted.

2.4 Discussion
In this study, simulations were used to isolate some of the sources of variation
encountered in 1H-MRS such as: B0, SNR, algorithm seeding accuracy and
quantification template completeness. Quantitative understanding of these sources of
variability is important for study protocol optimization. Simulations were chosen to
minimize or remove competing sources of variability. A large number of simulated
spectra could easily be generated to improve statistical confidence.
Inexact seeding was chosen to examine variability associated with the initialization of the
quantification algorithm parameters. Iterative fitting algorithms are more likely to
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encounter a local minimum and return an incorrect parameter estimate when poorly
seeded. Therefore, when one parameter is fit poorly the other parameters must
compensate. This led to correlation between metabolite concentration estimates as there
were more correlations and decreased precision observed when the initial parameters
were fit with greater seeding variability. Quantitative relationships between IE1 and IE2
are more apparent when the influence of noise is minimized. With high SNR (1024) the
CV’s of IE2 are almost twice that of IE1. Therefore, greater seeding variability resulted
in a near linear increase in CV in the absence of noise. This demonstrates that a
substantial improvement can be seen in the CV of metabolite estimates by taking the time
to provide accurate initial estimates of the parameters to the fitting algorithm. Future
studies that aim to use simulations to study quantitative relationships should consider
using inexact fitting templates to better represent in vivo fitting.
The variability introduced with the initial seeding of the basis set can also be seen when
comparing to the exact seeding data with SNR of 1024. With the noise minimized and the
variability associated with the initial seeding removed, the main sources of variability
become the spectral separation and the linewidths. Both spectral separation and
metabolite linewidths increase with B0, so it would be expected that the spectral
separation would improve quantification precision while the linewidth would worsen it.
Because the precision was worse at higher B0, the increase in metabolite linewidths
influenced the fit more than the increase in spectral dispersion. This was not observed
when using inexact seeding, but can be explained by looking at the signal in the time
domain. The SNR definition chosen for this study corresponded to the amplitude of the
signal in the time domain at t=0, relative to the standard deviation of the noise. T2*
reduces as B0 increases leading to faster signal decay. Although the SNR, by definition,
remains the same between the different B0 examined, there is more signal at low B0 than
that which remains above the level of the noise during the sampling of the FID at higher
B0. The inexact seeding model better represents how the spectral dispersion and Jcoupling will affect the quantification precision, so the reduced CV at high B0 in Jcoupled metabolites indicates that the relative reduction in J-coupling (in ppm only)
improves the quantification precision, despite T2* reduction.
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When SNR=1024, two strongly coupled metabolites, GLU and GABA, showed
improvements in CV and reduced quantity of r(METa,METb) at 3 T compared to 1.5 T with
inexact seeding. This illustrates the benefits of weaker higher order J-coupling at higher
field strengths. In contrast, the majority of metabolites showed a slight reduction in CV at
1.5 T. The observed slight improvement in CV at 1.5 T compared to 3 T in most
metabolites is likely due to the signal decaying much slower at 1.5 T, resulting in more
points above the noise threshold to help the fitting algorithm converge to a final estimate.
Therefore, in the absence of the natural improvement in SNR at 3 T, the increased peak
separation did not translate to improved CV for the majority of metabolites.
Doubling SNR improved metabolite quantification, which agrees well with what has been
observed in previous studies3,4, and was consistent at each B0. The nearly two-fold (1.96)
increase in quantification precision when SNR is doubled using exact seeding
demonstrates an almost linear relationship between SNR and quantification precision.
The exact seeding presents an upper limit of improvements in CV from SNR alone so it
makes sense that quantification precision is reduced from this ideal relationship when
seeding variability is introduced. As the SNR increased, so did the number of significant
r(METa,METb) . It is likely that at low SNR the metabolite estimates are more heavily
influenced by the local noise around the spectral peaks than the overlapping metabolites,
and as the SNR improves more correlations become apparent.
Almost all metabolites showed large reductions in CV when increasing B0 using SNR
values that could be acquired in vivo (Table 2-2) with GLU, GLN, GABA, Myo, and
GSH having the greatest reductions. There seems to be additive improvements in CV
coming from both the increase in SNR and the weakened J-coupling at 7 T. This agrees
with Bartha et al20 who demonstrated an average increase in metabolite quantification
precision in vivo at 4 T compared to 1.5 T. However, Cho, PCho, GPCho, Cr, and PCr
did not have CV’s that varied greatly. This is somewhat surprising, as it would be
expected that their precision would improve as the influence of noise is reduced. These
metabolites must be easier to fit even in low SNR conditions due to their strong singlets.
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Despite a reduction in the number of significant correlations observed at 1.5 T compared
to 7 T, there still remain many correlations significant at 7 T. This is perhaps not
surprising, as the 1H-MRS spectrum is a superposition of spectral signatures from many
metabolites in close proximity. However, the magnitude of significant correlations of Jcoupled metabolites paired with GLU was generally decreased, which indicates that there
are indeed improvements in metabolite quantification due to the separation of some
metabolites at higher B0. It is apparent, through the strong dependency of the GLU-GLN
correlation on Bo, that GLU and GLN are increasingly more independently quantified at
higher B0 despite increases in LW. Metabolite pairs with spectral signatures dominated
by strong singlets and overlapping heavily (Fig. 2-4b) will have strong r(METa,METb) even at
high B0. The improvements in spectral dispersion appear to be insufficient to separate
their quantitative dependence on each other. Therefore, any incorrect estimate in one
metabolite is likely to introduce error into the other.
GSH demonstrated unexpected behavior as it moved from one polarity of r(METa,METb) to
the other as B0 increased (Fig. 2-4c). It may be because changes in spectral dispersion
and J-coupling can also lead to increased spectral overlap as peaks are shifting from
multiple metabolites. It would be interesting to see if these GSH pairings would continue
to approach maximum correlation (r(METa,METb)=1 or -1) when B0 increased further or if
they would reverse the trend and reduce correlation strength.
One study examined r(METa,METb)at 2.9T using a 2D J-resolved 1H-MRS sequence in the
anterior cingulate and the posterior cingulate21. Some of the correlations from the anterior
cingulate that the authors chose to highlight include GLU-GLN, GLU-GABA, GABACR, GLY-Myo, GPCho-PCho, NAA-NAAG. The same metabolite pairs were significant
in this study (using 3 T, nt=256, IE1 seeding, for comparison). However, there are some
notable differences between the two studies. Prescot et al21 determined the r(METa,METb)
from the inverted Fisher matrix, so they represent lower bounds of the covariance rather
than the measured or observed variance. They employed a 2D J-resolved PRESS
sequence, whereas the simulations in this study were made to represent the STEAM
sequence. As the authors mentioned, they did not include a MM basis set for
quantification. This had a substantial influence on concentration estimates in this study,
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although there was likely a greater presence of the fast relaxing MM due to the short TE.
Finally, Prescot et al21 conducted an in vivo study whereas this study used simulations.
By using simulations, the experiment was able to be repeated many times with potential
sources of variation, which would be present in an in vivo study, minimized or removed.
Considering this, it is difficult to truly compare the results, but it is encouraging that
similar significantly correlated metabolite pairs were discovered.
The SNR, B0, and type of seeding used had no influence on the accuracy of concentration
estimates. This means that these variables did not lead to errors consistently above or
below any metabolite’s known concentration, it was only the variance around the
estimate that changed. Macri et al.22 observed that when SNR was decreased by a factor
of 2 there were variations in some metabolites’ amplitudes. The difference in results is
likely due to the difference in methods. Macri et al.22 used the simulated deterioration of
in vivo spectra, whereas this study used fully simulated results with exact concentrations
known.
The omission of any metabolite leads to increased error from decreased accuracy in
estimates of metabolite concentrations (although Lac and Ala had very small influences).
This agrees with what has been found in a previous study, in that exclusion of lower
concentration metabolites during the fit can reduce accuracy of GLU and GLN
quantitation23. Metabolites that do not share spectral area with a particular metabolite can
still influence its concentration estimate indirectly through correlations with other
metabolites. The whole metabolite spectral signature, which often consists of many
resonances, must be increased uniformly due to the amplitude constraints put on each
metabolite. This can lead to compensatory variations throughout the spectrum. The fitting
algorithm can come to very different final results with only one metabolite’s spectral
signature omitted.
There were comparable consequences for omitting a metabolite at 7 T and 3 T. Although
it is common for high field 1H-MRS studies to include large quantification templates due
to the increased spectral dispersion and SNR, lower field strengths may require full
metabolite templates as well. It is important to include as many metabolites as reasonably
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possible (based on limitations of data quality) for reliable Ser estimates, for example.
Strict constraints would be necessary for metabolites with peak amplitudes on the order
of noise to reduce implications of inaccurate fits. Caution is to be taken and careful
interpretations of results are required when looking at any study with a limited basis set.
For example, in many studies GLU is fit as “GLX”, which can mean anything from GLU
+ GLN, to everything within that area (GLU, GLN, GABA, NAAG, GSH, MM). The
GLU spectral signature accounted for GLN, NAAG, and GABA spectral areas more than
other metabolites. If these metabolites are not included in the basis set, “GLX” would
include a large contribution from each.
As it was hypothesized, the strongly coupled metabolites benefited the most from
increases in B0. Other metabolites with strong singlets, such as Cr and Cho, did not show
much improvement in quantification, meaning studies with these metabolites of interest
may not require a high field scanner. Definite improvements can be seen in quantification
by including as many metabolites as possible in the template, and by providing accurate
first estimates of the fitting parameters. Attempts should always be made to maximize
SNR as well.
The main limitation of this study is also its main strength, in that it does not use in vivo
data. It would not be feasible to do such a study with in vivo data as there would be too
many variables. For example, both eddy current distortions and chemical shift
displacement would be difficult issues to address across B0, but both can be removed by
using simulations. This study used a parameterized MM baseline that was known to be
correct in the simulations. In vivo, MM are more difficult to parameterize. This could
increase the observed CVs in this study. An ultra-short TE STEAM sequence was chosen
due to its availability and popularity at all B0. However, others have demonstrated that
STEAM is not the ideal sequence at some B024–26. Future studies should address how
other pulse sequences and perhaps different echo times would respond to the sources of
variation identified in this work.
This study has explored specific sources of quantification variability commonly found in
human brain 1H-MRS spectra. Quantitative knowledge of the influence of these sources

77

of variability is important in acquisition protocol design and in data analysis method
design. The results of this study suggest that for most reliable concentration estimates of
GLU and GLN, one requires the highest field strength, highest SNR, most complete
template, and high accuracy seeding of the iterative fitting algorithm. Even in those
conditions, the largest sources of variability for GLU and GLN are overlap/correlation
with each other, NAAG, and GABA.
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Chapter 3

3

Neurometabolic abnormalities observed with magnetic
resonance spectroscopy at 7 T in the anterior cingulate
cortex and thalamus of patients with schizophrenia and
Major Depressive Disorder

The work presented in this chapter examined brain areas that are commonly implicated in
SZ using an ultra-high field MRI and 1H-MRS. A version of this chapter is currently
being edited for submission to the British Journal of Psychiatry.

3.1 Introduction
Current treatments of schizophrenia mostly target dopaminergic neurotransmission via
dopamine receptors and are effective at alleviating positive symptoms, but are often
unable to reduce negative and cognitive symptoms. Drugs that do have some degree of
effectiveness in treating cognitive and negative symptoms typically come with
undesirable side effects, and their mechanism is only partly understood1,2. To better
understand the source of SZ symptoms, an alternative mechanism to dopamine
abnormalities must be explored.
Glutamatergic theories of SZ propose that positive, negative, and cognitive symptoms in
SZ share a common origin in dysfunction of glutamate (GLU) neurotransmission3–5. This
proposal largely originated from animal studies that observed that agonist towards the Nmethyl-D-aspartate (NMDA) receptors, specifically, ketamine and phencyclidine (PCP),
replicate symptoms of SZ in their otherwise healthy hosts6. Later studies of humans
confirmed that the drugs similarly induce symptoms in healthy controls, and actually
worsen symptoms in people with SZ6.
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The exact mechanism by which GLU dysfunction could occur is not yet understood, but
the NMDA receptor may be involved. In the neuron, GLU is stored in vesicles until it is
required for neurotransmission and released into the synaptic cleft. GLU will then bind
with one of a number of receptors on the post-synaptic membrane, including the NMDA
receptor. When GLU has been released from the post-synaptic membrane receptor it is
actively transported into the adjacent glial cell where it can be converted to glutamine
(GLN) via glutamine synthetase and safely transported back into the presynaptic neuron
and effectively recycled for re-use in neurotransmission7. Both GLU and GLN have been
somehow implicated in SZ through studies using proton magnetic resonance
spectroscopy (1H-MRS) that have demonstrated abnormal concentrations throughout the
brain, with a tendency for GLN to be increased and GLU to be decreased early in the
illness with faster decline with age relative to controls8.
Another possible source of dysfunction in glutamatergic neurotransmission is glycine
(GLY), an agonist for the NMDA receptor. For GLU to successfully bind with the
NMDA receptor, GLY is also required to bind with the receptor at a separate site. The
GLY pathway has been the target of new drug interventions with limited success so
far2,5,9. To date, there have been no 1H-MRS studies of GLY in SZ, but it would be ideal
to be able to study this in vivo and in a localized area of the brain.
Of particular interest in SZ is the involvement of GLU, GLN, and GLY in critical brain
pathways that seem to be implicated in SZ known as the limbic basal ganglia thalamocortical (BGTHC) circuits10 by which motivation is translated to behaviour. Each circuit
cycles through the basal ganglia and through to the thalamus before reaching back out to
the cortex. The thalamus, therefore, plays a critical role in motivation and behaviour. The
anterior cingulate cortex (ACC) is another node of a BGTHC that has been implicated in
SZ through 1H-MRS8,11 and functional magnetic resonance imaging studies12. The dorsal
component of the ACC is involved in error detection and organization of conflicting
stimuli, to which activities that stimulate the ACC have demonstrated hypofunction in SZ
12

. Both the thalamus and the ACC are good brain areas to study a potential dysfunction

in glutamatergic neurotransmission in SZ.
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Most 1H-MRS studies of the ACC and thalamus in SZ have been quantified at lower
magnetic resonance imaging (MRI) field strengths, where GLU and GLN spectral
signatures overlap and difficult to reliably quantify individually. Recent advances in
technology have created stronger magnetic field strength MRI facilities. Stronger
magnetic field strengths translate to an increase in sample magnetization and a linear
increase in the signal-to-noise ratio (SNR), assuming body noise dominance. This is very
important in 1H-MRS acquisitions, as 1H-MRS is a low-SNR technique that can require
long scan times to acquire one quality spectrum from a localized voxel in the brain, and
longer scans increase the likelihood of subject movement during a scan. An additional
essential feature of stronger MRI field strengths is increased metabolite separation in the
1

H-MRS spectra, as the ratio of the magnitude of metabolites’ J-coupling constants to

their chemical shift dispersion (both measure in Hertz) decreases. This means that
metabolites that overlap significantly at low MRI field strengths, such as GLU and GLN,
become more resolvable at higher field strengths. It also becomes more likely that
reliable detection of lower concentration metabolites that are traditionally difficult to
quantify, such as GLY, may be quantifiable with the higher SNR and improved
metabolite spectral signature separation.
Specificity of results is difficult to address in studies comparing a psychiatric group to
healthy controls. Major Depressive Disorder (MDD) has previously been assessed with
1

H-MRS although findings have been inconsistent13. As symptoms of SZ can overlap

with those of MDD and GLU has also been implicated in mood disorders, the purpose of
this study was to examine metabolite signals in voxels located in the ACC and thalamus
of patients with SZ compared to healthy controls and a psychiatric control group of
people with MDD using 1H-MRS with a 7 Tesla head-only MRI.
Due to the previous findings of increased GLN8,11, and decreased GLU8 early in frontal
brain areas in SZ, these changes were expected in the ACC and TH of volunteers with SZ
relative to the healthy controls and the MDD group. GLY abnormalities were also
expected, but it is unknown which direction to expect the abnormalities. It has recently
been demonstrated that there is reduced myo-inositol (MYO) in MDD13–15, which was

83

also expected in the present study. No specific hypotheses were made regarding
remaining metabolites.

3.2 Methods
3.2.1

Participants

There were 16 participants in the SZ group, 17 in the MDD group, and 18 in the healthy
control group. All gave informed written consent according to the guidelines of the
Review Board for Health Sciences Research Involving Human Subjects at the University
of Western Ontario. Volunteers with neurological or major medical illnesses, clinically
significant head injury, other psychiatric disorders, MRI contra-indications, or substance
abuse within the previous year were excluded from the study. Any healthy volunteer with
a known family history of psychiatric disorder in a first or second degree relative was
also excluded.
A consensus diagnosis was established on all participants by a psychiatrist and trained
assistant with the Structured Clinical Interview for DSM-IV16. SZ subjects were rated
with the Scale for Assessment of Negative Symptoms and the Scale for the Assessment
of Positive Symptoms17,18 and MDD patients were assessed with the Montgomery Asberg
Depression Scale19 and the Young Mania Rating Scale20. Fourteen SZ patients were
being treated with atypical neuroleptics (Chlorpromazine Equivalent 409 ± 293mg) and 2
patients were not medicated. Eleven of the 17 MDD patients were being treated with
antidepressant medications at the time of the scan. Demographic information including
age, gender, handedness, education, parental education, clinical rating scores, and length
of illness were collected as in our previous study21 and are shown in Table 3-1.
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Table 3-1. Participant demographics
Group

Controls

n

18

Age

23.9

±

4.6

22.5

MDD

SZ

17

16

±

4.6

22.7

±

p

2.9

0.570

M/F

11/7

6/11

13/3

0.018

R/L

16/2

15/2

15/1

0.824

Educ

3.1

±

0.8

2.6

±

0.6

2.2

±

0.8

0.010

PEduc

3.1

±

0.9

2.9

±

0.8

3.3

±

0.8

0.424

HAM-A

12.8

±

10.5

HAM-D

12.8

±

8.9

Mania

5.1

±

6.7

Montg

18.0

±

10.4

CPZ (mg)

358

±

307

SANS

9.7

±

7.7

SAPS
Illness Duration
(months)

7.6

±

10.4

29.5

±

15.7

28.6

±

14.4

M/F – male/female
R/L – right/left
Educ – education rating of the participant (1- gr. 10 or lower, 2- completed high school, 3- 1-3 years of college/university, 4- >3 years
of college/university)
Peduc – education rating of the participant’s parent (1- gr.10 or lower, 2- completed high school, 3- 1-3 years of college/university,
4- >3 years of college/university)
H Anx – Hamilton Anxiety Scale
H Dep – Hamilton Depression Scale
Mania – mania rating from the Young Mania Rating Scale
Montg – result of the Montgomery Asperg Depression Scale
CPZ – chlorapromazine equivalent
SANS – Scale for Assessment of Negative Symptoms
SAPS – Scale for Assessment of Positive Symptoms
p – ANOVA test for significance (alpha=0.05, two-tailed), bolded values indicate significance

3.2.2

1

H-MRS Data Collection and Analysis

All measurements were acquired on a 7.0 T Agilent/Magnex head-only MRI (Agilent,
Inc, Walnut Creek, California, USA) with a Siemens AC84 head gradient coil (Siemens,
Erlangen, Germany), located at the Center for Functional and Metabolic Mapping at
Western University. A transmit-only, receive-only (TORO) head coil with 15 transmitters
and 23 receivers22 was used for all scans. A map of the transmit field for each transmitter
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was acquired at the beginning of the session to facilitate optimized homogeneity
correction of the transmit field for each scan using an automated B1-shimming
approach23. The magnetic field uniformity (B0-shim) was adjusted automatically over
the field of view with first-order and second-order shims using RASTAMAP24 before all
acquisitions.
The 1H-MRS voxels were 2.0 x 2.0 x 2.0 cm (8cm3) in size and located in the left
thalamus and left dorsal anterior cingulate. Voxels were placed and angled using
anatomical landmarks (Fig 3-1) on two, fast low-angle shot 2D anatomical imaging
sequences in the sagittal (45 slices, repetition time (TR) = 950 ms, echo time (TE)=5.23
ms, flip-angle (α)= 30°, gap between slices=1 mm, thickness= 2 mm, field of view (FOV)
220 × 220 mm, and matrix size of 220 × 200) and axial (20 slices, TR = 500 ms, TE
=5.23 ms, α =30°, gap between slices=1 mm, thickness= 2 mm, FOV =220 × 220 mm,
and matrix size 220 × 220) directions, both with lipid saturation.
Spectra were acquired using an ultra-short TE stimulated echo acquisition mode
(STEAM) sequence with outer volume suppression25 (TR=3s, TE=10 ms, mixing time ™
=32ms, 4000 complex pairs, 4 steady state scans, 1s acquisition time, 8 step phase cycle).
There were 64 averages of water suppressed spectra acquired individually for each voxel
location, with 16 water-unsuppressed spectra acquired to correct metabolite lineshapes
and as internal concentration reference. An 8-pulse VAPOR preparation sequence with
an additional water suppression pulse during the TM period25 was used for water
suppression. A separate metabolite suppressed spectrum was acquired to assess the
macromolecule content with inversion times as published in Penner et al26. Each
acquisition produced 23 spectra, one for each receiver, which required channel
combination before use27. Spectra were frequency and phase corrected before being
averaged together in a phase- and frequency-coherent manner. QUality Eddy Current
Correction (QUECC)28 reduced linewidth distortions before spectral fitting with fitMAN,
a time-domain fitting algorithm29. Metabolite concentrations were corrected for gray and
white matter content. All spectra were inspected visually for quality by a trained
spectroscopist.
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Figure 3-1. Sagittal and transverse cross-sections depicting the voxel locations.
Voxel were located in the left anterior cingulate cortex (A,B) and the left thalamus
(C,D) in neurological orientation. The AP line and midline shown as anatomical
landmarks for the sagittal and transverse cross sections, respectively.
Only metabolites with Cramer-Rao lower bounds (CRLB) less than 20% were included in
the analysis, with the exception of GLY, which had a CRLB limit of 30%. Metabolite
concentration estimates were also tested for outliers at the group-level.
One-tailed t-tests (p<0.05/3) will be employed to explore the directional hypotheses of
increased GLU and GLN in SZ relative to the healthy controls and the MDD group. A
one-tailed test will also be used for the decreased MYO in the MDD group relative to
controls and the SZ group. The statistical tests for GLY will be two-tailed t-tests
(p<0.05/3). A multivariate analysis of variance (MANOVA) will test for significant
differences in the remaining metabolites (glutathione (GSH), taurine (TAU), aspartate
(ASP), scyllo-inositol (SCY), ascorbate (ASC), total choline (TCH; choline +
phoshporylcholine + glycerophosphorylcholine), total creatine (TCR; creatine +
phosphocreatine), and total N-acetylaspartate (TNAA; N-acetylaspartate + Nacetylaspartylglutamate)). All statistical tests were completed using SPSS v.20 (IBM
Corp, Armonk, New York, USA).

87

3.3 Results:
1

H-MRS spectra were acquired with voxels in the ACC and thalamus of all participants

with the exception of one healthy control who did not wish to finish the scan of the
thalamus due to dizzyness. Average water linewidths were 13.2 ± 1.3Hz and 16.9 ± 2.1
Hz for the healthy controls, 12.1 ± 0.9Hz and 16.0 ± 1.8Hz for the MDD group, and 12.8
± 1.6Hz and 16.9 ± 2.2Hz for the SZ group in the ACC and thalamus, respectively,
indicating well shimmed data. There were no significant differences in the water
linewidths between groups. One spectrum from the ACC of volunteers from each of the
MDD and SZ groups needed to be excluded due to poor quality spectra, likely due to
excessive movement. Example spectra from each brain region along with the respective
fits of GLU, GLN, and GLY can be seen in Fig.3-2. In the thalamus, one subject from
the SZ group and one healthy control each presented with GLY concentrations CRLB of
35% and had to be excluded. The remaining GLY measurements were within the CRLB
criterion.
Increased GLN concentrations were observed in the thalamus of the SZ group relative to
the healthy controls (p=0.009) but not to the MDD group (p=0.072). There were no
significant between-group differences in GLU concentrations in neither the ACC (Table
3-2) nor the thalamus (Table 3-3). GLY concentrations were significantly reduced in the
thalamus of the SZ group relative to both the healthy controls (p=0.017) and the MDD
group (p=0.012), but no differences in GLY were observed in the ACC (p=0.385,
p=0.184, respectively). MYO was reduced in the MDD group relative to the healthy
controls (ACC: p=0.009; thalamus: p=0.014) and the SZ group (ACC: p=0.001;
thalamus: p=0.002). The MANOVA for the remaining metabolites was not significant for
the thalamus (p=0.126, Wilk’s Lambda) nor for the ACC (p=0.297, Wilk’s Lambda).
Although the MANOVA was not significant, a closer look at the pairwise comparisons
reveals a significant decrease in SCY in the ACC of the MDD group relative to the SZ
group (p=0.004) and a trend when compared to the healthy controls (p=0.026).
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Figure 3-2. Example 64 average spectra from (A) the ACC and (B) the thalamus.
Spectral fits are shown for GLU, GLN, GLY, and all remaining metabolites, with
the residual of the fit minus the data.

Concentrations of each metabolite, with the pairwise comparisons for each group can be
seen for the ACC and the thalamus in Table 3-2 and Table 3-3, respectively.

3.4 Discussion
3.4.1

GLU and GLN

The significant increase in GLN concentrations in the thalamus in the SZ subject group
was consistent with the originally stated hypothesis of increased GLN concentrations of
subjects with SZ relative to healthy controls (p=0.009) and agrees with previous
studies8,11. The increased GLN could mean a reduced efficiency of converting back to
GLU via glutamine synthetase or it could be directly related to NMDA receptor
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Table 3-2. Metabolite concentrations (mmol/kgww ± standard deviations) with statistical
comparisons for each subject group for a voxel in the ACC
ACC
HC

MDD

SZ

p(HC-MDD)

p(HC-SZ)

p(MDD-SZ)

GLU

10.01

±

1.25

10.37

±

0.66

10.73

±

1.21

0.354

0.064

0.363

GLN

2.04

±

0.53

1.90

±

0.72

1.96

±

0.96

0.592

0.385

0.408

GLY

0.88

±

0.28

0.99

±

0.22

0.86

±

0.24

0.234

0.837

0.184

GSH

1.28

±

0.41

1.16

±

0.24

1.41

±

0.35

0.334

0.303

0.060

TAU

1.64

±

0.33

1.58

±

0.39

1.73

±

0.41

0.671

0.484

0.284

ASP

2.81

±

1.46

2.10

±

1.19

2.86

±

1.34

0.134

0.925

0.128

MYO

8.02

±

0.79

7.19

±

0.72

8.36

±

1.34

0.009

0.327

0.002

SCY

0.51

±

0.15

0.39

±

0.11

0.55

±

0.18

0.026

0.406

0.004

ASC

1.11

±

0.35

1.10

±

0.71

1.37

±

0.68

0.984

0.237

0.249

TCH

2.38

±

0.33

2.36

±

0.22

2.40

±

0.25

0.805

0.792

0.625

TCR

8.89

±

0.99

8.92

±

0.74

9.52

±

0.95

0.929

0.052

0.075

TNAA

11.02

±

1.36

11.45

±

0.63

11.60

±

0.82

0.236

0.107

0.673

HC – healthy controls; MDD- major depressive disorder; SZ – schizophrenia
GLU – glutamate; GLN – glutamine; GLY – glycine; GSH – glutathione; TAU – taurine; ASP – aspartate; MYO – myo-inositol; SCY – scyllo-inositol; ASC – ascorbate; TCH – total choline; TCR – total
creatine; TNAA – total NAA.
p(HC-MDD) – HC vs MDD, alpha=0.05/3 (Bonferroni corrected), two-tailed. Bolded values indicate significance
p(HC-SZ) – HC vs SZ, alpha=0.05/3 (Bonferroni corrected), two-tailed. Bolded values indicate significance
p(MDD-SZ) – MDD vs SZ, alpha=0.05/3 (Bonferroni corrected), two-tailed. Bolded values indicate significance
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Table 3-3. Metabolite concentrations (mmol/kgww ± standard deviations) with statistical comparisons for each subject group
for a voxel in the TH
Thalamus
HC

MDD

SZ

p(HC-MDD)

p(HC-SZ)

p(MDD-SZ)

GLU

7.38

±

0.61

7.79

±

0.85

7.39

±

1.03

0.161

0.493

0.173

GLN

1.27

±

0.59

1.51

±

0.69

1.85

±

0.63

0.309

0.009

0.072

GLY

0.91

±

0.26

0.92

±

0.25

0.72

±

0.13

0.906

0.017

0.012

GSH

1.31

±

0.31

1.22

±

0.24

1.41

±

0.28

0.355

0.295

0.054

TAU

1.93

±

0.54

2.20

±

0.58

2.32

±

0.40

0.142

0.034

0.496

ASP

2.53

±

1.38

3.22

±

1.76

3.38

±

1.93

0.273

0.180

0.786

MYO

7.18

±

0.76

6.41

±

1.21

7.44

±

0.94

0.014

0.447

0.004

SCY

0.37

±

0.07

0.35

±

0.07

0.39

±

0.05

0.235

0.422

0.052

ASC

0.94

±

0.66

0.73

±

0.51

1.16

±

0.49

0.289

0.259

0.033

TCH

2.18

±

0.16

2.19

±

0.16

2.16

±

0.22

0.892

0.764

0.665

TCR

6.52

±

0.81

6.41

±

0.86

6.45

±

0.79

0.702

0.795

0.907

TNAA

11.07

±

0.86

10.95

±

0.97

10.84

±

0.87

0.722

0.465

0.703

HC – healthy controls; MDD- major depressive disorder; SZ – schizophrenia
GLU – glutamate; GLN – glutamine; GLY – glycine; GSH – glutathione; TAU – taurine; ASP – aspartate; MYO – myo-inositol; SCY – scyllo-inositol; ASC – ascorbate; TCH – total choline; TCR – total
creatine; TNAA – total NAA.
p(HC-MDD) – HC vs MDD, alpha=0.05/3 (Bonferroni corrected), two-tailed. Bolded values indicate significance
p(HC-SZ) – HC vs SZ, alpha=0.05/3 (Bonferroni corrected), two-tailed. Bolded values indicate significance
p(MDD-SZ) – MDD vs SZ, alpha=0.05/3 (Bonferroni corrected), two-tailed. Bolded values indicate significance
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hypofunction, which would cause increases in the glutamine synthetase activity and
would lead to increased GLN30.
The lack of findings in GLN and GLU concentrations in the ACC and in GLU
concentrations in the thalamus did not agree with the originally stated hypothesis. The
absence of an observed significant increase in GLN in the ACC could be due to the
duration of illness of the sample of SZ subjects, as it has also been shown that although
SZ subjects have an initial increase at the onset of the illness, they also decrease their
GLN concentrations faster than healthy controls. With the average duration of illness
being 29.50 ± 17.50 months, it is possible a significant decrease had already begun. It is
also possible that more subjects are necessary to observe any significant differences.
There were no significant differences in either GLU or GLN in the SZ group compared to
the MDD psychiatric control group, although a non-significant (trend-level) increase in
GLN in the thalamus was observed (p=0.072). It is likely that with more participants a
significant difference would be observed, but it is also possible that GLN changes relative
to healthy controls are easier to observe in SZ participants compared to MDD participants
due to the greater severity of negative and cognitive symptoms in SZ compared to MDD.
The MDD group also did not significantly differ from the healthy control GLU and GLN
concentrations. It has previously been shown that decreased GLU (often observed as
GLX (GLU+GLN)) is a common finding in MDD compared to healthy controls13,31, but
this was not observed in this study.

3.4.2

GLY as a potential therapeutic target

Studies have examined the serum and plasma of people with SZ to examine GLY
concentrations, among other neurotransmitters32,33, but no studies have examined GLY
concentrations in SZ using 1H-MRS. This is partly due to the difficulty in examining
GLY in vivo. At lower field strengths, the GLY peak overlaps strongly with the MYO
peak. As magnetic field strength increases so does their peak separation. In this study,

92

the use of a 7 T MRI provided adequate peak separation and signal to quantify GLY
separately from MYO. Recent techniques, however, have demonstrated reliable GLY
concentration changes can be detected following regular oral administration of GLY for
two weeks using a 4 T MRI and a TE-averaged PRESS sequence34.
The reduction in GLY observed in the thalamus of the SZ group corresponds very well
with the observed increases in GLN. GLY is a co-agonist of the GLU NMDA receptor.
Without an adequate supply of GLY, GLU neurotransmission, via the NMDA receptor,
will be impeded. The synaptic supply of GLY is normally maintained below the level of
saturation9, so any decrease in GLY could directly reduce NMDA activity, increasing
glutamine synthetase activity30 and potentially explaining the observed increases in the
GLN concentrations.
Many strategies towards altering glutamatergic activity via pharmacological interventions
have been explored but have presented with various challenges. GLU itself does not cross
the blood-brain barrier well35 and extracellular concentrations need to be controlled to
prevent GLU excitotoxicity7. Other strategies have targeted GLY or GLY transporters.
GLY is rapidly metabolized and does not cross the blood-brain barrier well either9, but
oral administrations have led to detectable changes in the brain34. The GLY activity is
modulated by GLY transporter proteins, GLYt2 and GLYt15. GLYt2 is involved in the
inhibitory function of GLY and GLYt1 regulates the concentrations of GLY in the
synaptic cleft9. New drug therapies are selectively targeting this GLYt1 transporter
protein to increase the synaptic supply of GLY in hopes of saturating the NMDA receptor
GLY subunit to increase its activity36,37. A potential future study could use high-field 1HMRS to detect GLY and GLN concentrations in the thalamus before and after
medication. Decreased GLN from the baseline value would potentially indicate increased
NMDA receptor activation causing reduced glutamine synthetase activity and less GLN
present. One study found that GLY concentrations increased in the plasma of subjects
with SZ after receiving clozapine treatment32 and another found that serum levels were
significantly lower in patients taking clozapine33. It is now possible to monitor the effects
of clozapine on brain levels of both GLY and GLN concentrations with reasonable
precision using 1H-MRS.
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3.4.3

Inositol in MDD

The main finding in the MDD group was the reduced MYO observed in the ACC and TH
and reduced SCY observed in the ACC. MYO has many functions, including being an
important osmolyte, a structural component of eukaryotic cells and a precursor for second
messengers involved in neurotransmission38. Although MYO is consumed regularly in
the average diet, it can be created de novo in the brain from glucose and it is readily lost
from brain tissue when cell integrity is compromised38. It has commonly been described
as a marker of glial cell integrity, but this has been brought into question as many
neurons contain just as much or more MYO than glial cells38. There is a possibility that
reduced MYO is due to the significant gender differences between the MDD group and
the other groups (p=0.018), but it is unlikely given that reduced MYO has previously
been reported in MDD patients frontal lobes13,14,39 in post-mortem brain tissue15 and in
cerebrospinal fluid40. Other studies have shown a normalization or an increase in MYO
in recovered MDD patients14,41 and it is believed that drugs that reduce mania in bipolar
disorder act by reducing MYO content42. MYO oral supplementation has been
investigated as a treatment for MDD. Taylor et al43 examined the results of four studies
consisting of unipolar and/or bipolar subjects taking daily inositol and found no
significant effect. However, a more recent meta-analyses by Mukai et el44 examined
seven studies of mixed MDD, bipolar, and premenstrual dysphoric disorder patients and
suggests that inositol may have some therapeutic effect for people with depression.
Although the MANOVA was not significant, it is interesting that SCY, an isomer of
MYO that typically has a concentration of 5-12% that of MYO in the human brain38, had
significantly reduced concentrations when looking at the pairwise comparisons of the
remaining metabolites. It is becoming increasing evident that there may be a role for
inositol in the regulation of mood. More studies are necessary to further elucidate the
exact role played and whether MYO (or even SCY) could be a potential target of
pharmacological intervention in MDD.
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3.4.4

Future studies

There are a number of avenues to explore based on these results. For the SZ group, a
confirmation study finding reduced GLY in the thalamus could be performed, followed
by a study investigating GLY concentrations as influenced by administration of oral GLY
supplementation. It would also be interesting to see how GLY concentrations in SZ
patients taking clozapine compare to those taking first or second generation
antipsychotics. Similarly, in the MDD group, a 1H-MRS study investigating before and
after effects of MYO supplementation in the diet should be explored.

3.4.5

Conclusions

As far as the authors are aware, this is the first 1H-MRS study of SZ or MDD using a 7 T
MRI and the first 1H-MRS study looking at GLY in SZ. No GLU differences were
observed in either the ACC or the thalamus, but decreased GLY was observed in the
thalamus along with increased GLN in the SZ group relative to healthy controls,
supporting the notion of NMDA receptor hypofunction in SZ. Decreased MYO was
observed in the MDD group relative to both the healthy control group and the SZ group
in both the ACC and the thalamus. Metabolic effects of drug interventions should be
explored next.
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Chapter 4

4

Increased glutamate levels observed upon functional
activation in the anterior cingulate cortex using the
Stroop Task and functional spectroscopy.

The study presented in this chapter was performed to demonstrate that it is possible to
detect changes in the main excitatory neurotransmitter, glutamate, upon functional
activation using a cognitive functional paradigm using a 7 T MRI and functional
magnetic resonance spectroscopy in a group of healthy controls. A cognitive task would
be desirable for this technique because it could then be used to examine psychiatric
disorders that have cognitive deficiencies. A version of this chapter has been published in
NeuroReport (2015; 26:107-112). No permission letters are needed to reproduce this
article in this dissertation.

4.1 Introduction
Proton magnetic resonance spectroscopy (1H-MRS) is a useful tool for the noninvasive
study of the brain’s chemistry. 1H-MRS has an inherently low signal-to-noise ratio
(SNR); thus, traditional studies have assumed constant metabolite concentrations during
the long scan durations required to acquire a spectrum with sufficient SNR for accurate
quantification. Advances in MRI technology such as higher magnetic field strengths,
improvements in radiofrequency head coils, pre-amplification, and signal detection
systems have considerably increased the available SNR for 1H-MRS. This has made it
feasible to examine the brain in a dynamic state using functional 1H-MRS (1H-fMRS). It
has been shown previously with 1H-fMRS that alterations in the local neurochemistry
occur when a particular area of the brain becomes engaged in task transaction1–10. One
metabolite of interest is glutamate (GLU), the main excitatory neurotransmitter in the
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brain, which has been shown to be related directly to the brain’s consumption of glucose
for the production of energy11 and has been implicated in the pathophysiology of
psychiatric disorders, such as schizophrenia12,13.
Few studies have used 1H-fMRS to date. Three studies have shown small (2–4%) but
significant increases in the GLU concentration in the occipital cortex upon functional
activation with a visual stimulus, such as a flickering checkerboard1,2,6. Recent results
showed a 2% increase in the motor cortex upon functional activation with a fingertapping paradigm 3. Two other studies have used pain as a stimulus and have identified
9.3 and 18.1% increases in the mean GLU concentration in the anterior cingulate cortex
(ACC) and the anterior insular cortex, respectively, when the participants are exposed to
the pain4,5. Finally, two studies have examined GLU changes in the lateral occipital
cortex using a repetition suppression task and have found GLU increases of 11%9 and
12%10.
Cognitive tasks are generally less sensitive for detection when assessed through standard
BOLD fMRI than visual (flickering checkerboard) or motor (finger tapping) tasks14. To
the best of our knowledge, there has been only one study to date that has used fMRS to
examine metabolite changes using a cognitive task as the activation paradigm8. This
study did not find any changes in GLX [GLU +glutamine (GLN)], but they did find that
GABA increased in concentration upon functional stimulation of the left dorsolateral
prefrontal cortex and then decreased in subsequent runs of the task. Although GLX, in
this case, combines GLU with GLN, it would be ideal to use a cognitive task to examine
the response of GLU independent of GLN as both are crucial to brain function. As GLU
abnormalities have been found in neuropsychiatric disorders in the ACC12,13, a cognitive
task that robustly activates the ACC is desirable for the investigation of abnormalities in
the dynamic regulation of GLU levels in this area.
In addition to influencing our perception of pain, the ACC is implicated in many other
cognitive functions, including selective encoding of stimulus properties15, general
attention16, and organization of conflicting stimuli17. The aim of this exploratory study is
to show that with 1H-fMRS of the ACC, it is feasible to detect GLU concentration
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changes using a cognitive task as the activation paradigm. The color-word Stroop Task is
a common psychological task that involves differentiating potentially conflicting word
and color stimuli under congruent (i.e. the word ‘RED’ written in red ink) and
incongruent (i.e. the word ‘BLUE’ written in red ink) conditions18. The Stroop Task was
chosen for this study because it activates the ACC and has been implicated previously in
schizophrenia17, a potential application of this technique.
It has been proposed that GLU concentrations will increase upon functional activation of
the ACC with a cognitive task because of the increase in the cycling rate of neuronal
GLU with GLN with an approximate 1 : 1 stoichiometry to the neuronal glucose
oxidation rate, which is directly related to functional MRI signal changes upon
stimulation11. No other specific hypotheses have been made in terms of other metabolites.

4.2 Methods
Seven healthy control individuals (age 39.8 ± 3.8 years) provided informed written
consent according to the guidelines of the Review Board for Health Sciences Research
Involving Human Subjects at Western University. The participants included five men and
two women.
In this study, the Stroop Task involved four conditions, incongruent, congruent, word
only (the name of the color written in white), and color only (written as ‘XXXX’), with
each condition represented in 25% of the trials. Four colors were chosen for the task: red,
green, blue, and yellow. The participants were asked to respond as quickly and accurately
as possible on a four-button keypad. They were allotted 2 s to respond, and stimuli were
separated by 1 s of cross fixation. The task was explained to each participant and
rehearsed outside of the scanner until it could be performed consistently with 80%
accuracy or greater. An angled mirror attached to the head coil allowed the participants to
visualize the words of the Stroop Task projected on the screen in the scanner
synchronously with the 1H-fMRS acquisition. Participants were initially positioned in the
scanner with the button press keypad in their hands ready to perform the task. This
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minimized additional movement at the onset of the Stroop Task. The fMRS acquisition
began with a 4-min resting period in which the participants were asked to fixate on a
cross in the center of the projection screen. The final 3 s of the resting period were used
to prompt the participant that the Stroop Task was about to start with the word ‘Ready’
projected onto the screen. The Stroop paradigm then lasted for 4 min and was followed
by a 4-min recovery period. The procedure was written using PsychoPy19. The accuracy
and response times were recorded to ensure participants’ compliance.
All measurements were acquired on a 7.0 T Agilent/ Magnex head-only MRI (Agilent,
Inc, Walnut Creek, California, USA) with a Siemens AC84 head gradient coil (Siemens,
Erlangen, Germany), located at the Center for Functional and Metabolic Mapping at
Western University. A transmit-only receive-only (TORO) head coil with 15 transmitters
and 23 receivers20 was used for all scans. A map of the transmit field for each transmitter
was acquired at the beginning of the session to facilitate optimized homogeneity
correction of the transmit field for each scan using a B1-shimming approach developed
in-house21. The magnetic field uniformity (B0-shim) was adjusted automatically over the
field of view with first-order and second-order shims using RASTAMAP22 before all
acquisitions.
The MRS voxels were 2.0 × 2.0 × 2.0 cm (8 cm3) in size. In every individual, a voxel
was centered medially and encompassed the bilateral ACC using two fast low-angle shot
2D anatomical imaging sequences in the sagittal [45 slices, repetition time (TR) = 950
ms, echo time (TE)=5.23 ms, flip-angle (α)= 30°, gap between slices=1 mm, thickness= 2
mm, field of view (FOV) 220 × 220 mm, and matrix size of 220 × 200] and axial (20
slices, TR = 500 ms, TE =5.23 ms, α =30°, gap between slices=1 mm, thickness= 2 mm,
FOV =220 × 220 mm, and matrix size 220 × 220) directions, both using lipid saturation.
Voxel positions were prescribed by the scanner operator (R.T.) using anatomical
landmarks as trained by a neuroanatomist (N.R.) to ensure consistent voxel placement
(Fig. 4-1).
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Figure 4-1. A sagittal cross-section of the brain with the MRS voxel placed in the
anterior cingulate cortex. MRS = magnetic resonance spectroscopy
MRS spectra were acquired individually during the performance of the Stroop paradigm
using an ultra-short echo time stimulated echo acquisition mode sequence with outer
volume suppression23 [TR =3 s, TE = 10 ms, mixing time (TM) = 32 ms, 4000 complex
pairs, four steady state scans, 1 s acquisition time, eight-step phase cycle] with 16 water
unsuppressed spectra and 240 water suppressed spectra, 80 spectra for each 4 min section
of the Stroop paradigm (Rest, Stroop, Recovery). An eight-pulse VAPOR preparation
sequence, with an additional water suppression pulse during the TM period23, provided
efficient water suppression. A separate metabolite suppressed spectrum was acquired to
assess the macromolecule content24. Each acquisition outputted 23 spectra, one for each
receiver, which required channel combination before use25. After the channels had been
combined, each spectrum was frequency and phase corrected before being averaged
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together. Quality Eddy Current Correction (QUECC)26 reduced linewidth distortions
before spectral fitting. Spectra were quantified using fitMAN, a time-domain fitting
algorithm27. All spectra were inspected visually for quality.
Because of our directional hypotheses for GLU concentrations, a three-level repeatedmeasures analysis of variance (rmANOVA) design using the metabolite concentrations at
each 4 min (80 spectral averages) section of the functional paradigm was examined using
SPSS v.20 (IBM Corp, Armonk, New York, USA) to determine significant variations
over time for GLU (α= 0.025, one tailed with Bonferroni correction). Because of the
exploratory nature of this paper, the remaining metabolites were also tested for
significance using a repeated measures multivariate analysis of variance (rmMANOVA)
(α =0.025, two tailed with Bonferroni correction). Only metabolites with Cramer–Rao
lower bounds less than 20% were included in the analysis.

4.3 Results
The average linewidths of the unsuppressed water signal were 12.8 ± 2.0 Hz after firstorder and second-order shim adjustments. The average metabolite linewidth in the resting
condition was 8.6 ± 0.8 Hz and no significant narrowing of the linewidths was observed
in the activated condition compared with the resting condition. The water signal was
suppressed sufficiently as the residual water signal was less than the height of the NAA
peak in every spectrum.
A total of 15 metabolites were quantified consistently with Cramer–Rao lower bounds
less than 20% for each of the resting, activated, and recovery spectra (Table 4-1). The
time course of group-averaged GLU activation in 1 min increments is shown in Fig. 4-2
(all stats were performed on the 4 min, 80 averaged spectra). The concentration increases
upon onset of the Stroop Task, plateau, and then decrease over 2 min toward the baseline.
When the GLU concentrations between the resting, Stroop, and recovery periods were
compared, there was a significant 2.6 ± 1.0% (0.24 ± 0.09 µmol/g) increase in the
activated state relative to the initial resting period (P= 0.02, one tailed), followed by a
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non-significant −2.4 ± 1.2% (− 0.23 ± 0.13 µmol/g) trend for the GLU signal to return to
baseline after the activation period had ended (P =0.06, one tailed). However, when GLU
concentrations were normalized to their baseline value in the resting period, the relative
decrease in the recovery period became significant before Bonferroni corrections (0.025
< P < 0.05). Six of the seven participants showed this increase in GLU upon activation
(1.0, 1.3, 5.3, −0.4, 6.0, 0.3, and 5.0%) and six of the seven participants showed the
subsequent decrease (1.2, − 2.0, −8.8, − 1.5, −1.1, − 2.9, and – 1.6%).

Table 4-1. Quantified metabolites with their resting concentrations (µmol/g) and
relative changes (%) during the task completion and the recovery period presented
as means ± SE
Concentration Change
(Task – Rest)

Concentration Change
(Recovery – Task)

Resting
Concentration
(µmol/g)
(%)
p
(%)
p
GLN
2.4 ± 0.3
-0.2 ± 5.6
0.738
6.8 ± 4.7
0.179
GLU
8.9 ± 0.3
2.6 ± 1.0
*0.021
-2.4± 1.2
0.046
TAU
2.4 ± 0.3
5.1 ± 7.3
0.509
-1.4 ± 5.6
0.539
ASP
2.5 ± 0.6
0.3 ± 5.9
0.853
-1.7 ± 3.5
0.404
NAAG
1.1 ± 0.3
2.6 ± 7.2
0.730
-4.6 ± 7.6
0.505
MYO
7.9 ± 0.5
0.9 ± 1.5
0.567
1.7 ± 1.4
0.261
SER
2.0 ± 0.3
7.5 ± 6.7
0.237
-2.4 ± 6.3
0.482
GLC
0.8 ± 0.2
-6.4 ± 10.2
0.955
14.9 ± 5.3
0.061
NAA
7.9 ± 0.3
2.6 ± 1.8
0.199
-1.1 ± 0.5
0.309
LAC
0.5 ± 0.1
22.9 ± 20.3
0.351
35.4 ± 13.1
0.155
GLY
0.7 ± 0.1
2.1 ± 1.5
0.200
-12.2 ± 7.0
0.130
SCY
0.4 ± 0.0
3.3 ± 2.8
0.279
1.5 ± 3.7
0.663
ASC
1.0 ± 0.1
-11.5 ± 11.6
0.764
33.1 ± 17.5
0.030
TCHO
2.1 ± 0.1
2.2 ± 1.2
0.111
-0.6 ± 0.6
0.399
TCR
7.7 ± 0.3
2.2 ± 1.2
0.122
-0.0 ± 0.6
0.920
GLX
11.3 ± 0.5
2.0 ± 1.7
0.302
-1.1 ± 1.1
0.324
ASC, ascorbate; ASP, aspartate; GLC, glucose; GLN, glutamine; GLU, glutamate; GLY,
glycine; GLX, glutamate + glutamine; LAC, lactate; MYO, myo-inositol; NAA, Nacetylaspartate; NAAG, N-acetylaspartylglutamate; SCY, scyllo-inositol; SER, serine;
TAU, taurine; TCHO (cho + PC + GPC), total choline; TCR (CR + PCR), total creatine.
*p < 0.025 significance (Bonferroni adjusted) for a two-tailed comparison, with the
exception of Glu, which is one-tailed due to it being a planned directional comparison
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Figure 4-2. A time-course of the average glutamatergic response to the Stroop Task
Each data point represents the temporal average of 20 spectra (1 min) per
participant combined and quantified and subsequently averaged over all
participants (n=7). Error bars indicate the inter-individual SEM at each point. The
trend line is a fourth-order polynomial fit to the data. The shaded area indicates the
4 min of Stroop activation.
Other than GLU, the remaining metabolites were not significant in the rmMANOVA. It
should be noted, though, that in the univariate pair-wise comparisons, ascorbate (Asc)
increased 33.1 ± 17.5% (0.20 ± 0.06 µmol/ g) during the 4-min recovery period relative
to the activation period (P= 0.03, two tailed). However, this is only a trend because of the
Bonferroni correction.
All participants recorded at least 90% correct responses. Group-averaged response times
were 725 ± 278 ms for the congruent condition, 976 ± 261 ms for the incongruent
condition, 750 ± 270 ms for the word-only condition, and 721 ± 230 ms for the coloronly condition. Only correct responses were considered.
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4.4 Discussion
Using a Stroop Task as the functional paradigm for an 1H-fMRS examination of the
dynamic metabolic response to activation in the ACC, an observed significant increase of
2.6 ± 1.0% was found in GLU upon onset of the task, followed by a non-significant trend
to return to the baseline in a small sample size of healthy controls (n=7). The high
percentage of correct responses shows that there was high compliance with the Stroop
Task among the participants.
The increase in GLU is comparable with recent 1H-fMRS studies of the occipital
cortex1,2,6 and the motor cortex3, which found GLU increases from 2 to 4% over the
course of minutes, with a subsequent decrease upon cessation of the stimuli. Figure 4-2
indicates that the concentration increased to its new steady state within the first minute of
activation. This is relatively faster than that in the above studies, which show that it takes
1–2 min before the concentration reaches its new state. One possible explanation is that
because of the involvement of ACC in attention networks16, and, specifically, selective
encoding of stimulus properties15 the ACC had already been in a state of minor
activation. This is consistent with the final data point of the first resting condition in Fig.
4-2 that is seemingly already ascending toward the peak concentration. The resting GLU
concentration is slightly lower than what was observed in other 1H-fMRS studies at 7 T1–
3,6

; however, different scanners, techniques, and brain areas studied led to natural

variation in the observed values between studies.
One departure from previous 1H-fMRS studies at 7 T1–3,6 is that a significant difference in
lactate or glucose was not observed. These are difficult metabolites to quantify reliably;
thus, perhaps more participants would be needed to observe significant differences. It is
also possible that the lactate response was specific to certain tasks or brain areas.
It is conceivable that the ACC accumulates GLU faster than other brain regions upon
stimulation as can be extrapolated from a study of the ACC using a painful stimulus4.
Mullins and colleagues used 1H-fMRS at 3 T to detect a 9.3% increase in GLU and an
11.4% increase in GLX (GLU+ GLN). The GLU increases observed by Mullins et al.4
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are markedly higher than the response detected in the present study. This could be
because of the nature of the experimental stimuli (pain versus cognitive task) such that
the brain may have adapted a separate GLU response to painful stimuli as a similar
increase in GLU was observed with a painful stimuli in the anterior insula cortex5. Two
studies have used event-related 1H-fMRS to detect >10% increases in the lateral occipital
cortex9,10. It is possible that with an event-related Stroop Task, larger similar increases in
GLU in the ACC could be observed. However, with the current block design, the
magnitude of GLU changes agrees more with the previous work in the visual cortex1,2,6
and the motor cortex3.
One study at 3 T presented GABA changes with a working memory task in the
dorsolateral prefrontal cortex, but did not detect any changes in GLX (GLU + GLN)8.
The study used a dedicated pulse sequence to detect GABA specifically, which can
otherwise be a difficult metabolite to quantify as it was not consistently quantified
reliably in this study. They observed an initial increase in GABA concentrations, but
subsequent decreases with repeated runs of the task. In a future study, it would be
interesting to observe how GLU would respond to repeated runs of the Stroop Task.
Another study that was carried out at 3 T has used an 1H-fMRS technique to study the
ACC using visually evoked sexual arousal7 and found significant 10–20% increases in
GLX with activation. At lower field strength, it is often necessary to measure a
combination of GLU and surrounding metabolites that can include GLN, glutathione,
GABA, and sometimes macromolecules together as GLX. It is not clear which
metabolites were included in their GLX definition, making it harder to compare these
results. A common definition of GLX is simply GLU plus its precursor GLN, as was used
in the pain study4 and the working memory study8 mentioned above. Using this
definition, GLX was examined in this study, but no significant differences were
observed.
The increase in Asc in the recovery period, although not significant after Bonferroni
correction or at the multivariate level, is intriguing. It has been reported previously by
Wilson et al.28 that GLU triggers the release of Asc from astrocytes and increases the
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extracellular concentration of Asc. Asc is an antioxidant. This is important because GLU
neurotransmission leads to increased mitochondrial activity and as a result increased free
radicals29. Wilson et al.28 showed that this effect takes some time to observe; thus, it is
possible that the increase in GLU during the activated phase led to the delayed increase in
Asc concentration that was observed in the recovery phase.
GLU is the main excitatory neurotransmitter in the brain. It is synthesized from glucose
in the mitochondria, released into the synaptic cleft through exocytosis, and then binds
with the postsynaptic membrane to induce neurotransmission30. It is then taken up into
the adjacent glial cell, where it is converted into GLN before being transferred back into
the neuron and converted back into GLU30. There is an increase in glucose consumption
during functional activation that specifically supports the increased turnover rate of the
GLU/GLN cycle 11. Therefore, an increase in oxidative metabolism could lead to the
increased number of GLU molecules flowing within the GLU/GLN cycle during the
functional activation of the ACC with the Stroop Task leading to the increased GLU
observed in bulk brain tissue using MRS. The lack of change in GLN concentrations may
indicate that the conversion of GLN back into GLU in the neuron is not a rate-limiting
step in the GLU/GLN cycle.
This proof-of-concept study shows that the Stroop Task is a robust task that can be used
for 1H-fMRS studies in the ACC. This introduces a new method to study the
abnormalities of GLU modulation in brain disorders. Schizophrenia research may
particularly benefit from this method as it is a population that has been shown to have
abnormal resting levels of glutamatergic metabolites in the ACC compared with healthy
controls12,13 and impaired ACC activation during performance of the Stroop Task17.
Dysfunction of glutamatergic metabolism may manifest itself as an inability to
dynamically upregulate GLU cycling or excessive upregulation of GLU, or even GLN,
concentrations during performance of the Stroop Task. The limitations of the study
include its small sample size and the possibility that the GLU changes observed are
because of movement-induced phase shifts from the participant responding to the task,
although it is unlikely that a phase shift would induce consistent increases in GLU rather
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than decreases. Future studies should have a larger sample size and focus on 1H-fMRS in
neuropsychiatric disorders.
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Chapter 5

5

Functional magnetic resonance spectroscopy of
glutamate in schizophrenia and major depressive
disorder: Anterior cingulate activity during a color-word
Stroop task.

The study presented in this chapter aimed to utilize functional magnetic resonance
spectroscopy with a cognitive functional paradigm to obtain dynamic measurements of
glutamate and glutamine in a psychiatric group for the first time. A version of this work
is currently in press to be published in npj Schizophrenia (Nature Partner Journals
Schizophrenia; NPJSCHZ#00068).

5.1 Introduction
Schizophrenia (SZ) has been suggested to be associated with dysfunction in brain areas
that utilize glutamate (GLU) for neurotransmission1. It has been postulated that GLU Nmethyl-D-aspartate (NMDA) receptor hypofunction may contribute to symptoms of SZ2–4
and this body of literature has been recently reviewed5,6. This, and other lines of evidence
has led to the notion that GLU abnormalities can explain a wider range of symptoms of
SZ than dopamine abnormalities alone, thus characterization of GLU abnormalities in SZ
is sorely needed in light of potential GLU-modulating treatment strategies6.
Proton magnetic resonance spectroscopy (1H-MRS) has demonstrated abnormal brain
GLU concentrations, with its metabolic precursor/by-product, glutamine (GLN), in
individuals with SZ7,8. However, findings may not be specific to this illness. Both major
depressive disorder (MDD) and bipolar disorder have demonstrated abnormalities of
GLU in multiple brain areas using 1H-MRS9–11. While MDD has been consistently
reported to have lower glutamatergic metabolites (GLU, GLN, or GLX (GLU+GLN)),
bipolar disorder has demonstrated inconsistent results, with a tendency to be elevated9–11.
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The consistency of studies of GLU in MDD makes it a preferable choice for a psychiatric
control group.
An increasing number of studies demonstrate the utility of functional 1H-MRS (1HfMRS) in dynamic measures of metabolic content12–24. Much like its parent technique,
1

H-MRS, 1H-fMRS assesses concentrations of brain metabolites that are orders of

magnitude smaller than the water content. Essentially, 1H-fMRS is a time course of 1HMRS spectra that typically measures slow metabolic responses to prolonged stimuli in a
small volume of tissue within the brain13–16,18–20.
Increases in concentrations of glutamatergic metabolites have been demonstrated in 1HfMRS studies of healthy controls in the occipital lobe using visual stimuli14,16,17,19, the
lateral occipital cortex using a repetition suppression task23,24, the motor cortex using a
finger tapping paradigm18 and the anterior cingulate cortex (ACC) using pain
paradigms21,22, a sexual arousal paradigm13, and the color-word Stroop task20. Increases
in glutamatergic metabolites upon stimulation is not surprising given the tight coupling of
GLU and GLN cycling to neural response25. 1H-fMRS with controlled rest and activation
periods could provide unique information about the dynamic nature of glutamatergic
abnormalities in SZ.
In the simplest of tasks, stimuli received by the brain must be organized and encoded for
further use by brain centers involved in cognition. It is postulated that deficits of stimulus
encoding are central to cognitive deficits in schizophrenia26,27. Previous literature using
the Stroop task in healthy controls and in SZ has shown that this is a task that both
participant groups conduct to the same level of proficiency (rate of correct answers) and
robustly activates the ACC, although with some hypofunction in SZ28,29.
The purpose of this study is to measure ACC glutamatergic concentrations dynamically
during the performance of a color-word Stroop task in SZ compared to healthy controls
and psychiatric controls with MDD using a 1H-fMRS technique. It is hypothesized that
there will be smaller GLU responses along with slower response times in the SZ group
compared to both the healthy controls and MDD group due to the increased number of
encoding subprocesses (constituent cognitive operations), indicating involvement of more
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brain areas as well as diversion of activity away from the ACC26,30. Within groups, it is
hypothesized that there will be an increase in GLU concentrations during activation of
the ACC, with a subsequent return to baseline after the task. Because neuronal GLU
levels have been shown to be related to cognition31, it is expected that concentrations of
the glutamatergic metabolites will negatively correlate with the response times.

5.2 Methods
5.2.1

Participants

There were 16 participants in each of the healthy, MDD, and SZ groups who gave
informed written consent according to the guidelines of the Review Board for Health
Sciences Research Involving Human Subjects at the University of Western Ontario. The
number of participants was chosen based on previous 1H-fMRS studies that have
observed GLU changes of 2-4%14,16–20. Volunteers with neurological or major medical
illnesses, clinically significant head injury, other psychiatric disorders, MRI contraindications, or substance abuse within the previous year were excluded from the study.
Any healthy volunteer with a known family history of psychiatric disorder in a first or
second degree relative was also excluded.
A consensus diagnosis was established on all participants by a psychiatrist and trained
assistant with the Structured Clinical Interview for DSM-IV32. SZ subjects were rated
with the Scale for Assessment of Negative Symptoms and the Scale for the Assessment
of Positive Symptoms33,34 and MDD patients were assessed with the Montgomery Asberg
Depression Scale35 and the Young Mania Rating Scale36. Fourteen SZ patients were
receiving atypical neuroleptics with Chlorpromazine Equivalent 409 ± 293mg (3 taking
olanzapine; quetiapine/venlafaxine; 2 taking risperidone; quetiapine/paliperidone/
escitalopram; 4 taking paliperidone; clozapine; risperidone/escitalopram; quetiapine/
escitalopram) and 2 patients were not medicated. Ten of the 16 MDD patients were
receiving antidepressant medications at the time of the scan (bupropion/citalopram/
methylphenidate; venlafaxine; lamotrigine; desvenlafaxine; bupropion/citalopram;
escitalopram; citalopram; sertraline; citalopram/mirtazapine/quetiapine; levothyroxine/
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melatonin). Demographic information including age, handedness, education, parental
education, clinical rating scores, and length of illness were collected according to our
previous study37 and are shown in Table 5-1.

Table 5-1. Participant demographics
Group

Controls

Age

23.9

±

4.7

MDD
21.7

±

SZ
3.3

22.7

±

M/F

11/5

6/10

13/3

R/L

14/2

14/2

15/1

Educ

3.1

±

0.9

PEduc

3.1

±

0.9

2.9

2.6

±

0.6

2.2

±

0.8

3.3

±

0.8

CPZ (mg)

358

±

307

SANS

9.7

±

7.7

SAPS

7.6

±

10.4

3.0

±

0.6

H Anx

12.7

±

10.9

H Dep

12.4

±

9.1

Mania

5.4

±

6.8

Montg

17.4

±

10.4

M/F - male/female
R/L - right/left
Educ - education rating of the participant (1= in high school, 2=completed high school, 3=some college, 4= completed college)
PEduc - education rating of the participant’s parent (1= in high school, 2=completed high school, 3=some college, 4= completed
college)
H Anx - Hamilton Anxiety Scale
H Dep - Hamilton Depression Scale
Mania - mania rating from the Montgomery Asperg Depression Scale
Montg - result of the Montgomery Asperg Depression Scale
CPZ - chlorapromazine equivalent
SANS - Scale for Assessment of Negative Symptoms
SAPS - Scale for Assessment of Positive Symptoms

5.2.2

Anterior cingulate activation paradigm

We have previously described details of the color-word Stroop Task chosen for the
functional paradigm20. Briefly, it was a four-condition (congruent, incongruent, wordonly, color-only) by four-color (red, green, blue, yellow) design. The subjects were asked
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to respond as quickly and accurately as possible on a four-button keypad with the color of
the ink as the correct answer for all but the word-only conditions within which the answer
was the color-word. Stimuli were presented for two seconds followed by one second of
cross fixation. In the scanner, subjects first engage in cross-fixation for four minutes prior
to a four-minute block of activation (Stroop1), which is then followed by four minutes of
recovery (Recovery1). In contrast to the previous study by Taylor et al20, an additional
four minutes of Stroop activation (Stroop2) was acquired after Recovery1, which was
then followed by another four-minute recovery period (Recovery2). This additional block
of activation will help assess the glutamatergic response to repeated, prolonged Stroop
stimuli in the ACC. The procedure was written and presented using PsychoPy38, which
also recorded accuracy and response times. A confirmatory fMRI was acquired post-1HfMRS to ensure activation within the fMRS voxel. The fMRI lasted nine minutes and
was divided into one-minute blocks cycling between resting (cross-fixation) and Stroop
activation, for a total of four minutes of Stroop activation. Image preprocessing and
statistical analysis were conducted using Statistical Parametric Mappping (SPM8;
Wellcome Department of Neurology, London, UK) within Matlab 7.1 (The Mathworks
Inc., MA).

5.2.3

1

H-fMRS Data Collection and Analysis

All measurements were acquired on a 7.0 T Agilent/Magnex head-only MRI (Agilent,
Inc, Walnut Creek, California, USA) with a Siemens AC84 head gradient coil (Siemens,
Erlangen, Germany), located at the Center for Functional and Metabolic Mapping at
Western’s Robarts Research Institute. A transmit-only receive-only (TORO) head coil
with 15 transmitters and 23 receivers39 was used for all scans with a B1-shimming
approach to facilitate optimized homogeneity correction of the transmit field for each
scan40. The magnetic field uniformity (B0-shim) was adjusted automatically over the
field of view with first-order and second-order shims using RASTAMAP41.
The 1H-MRS voxels were 2.0 × 2.0 × 2.0 cm (8 cm3) in size. In every individual, a voxel
was centered medially and encompassed the bilateral ACC (Fig. 5-1) using two fast low-

119

angle shot 2D anatomical imaging sequences in the sagittal (45 slices, repetition time
(TR)=950 ms, echo time (TE)=5.23ms, flip-angle (α)=30°, gap between slices=1 mm,
thickness=2 mm, field of view (FOV)=220 × 220 mm, matrix size=220 × 200) and axial
(20 slices, TR=500ms, TE=5.23ms, α=30°, gap=1mm, thickness=2mm, FOV=220 ×
220mm, matrix size=220 × 220) directions, both with lipid saturation. The voxels were
placed in the areas of the ACC where activation was expected based on previous fMRI
studies that used a color-word Stroop task42,43.
1

H-MRS spectra were acquired individually throughout the Stroop paradigm using an

ultra-short TE stimulated echo acquisition mode sequence with outer volume
suppression44 (TR=3s, TE=10ms, mixing time (TM)=32ms, 4000 complex pairs, 4 steady
state scans, 1s acquisition time, 8 step phase cycle) with 16 water unsuppressed spectra
and 400 water suppressed spectra, 80 spectra for each 4 min section of the Stroop
paradigm (Resting, Stroop1, Recovery1, Stroop2, Recovery2). An eight-pulse VAPOR
preparation sequence, with an additional water suppression pulse during the TM period44,
provided efficient water suppression. A separate metabolite-suppressed spectrum was
acquired to assess the macromolecular content45 for each individual. This metabolitesuppressed spectrum was modelled using a Hankel-Lanczos singular value
decomposition (HLSVD)46,47 routine and included in the fitting template. Each
acquisition produced 23 spectra, one for each receiver, which required channel
combination before use48. Spectra were frequency and phase corrected before being
averaged together. QUality Eddy Current Correction (QUECC)49 reduced linewidth
distortions before spectral fitting with fitMAN, a time-domain fitting algorithm50.
Metabolite concentrations were calculated with corrections for gray and white matter
content, as previously described in Stanley et al51. All spectra were inspected visually for
quality. To ensure reliable quantification, only metabolites with Cramer-Rao lower
bounds (CRLB) less than 10% were included in the analysis.
To illustrate the dynamic response of GLU throughout the acquisition, spectra were
subdivided and averaged into 20 spectra (one-minute intervals). These were fit for each
person, then combined via a moving average for each group.
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A 5x3 repeated-measures analysis of variance (rmANOVA) design using the metabolite
concentrations at each 4 min (80 spectral averages) section of the functional paradigm
was examined using SPSS v.20 (IBM Corp, Armonk, New York, USA) to determine
significant variations over time and across groups. One-tailed tests were employed for
GLU due to the directional hypotheses of concentration increases with activation by the
Stroop Task followed by decreases during the recovery. GLN and GLX were similarly
explored; GLX, with one-tailed tests as GLU is the main contributor to GLX
concentration, and GLN with two-tailed tests. For pairwise comparison, the blocks of the
Stroop paradigm were compared to both the previous block and the sequential block.
Metabolite changes will similarly be explored with concentrations that are normalized to
their resting values. To accommodate multiple comparisons, alpha was divided by four
(p<0.05/4). Kolmogorov-Smirnov tests were used to ensure the assumption of normality.

5.3 Results:
Significant Family-Wise Error (FWE) corrected (p<0.05) activation of the ACC was
observed in the confirmatory fMRI (Fig.5-1c). The activation observed was within the
location of voxel placement in the ACC.
Unsuppressed water spectra were acquired with average linewidths of 10.79±1.08 Hz
after shimming and the water peak was effectively suppressed in the metabolite spectra
(Fig. 5-2). GLU and GLN concentrations were estimated from the fit (Fig. 5-1) with
CRLB less than 1% and 10%, respectively, indicating high quality fits of the data. A
moving average of fluctuations in GLU levels throughout the activation paradigm is
presented in Fig. 5-3 for each participant group.
The rmANOVA (alpha=0.05) yielded a significant main effect of time for GLU
(p<0.001) and GLX (p<0.001) but not GLN (p=0.132). Strongly significant increases
occurred for GLU (p=0.002) and GLX (p=0.001) in Stroop1 over all groups. There were
no significant time by group interactions (GLU, p=0.377; GLN, p=0.317; GLX, p=0.616)
and there were no main effects of group (GLU, p=0.797; GLN, p=0.137; GLX, p=0.700).
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The planned pairwise comparisons (alpha=0.05/4) of adjacent periods of the Stroop Task
yielded significantly increased GLU (p=0.006) concentrations in the healthy controls
during Stroop1 (Table 5-2). GLU then decreased towards the resting value in Recovery1
(p=0.007). In the SZ group, GLX concentrations had a trend to increase Stroop1
(p=0.016). The SZ group was the only group to show significant GLN changes, going
from 1.21±0.52 mmol/kgww at rest to 1.44±0.50 mmol/kgww (p=0.004, two-tailed) in
Stroop1, then returning to 1.18±0.48 mmol/kgww in Recovery1 (p=0.001, two-tailed). The
MDD group did not show any significant changes in glutamatergic concentrations during
Stroop1.
Stroop2 yielded unexpected decreases in GLU and GLX concentrations relative to
Recovery1. Using two-tailed tests (as the assumptions for one-tailed tests were no longer
valid), the MDD group showed significantly decreased GLU and GLX (p=0.003,
p=0.006, respectively) and the SZ group showed a near-significant decrease for GLU
(p=0.024).
Combining all groups yielded significant decreases in GLU (p=0.003) and GLX
(p=0.008). Statistical comparisons using concentrations normalized to resting values
yielded highly similar results (Table 5-3). A post-hoc test (alpha=0.05) comparing the
GLU concentrations during the two Stroop conditions indicated lower concentrations in
Stroop2 for the MDD group (p=0.001) and the SZ group (p=0.026) but not the healthy
control group (p=0.053). GLU concentrations in Stroop2 were found to be lower in every
group when the concentrations were normalized to the resting values (p=0.009, p=0.002,
p=0.034 for control, MDD, and SZ groups, respectively).
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Figure 5-1. (A) Sagittal and (B) transverse cross-sections depicting the position of
the 1H-fMRS voxel located in the bilateral ACC of one participant.
The voxel was centered on the junction of the right cingulate sulcus with the
paracentral sulcus, angled to the AP line and placed superior to the first fold of grey
matter above the corpus callosum in the sagittal cross-sections and centered on the
interhemispheric fissure in the transverse cross-sections. (C) The Family-Wise
Error (FWE) corrected (p<0.05) confirmatory fMRI on a normalized average brain
for all groups showing significant activation within the ACC in the right hemisphere
of all participant groups and Stroop conditions combined.
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Table 5-2. Pairwise comparisons for adjacent blocks of the 1H-fMRS paradigm for GLU, GLN, and GLX concentrations
Group
HC

MDD

SZ

All

Resting

Stroop1

p(S1-B)

Recovery1

p(R1-S1)

Stroop2

p(S2-R1)

Recovery2

p(R2-S2)

[GLU]

8.79

±

0.85

9.07

±

0.91

0.004

8.85

±

0.85

0.016

8.69

±

1.08

0.261

8.95

±

1.11

0.072

[GLN]

1.37

±

0.52

1.41

±

0.56

0.533

1.46

±

0.50

0.564

1.40

±

0.56

0.443

1.43

±

0.52

0.775

[GLX]

9.98

±

1.02

10.31

±

0.97

0.012

10.13

±

1.02

0.074

9.92

±

1.38

0.224

10.2

±

1.24

0.12

[GLU]

9.24

±

1.4

9.38

±

1.47

0.079

9.27

±

1.53

0.121

8.91

±

1.52

0.018

8.95

±

1.4

0.788

[GLN]

1.75

±

0.84

1.84

±

0.97

0.275

1.85

±

1.00

0.858

1.86

±

1.07

0.876

1.76

±

0.81

0.285

[GLX]

10.63

±

2.16

10.86

±

2.36

0.049

10.75

±

2.45

0.184

10.31

±

2.5

0.016

10.35

±

2.16

0.823

[GLU]

9.11

±

1.33

9.24

±

1.23

0.105

9.20

±

1.21

0.367

8.94

±

1.49

0.076

8.91

±

1.41

0.804

[GLN]

1.29

±

0.51

1.52

±

0.48

0.005

1.24

±

0.49

0.002

1.26

±

0.38

0.811

1.30

±

0.43

0.737

[GLX]

10.16

±

1.78

10.47

±

1.72

0.015

10.21

±

1.58

0.020

9.97

±

1.87

0.173

9.96

±

1.75

0.963

[GLU]

9.05

±

1.21

9.23

±

1.21

0.001

9.11

±

1.21

0.018

8.85

±

1.35

0.003

8.94

±

1.29

0.288

[GLN]

1.46

±

0.65

1.58

±

0.69

0.009

1.51

±

0.71

0.142

1.50

±

0.74

0.844

1.48

±

0.61

0.769

[GLX]

10.26

±

1.71

10.55

±

1.75

0.001

10.37

±

1.77

0.065

10.07

±

1.93

0.005

10.17

±

1.73

0.314

p(S1-B) = Stroop1 vs resting, (alpha=0.05/4 (Bonferroni corrected); one-tailed (GLU, GLX), and two-tailed (GLN)), bolded values indicate statistical significance
p(R1-S1) = Recovery1 vs Stroop1, (alpha=0.05/4 (Bonferroni corrected); one-tailed (GLU, GLX), and two-tailed (GLN)), bolded values indicate statistical significance
p(S2-R1) = Stroop2 vs Recovery1, (alpha=0.05/4 (Bonferroni corrected); two-tailed (GLU, GLN, GLX)), bolded values indicate statistical significance
p(R2-S2) = Recovery2 vs Stroop2, (alpha=0.05/4 (Bonferroni corrected); two-tailed (GLU, GLN, GLX)), bolded values indicate statistical significance
HC = Healthy controls
MDD = Major Depressive Disorder
SZ = Schizophrenia
All = the combination of all participants across groups
[GLU] = The concentration of glutamate (mmol/kgww)
[GLN] = The concentration of glutamine (mmol/kgww)
[GLX] = The concentration of GLX (glutamate + glutamine; mmol/kgww)

124

Table 5-3. Pairwise comparisons for adjacent blocks of the 1H-fMRS paradigm, normalized to the resting concentration for
GLU, GLN, and GLX
Group
HC

MDD

SZ

All

Resting

Stroop1

p(S1-B)

Recovery1

p(R1-S1)

Stroop2

p(S2-R1)

Recovery2

p(R2-S2)

GLU_N

1.000

±

0.000

1.032

±

0.055

0.005

1.004

±

0.059

0.006

1.001

±

0.052

0.808

1.012

±

0.075

0.340

GLN_N

1.000

±

0.000

1.044

±

0.214

0.598

1.041

±

0.282

0.968

0.982

±

0.180

0.491

1.002

±

0.157

0.715

GLX_N

1.000

±

0.000

1.033

±

0.060

0.013

1.012

±

0.062

0.027

1.003

±

0.043

0.602

1.015

±

0.075

0.363

GLU_N

1.000

±

0.000

1.016

±

0.049

0.082

1.003

±

0.059

0.101

0.963

±

0.055

0.005

0.969

±

0.035

0.634

GLN_N

1.000

±

0.000

1.048

±

0.249

0.547

1.068

±

0.275

0.766

1.005

±

0.290

0.451

0.954

±

0.276

0.333

GLX_N

1.000

±

0.000

1.022

±

0.060

0.066

1.009

±

0.069

0.135

0.967

±

0.084

0.011

0.974

±

0.043

0.598

GLU_N

1.000

±

0.000

1.016

±

0.031

0.081

1.014

±

0.061

0.420

0.981

±

0.071

0.017

0.979

±

0.076

0.892

GLN_N

1.000

±

0.000

1.264

±

0.386

0.001

1.048

±

0.381

0.002

1.071

±

0.313

0.778

1.087

±

0.326

0.757

GLX_N

1.000

±

0.000

1.034

±

0.049

0.011

1.013

±

0.08

0.027

0.982

±

0.081

0.065

0.985

±

0.087

0.840

GLU_N

1.000

±

0.000

1.021

±

0.045

0.002

1.007

±

0.058

0.010

0.981

±

0.061

0.002

0.986

±

0.066

0.449

GLN_N

1.000

±

0.000

1.124

±

0.309

0.014

1.053

±

0.311

0.088

1.021

±

0.267

0.490

1.016

±

0.266

0.865

GLX_N

1.000

±

0.000

1.030

±

0.056

0.001

1.011

±

0.069

0.003

0.984

±

0.074

0.006

0.991

±

0.071

0.341

p(S1-B) = Stroop1 vs resting, (alpha=0.05/4 (Bonferroni corrected); one-tailed (GLU, GLX), and two-tailed (GLN)), bolded values indicate statistical significance
p(R1-S1) = Recovery1 vs Stroop1, (alpha=0.05/4 (Bonferroni corrected); one-tailed (GLU, GLX), and two-tailed (GLN)), bolded values indicate statistical significance
p(S2-R1) = Stroop2 vs Recovery1, (alpha=0.05/4 (Bonferroni corrected); two-tailed (GLU, GLN, GLX)), bolded values indicate statistical significance
p(R2-S2) = Recovery2 vs Stroop2, (alpha=0.05/4 (Bonferroni corrected); two-tailed (GLU, GLN, GLX)), bolded values indicate statistical significance
HC = Healthy controls
MDD = Major Depressive Disorder
SZ = Schizophrenia
All = the combination of all participants across groups
GLU_N = The concentration of Glutamate normalized to the resting period
GLN_N = The concentration of glutamine normalized to the resting period
GLX_N = The concentration of GLX (glutamate + glutamine) normalized to the resting period
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Table 5-4. Behavioural response times (correct-only) to the incongruent Stroop condition and correlation to glutamate and
glutamine concentrations and percent changes during those trials
Trial

Stroop1

Stroop2

Subject
Group

Response
Time (s)

Correlations
GLU

p

ΔGLU

p

GLN

p

ΔGLN

p

HC

0.92

±

0.16

-0.42

0.077

0.04

0.446

-0.45

0.081

-0.34

0.151

MDD

0.95

±

0.12

-0.37

0.08

-0.30

0.126

-0.41

0.063

-0.67

0.003

SZ

1.03

±

0.08

-0.35

0.099

-0.23

0.207

-0.50

0.033

-0.65

0.006

All

0.97

±

0.13

-0.32

0.017

-0.15

0.166

-0.40

0.005

-0.33

0.019

HC

0.84

±

0.15

-0.39

0.107

0.28

0.178

-0.60

0.026

-0.58

0.031

MDD

0.89

±

0.13

-0.30

0.133

-0.28

0.144

-0.20

0.249

-0.45

0.055

SZ

0.93

±

0.13

0.38

0.083

0.14

0.309

-0.17

0.287

-0.20

0.244

All

0.89

±

0.14

-0.08

0.313

0.04

0.387

-0.28

0.040

-0.28

0.045

GLU = glutamate correlation coefficient (Pearson r) with response times
ΔGLU = The normalized glutamate concentration change
GLN = glutamine correlation coefficient (Pearson r) with response times
ΔGLN = The normalized glutamine concentration change correlation coefficient (Pearson r) with response times
p = probability that the correlation is due to chance (alpha=0.05/4 (Bonferroni corrected), one-tailed), bolded values indicate statistical significance
HC= healthy controls
MDD = major depressive disorder
SZ = Schizophrenia
All = the combination of all participants across groups
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Table 5-5. Correlation values between behavioural response times for each Stroop condition and GLU and GLN
concentrations during Stroop1
Stroop1
Group

HC

MDD

SZ

All

Stroop2

Metabolite

Congruent

Incongruent

Word Only

Color Only

All

Congruent

Incongruent

Word Only

Color Only

All

GLU

-0.394

-0.419

-0.152

-0.614

-0.471

-0.551

-0.454

-0.085

-0.558

-0.494

ΔGLU

0.232

0.042

-0.070

0.034

0.074

0.173

0.253

0.190

0.443

0.255

GLN

-0.559

-0.453

-0.296

-0.552

-0.546

-0.424

-0.643

-0.468

-0.301

-0.540

ΔGLN

-0.131

-0.343

-0.245

-0.084

-0.242

0.000

-0.216

-0.386

-0.176

-0.209

GLU

-0.009

-0.368

-0.390

-0.276

-0.304

0.076

-0.270

-0.181

0.013

-0.123

ΔGLU

-0.344

-0.304

-0.081

-0.348

-0.310

-0.212

-0.137

-0.298

-0.074

-0.203

GLN

-0.291

-0.443

0.029

0.105

-0.220

0.010

-0.250

-0.305

-0.229

-0.215

ΔGLN

0.319

-0.525

0.217

0.432

0.172

-0.181

-0.583

-0.200

-0.472

-0.436

GLU

0.091

-0.352

0.192

0.129

0.028

0.115

0.334

0.002

0.454

0.302

ΔGLU

-0.088

-0.228

0.166

0.121

0.003

-0.062

-0.429

0.128

-0.238

-0.147

GLN

-0.077

-0.439

-0.296

-0.132

-0.267

-0.345

-0.290

-0.157

-0.259

-0.324

ΔGLN

-0.089

-0.676

-0.383

-0.366

-0.427

-0.024

-0.239

-0.019

-0.016

-0.094

GLU

-0.055

-0.321

-0.140

-0.214

-0.222

-0.035

-0.097

-0.069

0.069

-0.041

ΔGLU

-0.092

-0.149

-0.017

-0.131

-0.115

-0.021

-0.092

0.033

-0.113

-0.063

GLN

-0.207

-0.404

-0.301

-0.214

-0.331

-0.163

-0.310

-0.259

-0.237

-0.284

ΔGLN

-0.003

-0.330

-0.150

-0.024

-0.154

0.017

-0.213

-0.068

-0.010

-0.092

GLU = glutamate correlation coefficient (Pearson r) with response times
ΔGLU = The normalized glutamate concentration change
GLN = glutamine correlation coefficient (Pearson r) with response times
ΔGLN = The normalized glutamine concentration change correlation coefficient (Pearson r) with response times
HC= healthy controls
MDD = major depressive disorder
SZ = Schizophrenia
All = the combination of all participants across groups
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Figure 5-2. (A) An example resting 80 average water suppressed spectrum.
This is taken from the ACC of a volunteer with SZ. A 2Hz Lorentzian line
broadening has been applied. (B) Resultant estimates of the glutamate and (C)
glutamine spectral fits. (D) The residual (spectrum minus the fit of all metabolites)
of the spectrum
Every group was able to respond to the stimuli correctly with at least 90% accuracy.
Mathematical modeling of Stroop performance confirmed an increased number of
subprocesses (constituent cognitive operations) among the SZ group26,27,52,53. The
response times to the incongruent condition during Stroop1 significantly correlated with
GLN concentrations when averaged together over all groups (p=0.005; Table 5-4),
whereas GLU concentrations only presented with a trend (p=0.017). The MDD and SZ
groups responses significantly correlated with the normalized GLN responses (p=0.003,
p=0.006, respectively), and no group’s response times were significantly correlated with
the normalized GLU responses. No significant correlations were observed in Stroop2.
The full table of correlations between GLU and GLN concentrations and response times
for each of the four Stroop conditions can be found in Table 5-5.
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5.4 Discussion:
The GLU response in the ACC of healthy controls (3.2%) compares well with the 2.6%
reported previously using the Stroop Task20 and with the 2-4% reported previously in
other brain areas14,16–19. A main effect of time was observed for all groups in Stroop1
compared to Resting, nevertheless, planned contrasts were significant for the healthy
controls only. GLU and GLN cycling correlates with neuronal glucose consumption in
activated conditions25 and hypofunction of the ACC with color-word Stroop Tasks has
been demonstrated in SZ with fMRI28,29. In SZ, it seems that the number of processing
steps involved in stimulus encoding is increased26,27,52,53. The increased processing steps
may involve more brain areas than in controls and cause a blunted activation state of the
ACC, which could explain the relatively smaller increase in GLU.

Figure 5-3. Four-minute moving average time courses of glutamate concentrations.
Each point represents the percent change from resting concentration (averaged over
four minutes) for (A) healthy, (B) Major Depressive Disorder, (C) Schizophrenia
groups, and (D) all groups combined. Shaded areas indicate that the Stroop task is
being performed during that time. Error bars represent inter-individual standard
error of the mean
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The observed decreases in GLU and GLX during Stroop2 relative to Stroop1 and
Recovery1, particularly in the patient groups, were unexpected. Learning effects on GLU
as the task progresses are a possible explanation owing to the increased amount of
practice participants have received by the time of the second task. The observed decrease
in response times during Stroop2 relative to Stroop1 does indicate that the task became
easier. This study is now the second to report a decrease in a neurotransmitter using a
cognitive task with 1H-fMRS, as a similar result has been observed in prefrontal cortex
GABA concentrations during a working memory task, which initially showed an increase
in GABA concentrations followed by three subsequent runs with decreases15. This
finding is not observed in the visual or motor tasks14,16–19, so it is not likely that the
reduced GLU is due to an inadequate duration of Recovery1. Future fMRS studies using
cognitive stimuli should observe a longer recovery time between functional runs to
further explore this finding.
The behavioural response times for the incongruent condition during Stroop1 negatively
correlated with the GLN concentrations. More GLN readily available could mean quicker
responses are possible because less time is required to create GLU for neurotransmission.
The normalized changes in GLN during the task were much stronger predictors than
GLU, which seemingly had no correlation, indicating the role of GLN in
neurotransmission may have substantial influence on cognitive capabilities.
No between-group comparisons yielded significant results but there are still some points
worth noting for possible future testing. First, the resting GLU levels were slightly higher
in the MDD and SZ groups than the healthy controls. Elevated GLU concentrations can
lead to excitotoxicity54,55 so levels are carefully controlled by re-uptake transporters. It is
possible that resting GLU in MDD and SZ groups are closer to a GLU ceiling making
GLU upregulation more difficult. It should also be noted that GLU and GLN are involved
in many other brain functions, including metabolism, which is likely also in a dynamic
state.
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Secondly, the SZ group appeared to have a slower GLU response and recovery to
Stroop1 when compared to controls and MDD subjects yet showed significant differences
in the GLN concentrations during Stroop1 and Recovery1. When GLU is released from
the receptor on the post-synaptic membrane it is taken up into the adjacent glial cell55 and
converted to GLN via glutamine synthetase so that it can be transferred back into the
neuron55 where the GLN is converted back into GLU via the phosphate-activated enzyme
glutaminase (PAG)56. Insufficient PAG would slow the conversion of GLN to GLU,
resulting in a slower GLU-GLN cycle and a prolonged recovery from a
neurotransmission event. However, no significant difference was observed in the
expression of PAG in the ACC in one post-mortem study57 and increased expression was
found in the thalamus in another58. Another possible explanation comes from studies that
have demonstrated that NMDA hypofunction causes increased glutamine synthetase
activity resulting in increased GLN59. Consistent with this observation, another study has
shown that increased ketamine administration in healthy controls leads to increased GLN
concentrations in the ACC60. It is possible, that the increased GLN observed in the SZ
group arose from NMDA hypofunction when the ACC was challenged.
There is evidence to support a possible glutamatergic dysfunction in MDD as well9.
While the exact mechanism is yet to be understood, some lines of evidence suggest
astrocytic dysfunction may contribute to the pathophysiology of MDD9,61,62. Astrocytes
are pivotal elements in the GLU-GLN cycle and it is possible that any disruption to the
efficiency of their operations in MDD could have contributed to the lack of a significant
increase during Stroop1, or to the significant decrease in Stroop2. Previous studies have
demonstrated decreased ACC GLU in the MDD9–11, which was not observed in this
study. This could be due to the different placement of voxels within the relatively large
ACC or possibly a result of treatment effects. It could also be due to the significant
difference in gender in the subject population. In this study, the MDD group had a larger
incidence of females than the healthy controls. This is another confound that is difficult
to avoid, as women have a higher prevalence of MDD than males at a ratio of 1.64:1 in
Canada63. This must be considered when interpreting the results as gender has previously
been shown to influence GLU64 and GLN65 concentrations.
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A limitation of the study is the possible influence of the medications, which have been
shown to affect glutamatergic concentration levels66,67. Antipsychotic and antidepressant
medications are often unavoidable confounds of studies involving SZ and MDD patients.
Although the subjects in this study were in relatively early stages of the illness (30 ± 16
months and 29 ± 14 months for the SZ and MDD groups, respectively), medications have
been shown to influence the GLU concentration of medicated SZ patients in as early as 4
weeks67. This could have influenced the baseline levels of GLU and, possibly, the GLU
responses to functional activation.
Although the confirmatory fMRI suggests correct voxel placement, another limitation of
this study is that there was no fMRI guidance prior to the 1H-fMRS acquisition. The
confirmatory fMRI was acquired post-fMRS to decrease the impact of task learning
effects to elicit the strongest ACC response, to which the reduction in response times and
GLU changes observed during Stroop2 do suggest that considerable learning effects
occur.
Detailed analyses of the confirmatory fMRI and mathematical modeling of the
behavioural response times are beyond the scope of this work and will be presented in
other venues52.

5.5 Conclusion:
GLU concentrations measured with 1H-fMRS were demonstrated to significantly increase
in a healthy control group upon functional activation of the ACC using a color-word
Stroop task but not in a MDD or SZ group. This is the first study to perform 1H-fMRS in
the ACC at 7 T in a psychiatric population. Use of a psychiatric control group (MDD)
demonstrated that the increases in GLN were specific to SZ, but the blunted GLU
response during Stroop1 was not. Observed response times of the MDD group were
slower than the healthy controls, but were not as slow as the SZ group, indicating a
stronger deterioration of function in SZ. Future studies should try to include psychiatric
control groups to assess the specificity of the results. Future studies should examine
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other cognitive tasks that activate the ACC, perhaps with varying levels of complexity to
get a better understanding of the GLU and GLN response in SZ, with longer response
times and varying stimulus encoding loads to study the GLU recovery process in greater
detail.
Supplementary information is available at npj Schizophrenia’s website.
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Chapter 6

6

Summary, Future Work, and Conclusions

This section will begin with a discussion of each paper to put into perspective how they
all fit together to complete a story. There will then be suggestions for possible future
avenues of research based on the results of this thesis, with some recommendations for
ways in which the methodologies can be improved. This will be followed by a brief
conclusion.

6.1 Summary of chapters
6.1.1

Simulations

Simulations were designed to isolate common sources of variation in metabolite
quantification precision (i.e. how consistent the measurements are), accuracy (i.e. how
close the measured concentrations are to the correct values) and correlations between
metabolite concentration estimates (i.e. how do the concentration estimates interact with
each other) using simulated human brain spectra of four commonly used B0, 1.5 T, 3.0T,
4.0T, and 7.0T. Three SNR were assumed for each B0, one with 64 spectral averages,
another with 256 spectral averages, and one with a theoretical SNR of 1024 (practically
unachievable in water suppressed human brain spectra). The precision and the
completeness of the initial estimate of the metabolite fitting template were also assessed.
The focus of the study was on J-coupled metabolites, such as GLU and GLN, but all
metabolites were evaluated.
With the exception of the fitting templates with omitted metabolites, the accuracy of
metabolite concentration estimates was generally unaffected for all conditions studied. It
was found that the precision generally improved as B0 increased, with the largest
improvements in quantification precision coming from J-coupled metabolites. J-coupled
metabolites also had the strongest reductions in correlations between metabolite
concentration estimates when B0 increased, meaning they can be quantified more
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independently. Precision also improved when SNR increased as a consequence of
increasing B0. An important observation that was independent of B0 is that the precision
of the initial estimate of the spectral fitting template did affect quantification precision, so
care is needed in providing a reasonable initial estimate.
This study has confirmed the hypothesis that there are significant benefits to using higher
B0 for 1H-MRS studies aiming to reliably quantify GLU and GLN. The increase in SNR
reduces the number of averages necessary to acquire quality spectra, which is important
for any application of 1H-fMRS. A stronger B0 will also help in quantifying lower
concentration and heavily overlapped metabolites, such as GLY. Therefore, a 7 T MRI
and ultra-short echo time STEAM sequence were employed for all the 1H-MRS and 1HfMRS work included in this thesis.

6.1.2

Single-voxel 1H-MRS

The aim of this study was to examine concentrations of GLU, GLN, and GLY in the
ACC and thalamus of SZ compared to healthy controls and MDD using the
aforementioned benefits in metabolite quantification that is possible with a 7 T MRI. The
key findings of the study were increased GLN and decreased GLY in the thalamus of
people with SZ compared to the healthy control group, and decreased MYO in both the
ACC and thalamus of the MDD group compared to the healthy control group and SZ
groups. No differences in GLU were found in any group. It was the first study to examine
GLY concentrations in the brains of a schizophrenic population in vivo using 1H-MRS.
The increased GLN and decreased GLY in the SZ group fit well with the NMDA
hypofunction model of SZ and agree with the hypotheses of increased GLN and
abnormal GLY concentrations in SZ. As demonstrated in Fig 1-3, GLY availability is
critical to GLU neurotransmission via the NMDA receptor. Therefore, insufficient
concentrations of GLY in the synaptic cleft could lead to a deficiency in NMDA
function. The increased GLN fits into this model as well. NMDA hypofunction
increases the activity of glutamine synthetase, which then increases the concentrations of
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GLN1. The thalamus is involved in the transmission of most sensory input and is a
central hub of the BGTHC circuits that mediate communications between motivation and
action. It is a critical location for communication to areas involved in both the positive
symptoms of SZ via the substantia nigra and nucleus accumbens, and the negative
symptoms of SZ via the prefrontal cortex and the ACC. There were no glutamatergic
changes in the ACC of the SZ group relative to either healthy control or MDD groups.
This was unexpected based on previous studies in the literature2, including previous
results from this lab3,4, and contradicted that part of the hypothesis. This could be due to
the time gap between diagnoses to the time of the scan, which was on average 30 months
for this subject group. It has previously been shown that the concentration of GLN is
initially higher in the ACC of people with SZ, and this concentration gradually decreases
over time2,5. It is possible that there initially was an increase in GLN, but, due to the
length of illness, the concentration decreased and was no longer significant.
It was also expected that the MDD group would present with GLU abnormalities relative
to the SZ and control groups. There is growing evidence that excitatory synapses and
NMDA receptors play a role in MDD symptomatology6. Ketamine, the NMDA
antagonist known to induce SZ-like behavior in healthy controls7, when administered in
low doses has anti-depressant properties in people with MDD6. A dysfunction in the
NMDA receptors in MDD could explain the lack of observed significant differences in
GLN between the SZ group and the MDD group.
It should be noted that the SZ and MDD groups in this study were no longer drug-naïve.
It has previously been demonstrated that medications can influence GLU concentrations
in a short time frame8,9 and that GLU concentrations vary throughout the disease
progression2,5. It is, therefore, a possibility that medications and/or disease duration had
some influence on the results. Obtaining data from unmedicated patients early in their
illness is, of course, challenging. SZ is only prevalent in about 1% of the population with
the typical disease onset during adolescence. A drug-naïve first-episode study would rely
on an influx of young adolescents experiencing psychiatric symptoms that agree to
volunteer for an MRI and often require their parents’ permission. With this study in
particular, due to technical challenges associated with implementing the 1H-MRS
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protocol on the 7 T scanner (planned decommissioning within 2 years of the start of the
study), the available time-window only permitted the scanning of young patients with SZ,
still early in their illness (30 ± 15 months), but not drug-naïve. It is possible that this
could have influenced GLU concentrations in the ACC and thalamus. Future studies
should explore a longitudinal design starting at the first-episode, never-treated time point.
Another confound of this study is that as many as 60% of people with SZ are smokers10,
and smoking has been shown to affect GLU levels in the thalamus11. The prevalence of
smokers in SZ is believed to be partially due to the increased dopamine activity from
smoking10. Cigarette smoking was not an exclusion criteria for this study, so it needs to
be considered when interpreting the results.
Reduced MYO concentrations were observed in the thalamus and the ACC of the MDD
group relative to the healthy control and SZ groups. MYO is an osmolyte in the brain
and is a precursor to many phosphorylated derivatives and second messengers that have
various important functions12. It has also traditionally been a marker for glial cell
integrity although some have questioned this claim12. However, if the assumption is
made that MYO concentrations are reflective of glial cell integrity, then these results do
support the theory of a reduction in glial cell density in MDD. The glia are actively
involved in the GLU-GLN cycle, so disruption of these processes could directly influence
GLU neurotransmission and impede healthy brain function. With MYO being involved
in so many brain functions, it is difficult to interpret what exactly is causing this decrease
in MYO. It is curious, though, that treatments of mania often reduce MYO
concentrations12 and that increased MYO concentrations have been reported in recovered
MDD subjects13. Although this is speculative, it seems likely that the MYO
concentrations somehow influence (or are influenced by) mood. Inositol has been
examined as a possible treatment for MDD previously. The results are mixed, but one
meta-analyses determined that there may be a clinical benefit to inositol as a treatment14.
The number of studies, however, are still small12,13,14, so more are necessary to confirm
this finding.
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It is important to note that there was a significant difference in the number of females to
males in the MDD group compared to the SZ and healthy control groups. This is difficult
to avoid due to the increased prevalence of MDD in females compared to males (1.64:1
in Canada). There have yet to be any studies that have demonstrated differences in MYO
concentrations between males and females, but still an important point to consider.
This study found interesting significant differences in metabolite concentrations between
SZ, MDD, and healthy control subjects. However, this study was conducted in a resting
state with one static measurement as hundreds of other studies of SZ with 1H-MRS have
done. As the very definition of SZ is entirely based on behavioural abnormalities, one
may wonder why an entire literature was formed around MRS measurements of resting
individuals with SZ. Although good rationales and hypotheses have been developed to
explain abnormalities in resting levels of glutamate in SZ, it is reasonable to think that
NMDA hypofunction may affect the ability to dynamically modify GLU concentrations
to transact functional activation. It may be possible to visualize manifestations of NMDA
hypofunction by acquiring dynamic measurements of metabolite concentrations using 1HfMRS of glutamate. GLU changes occurring during performance of a behavioural task
had never been demonstrated using 1H-fMRS at 7 T in healthy humans. Before we could
begin a study using this technique in individuals with SZ, the technique needed to be
developed and demonstrated in healthy controls.

6.1.3

1

H-fMRS in healthy controls

The purpose of this paper was to first demonstrate that 1H-fMRS with a cognitive
behavioural task can induce detectable GLU changes using an ultra-high field 7 T MRI in
healthy controls. Prior to this study, the only 1H-fMRS studies that had successfully
demonstrated GLU changes upon functional activation were conducted in the visual
cortex using a visual paradigm17–19, the motor cortex using a finger tapping paradigm20,
the lateral occipital cortex using a repetition suppression task21,22, the anterior insula
using a pain paradigm23, the dorsal anterior cingulate using a pain paradigm24, and the
pregenual anterior cingulate using a pain paradigm25 and a sexual arousal paradigm26.
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None of these past 1H-fMRS studies had used a cognitive paradigm. Impairments in
cognition have been well studied in SZ and there exists a number of well-established
paradigms to study these impairments. After much debate over which cognitive task
would provide the most robust activation of the ACC while allowing performance of the
task in a prolonged manner and comparable performance accuracy between patients and
controls, the color-word Stroop task was used as the cognitive task for this study, but
certain implementation challenges remained and are discussed below.
First, the location of the 1H-fMRS voxel has typically been placed in the area that elicits
the strongest blood-oxygen level dependent (i.e. BOLD) response in fMRI to a specific
task because of the assumption that the BOLD response is indicative of increased
functional activation. Cognitive and behavioural tasks elicit weaker BOLD responses
relative to the visual and motor tasks27, so it may be expected that a difference in GLU
may be harder to detect. The Stroop task was chosen as the cognitive task to maximize
the possibility of detecting GLU, as it still induces a relatively robust fMRI activation in
the ACC (although not as prominent as visual and motor tasks in their respective brain
regions).
Cognitive tasks typically require some kind of motion to respond to the stimuli, usually
via a button press or verbal communication. This creates the possibility of increased
motion artifacts in the spectra. Although it is possible to have the subjects perform the
cognitive stimuli silently in their minds, it would then not be possible to confirm the
subject was attentive and performing the task with the presumed accuracy demonstrated
during practice. This would also ignore a considerable amount of valuable data in the
processing of the responses (i.e. mean response times, variances, percent correct, etc)
between subject groups. Therefore, care was taken to setup the subject in the MRI in a
position such that they are ready to respond in an attempt to minimize any movement
when responding on the four-button keypad provided.
An additional obstacle in using a cognitive task is that the neural response is more
complex, such that different mechanisms become involved as the task is performed. The
subject learns to perform the task more efficiently, which may blunt the response. Visual
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and motor responses activate specific areas of the brain and can be activated repeatedly,
so these 1H-fMRS studies have utilized fMRI guidance to locate the voxel. With
cognitive tasks, performing the fMRI guidance would mean that the subjects would have
increased exposure to the task, which may reduce activation in the area of interest during
the 1H-fMRS acquisition and make GLU changes harder to detect. By locating a
consistent site of activation, it is possible to use anatomical landmarks to avoid this
problem.
One final challenge is that some people will find certain cognitive tasks harder than other
people. Prior to the 1H-fMRS acquisition, it is important to ensure all participants can
perform the task to the same level of proficiency by giving them some practice and
meeting a specific criterion. For this study, all subjects had to achieve 80% correct
responses on a desktop computer outside of the scanner prior to being examined.
A significant detectable increase in GLU concentrations in the ACC was observed in a
small sample (n=7) of healthy controls after functional activation with the color-word
Stroop task agreeing with the originally stated hypothesis. The magnitude of the GLU
response was consistent with the visual and motor cortex 1H-fMRS studies that also used
prolonged stimulation periods (i.e. on the order of minutes)17–20 but had a smaller
response than event-related 1H-fMRS of the ACC using pain stimuli23–25. It is possible
that there is a separate, rapid, GLU response to event-related stimuli, in particular, pain.
Pain is one the bodies most ancient and evolved responses, so it is possible that it has
adapted a separate GLU response for faster reactions, perhaps utilizing the rapid synaptic
currents produced by the AMPA GLU receptors28.
A limitation of this study is the small sample size of participants. Although the sample
size was low, 6 of the 7 participants showed increases in GLU in the first run of the task
and 6 of the 7 showed decreases in the recovery period. This demonstrates that the Stoop
task is a robust cognitive paradigm to detect GLU changes with functional activation in
the ACC.
With the Stroop 1H-fMRS paradigm able to successfully detect GLU increases in healthy
controls, the next step was to examine GLU dynamically in psychiatric populations.
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6.1.4

1

H-fMRS in schizophrenia and major depressive disorder

The objective of this study was to gain insight into the health of GLU neurotransmission
and the GLU-GLN cycle in SZ using a dynamic 1H-MRS protocol. This was
accomplished using a 1H-fMRS technique similar to the one developed in the previous
chapter was applied to the ACC of SZ, MDD, and healthy control groups using a colorword Stroop paradigm and a 7 T MRI. Each participant underwent a twenty-minute
Stroop paradigm consisting of five, four-minute blocks that cycled between resting and
stimulated conditions (i.e. rest, Stroop, recovery, Stroop, recovery), in which eighty
spectral averages were acquired during each block. Prior to entering the MRI, each
participant needed to perform the Stroop task with >80% accuracy to ensure comparable
levels of proficiency between participants. Metabolite concentrations were extracted from
the fits of the spectra from each block and tracked temporally. The healthy controls were
the only group to significantly increase the concentrations of GLU during the first run of
the task, which was then followed by a significant decrease in the recovery period.
Neither the SZ nor MDD group presented with significant GLU concentration increases
during the first run of the Stroop task, but the SZ group did present with significant
increases in GLN concentrations. The GLU concentrations in the MDD group decreased
significantly during the second run of the task, and there was a significant decrease over
all groups. In addition, there was an overall significant negative correlation between the
GLN concentrations and the response times, suggesting that the GLN levels are important
to efficient cognitive functioning. This was the first study to examine GLU
concentrations using 1H-fMRS in a psychiatric population.
The increase in GLU concentrations in the healthy control group is consistent with the
Stroop 1H-fMRS from chapter 4 and is again comparable to the visual and motor 1HfMRS studies17–20. Both the MDD group and the SZ group did increase their GLU
concentrations in the first run of the task, but not significantly. This blunted or aberrant
response may suggest an inefficiency in the functioning of GLU within the ACC as
NMDA receptors and excitatory synapses are implicated in both disorders6,29,30. If the
NMDA receptors are not functioning optimally then the GLU-GLN cycle will be directly
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affected, which could explain the smaller increase (below statistical significance
threshold) in GLU concentrations in the SZ group. Specifically in the SZ group, the
increase in the GLN concentration could suggest hypofunction of NMDA receptors when
the region is stimulated, as NMDA hypofunction leads to increased GLN concentrations1.
The decrease in the GLU concentrations during the second run of the Stroop was an
unexpected result, based on what has previously been reported in 1H-fMRS studies that
have repeated visual or motor stimuli. This suggests two possible explanations. First, it
is possible that the ACC is no longer required to the same magnitude due to processes
involved in learning and improving the task, such that, with practice, different brain areas
begin to contribute; Second, the GLU response observed is on the order of minutes, so it
may be that four minutes was not enough for all the mechanisms involved to fully
recover.
An important outcome of this study is that the mental state of the participant needs to be
controlled for in “resting” 1H-MRS studies examining GLU or GLN to avoid
confounding the results. Instructions should be provided to the participant not unlike the
instructions that would be given prior to a resting state fMRI scan: relax, close their eyes,
try not to sleep and try to let their mind wander. Alternatively, a cross-fixation could be
applied to control the mental state. This has not been a common procedure in past 1HMRS studies, which could have had some influence on the results. Going forward, a
method for controlling the resting state should be a component of every 1H-MRS protocol
examining GLU or GLN.
There are similar limitations present in this study as the study mentioned in chapter 3.
There was significantly more females in the MDD group than in the SZ and healthy
control groups, the subjects were not drug-naïve, and smoking was not controlled for in
the subject recruitment. The effects of these limitations have already been discussed in
detail in chapter 6.1.2.
One limitation of studying cognitive tasks in psychiatric populations is that avolition is
one of the key negative symptom of SZ, so the differences observed in the fMRI or 1HfMRS data could be due to a lack of effort. This is a difficult confound to control, but a
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task that is challenging and engaging should help. In our Stroop task, we controlled
performance based on the number of correct answers and we showed that participants
with SZ were able to conduct the task with similar levels of proficiency (>90%). It may
be debatable whether control for performance accuracy is equivalent to controlling for
motivational/effort level.

6.2 Future Work
The results of these studies advance the literature and provide avenues for further
exploration with more questions yet to be answered. There are many possible directions
to move forward, some of which are briefly discussed below.

6.2.1

Simulations

This manuscript has received comments from reviewers after it was submitted for
publication to Magnetic Resonance in Medicine and is currently in revisions in
preparation to resubmit. The discussion below pertains to the comments and issues
mentioned by the reviewers along with some suggestions for future work.
This simulation study demonstrated that with higher B0 it is possible to improve
metabolite quantification when using the time-domain fitting algorithm, fitMAN31.
Whether these results are transmittable to other fitting algorithms has been brought into
question. Many fitting algorithms share a common theme of reducing residuals between
the data and the fit using a priori information. It has previously been demonstrated that
the frequency-domain fitting algorithm LCModel32 and the time-domain fitting algorithm
AMARES33 produce very similar concentrations in a study utilizing metabolite
phantoms. The challenges relating to metabolite quantification including SNR, metabolite
signature overlap and J-dephasing are not specific to fitMAN and would be challenges in
other fitting algorithms as well. Similarly, all minimization routines need to have an
initial estimate to minimize. It is expected that identical results would be obtained using
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other common fitting algorithms like LCModel or AMARES. A similar simulation study
utilizing multiple fitting algorithms could be performed to confirm.
Many 1H-MRS studies utilize Cramer-Rao Lower Bounds (CRLB) to report the quality of
the spectral fits. The CRLB are useful because they provide information on the
minimum variance to be expected from the fitting parameters from a single fit. The
advantage of examining the coefficient of variation (CV) is that all sources of variation
are considered, including the variation from the fitting parameters, and provides a more
realistic expectation of variation one would expect from a spectral acquisition. Still, due
to the prevalence of CRLB in the research community, it would be wise to examine the
same quantification relationships using the CRLB as well as the CV. This would provide
information towards the minimum variance coming from the fitting of the parameters,
and the difference would give an estimate on the variation that arises from other sources
as well. In general, simulations are a good way to examine sources of quantification
variation, mainly because the sources can be isolated, and the simulations can be repeated
in a Monte Carlo format to achieve a desired power.
There are a number of ways in which the simulation study could be further explored.
First, it should implement even more metabolites that are present in very low
concentrations. There are still many more metabolites that contribute to the spectral area
in 1H-MRS that cannot typically be quantified reliably. The increase in SNR obtained by
working at 7 T pushes some lower concentration metabolites not typically part of human
brain 1H-MRS quantification template above the detectability threshold. Addition of
candidate metabolites to the simulation would be useful to get an idea of whether the
spectral area from these metabolites are currently being consistently absorbed into the fit
of any other specific metabolites when they are omitted from the fitting templates, which
would lead to inaccuracies in measured metabolite concentrations.
Another way to extend the simulation study would be to isolate the effects of each of the
constrained parameters on quantification. That is, to use inexact seeding for a single
parameter, while using exact seeding for the remaining parameters. This would
characterize which parameters, when seeded poorly, reduce quantification performance
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the most (i.e. chemical shift, amplitude, linewidth, or phase). This would be an easy
study to perform that can be run similarly with Monte Carlo simulations, all performed
with a batch script on a computer. A study like this would help to further our
understanding of which parameters affect quantification precision and accuracy the most.
Practical knowledge suggests, for example, that small errors in initial chemical shift have
greater impact than smaller errors in initial amplitude or phase. However, the sensitivity
of parameter seeding has not been formally studied (beyond what one can deduct from
analytical formulations of CRLB and Fisher information matrices).

6.2.2

Single-voxel 1H-MRS in SZ and MDD

The 1H-MRS study of the ACC and the thalamus in people with SZ and MDD produced
some interesting results that should certainly be explored further. Ideally, a similar study
would be conducted to confirm the findings, specifically for the reduced GLY in the
thalamus as the standard CRLB limit for this study was increased for GLY measurements
from 20% to 30%. It would be a more conclusive result if the CRLB limit for GLY could
be reduced to the more commonly accepted 20% limit. One way this could be done is by
increasing the SNR via longer scans with more averages (i.e. from 64 averages to 256
averages). Increased SNR can also be accomplished by increasing the size of the voxel,
but this has its own drawbacks in that the voxel would be include brain areas beyond the
thalamus.
The spin-echo full-intensity acquired localized spectroscopy (SPECIAL) sequence34 is a
relatively new 1H-MRS pulse sequence that is capable of getting the short TE that is
possible with STEAM, while still getting the SNR that is possible with PRESS, and has
been previously utilized at 7 T19,20. Implementation and optimization of a new pulse
sequence is a significant endeavor. However, using a SPECIAL sequence with 256
averages in the same region in the thalamus would, theoretically, improve the spectral
SNR by a factor of 4 compared to the STEAM sequence with 64 averages that was used
in this study. Given that the SPECIAL sequence would not compromise the metabolite
spectral lineshapes, a significant improvement in the precision of metabolite
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concentration estimates would be expected. A SPECIAL pulse sequence should be
implemented and optimized for future 1H-MRS studies.
One group used an echo time-averaged (TEAV) sequence35 that utilizes the f1=0
component of a PRESS-2D J-resolved acquisition36,37 to reliably detect GLY
concentrations in vivo using 1H-MRS at 3 T before and after ingestion of GLY
supplementation in healthy controls38. They were able to quantify GLY as a ratio to
creatine measurements with CRLB of 20 ± 2.9% and 17 ± 5.1% for their before and after
scans, respectively, although one subject’s CRLB exceeded 40% and was removed. It is
likely that the achieved CRLB would have been improved to below the standard CRLB
limit of 20% using a 7 T scanner.
Using the improved quantification precision that would be attainable with these
techniques, a study that examines the concentrations of GLY before and after oral
administration in a SZ group compared to healthy controls and a placebo group would be
valuable. This would be especially useful if the target SZ group was first-episode and
drug naïve at the start of the GLY administration and then were followed longitudinally
over time. If a detectable increase in GLY concentrations after oral administration is
found in the thalamus of people with SZ, then a correlation between SANS and SAPS
scores, or any changes in them, would be especially interesting.
The same can be said for the MDD group and the observed reduced MYO concentrations.
A study that tracks MYO levels before and after its ingestion over a period of time and
similarly tracked the levels of depression would be valuable. Using the SPECIAL pulse
sequence would not really be necessary to measure MYO concentrations as it is not
usually a difficult metabolite to quantify reliably, but would add to quantification
precision nonetheless.
Unfortunately, 1H-MRS voxels tend to be larger than what is ideal to study a brain area of
interest due to the inherent SNR limitation in 1H-MRS. At higher B0, the voxels can
afford to be smaller so that the results will have increased specificity for a particular brain
area. Although the technology may not be there yet, it would, one day, be interesting to
study the individual thalamic nuclei that compose the thalamus using high B0 and small
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voxels. In a typical MRI image (T1 or T2 weighted), thalamic nuclei are not readily
resolvable. However, using a segmentation algorithm called Thalamus Optimzed MultiAtlas Segmentation (THOMAS)39, it may be possible to localize a specific thalamic
nucleus to place a small 1H-MRS voxel. There are a couple of limitations to this
approach. First, it would likely require longer acquisition times to account for the reduced
SNR in a small voxel. Second, the probability of significant subject motion displacing the
voxel from the nucleus of interest is greatly increased both due to the size of the voxel
and, as a consequence of the smaller voxel, the increased acquisition times. Still, a study
like this could one day aid in the understanding of glutamatergic abnormalities in SZ.
Clozapine is the only accepted pharmaceutical to treat the negative symptoms of SZ, and
it is believed to influence GLY in some way40–42. A 1H-MRS study comparing the GLY
concentrations of people with SZ taking clozapine to people with SZ not taking clozapine
and healthy controls would be of interest. A similar study has been performed examining
the serum concentrations of people with SZ taking clozapine compared to those not
taking it and found lower GLY levels in the people taking clozapine40. Another study
examined plasma levels of people with treatment-resistant SZ before and after taking
clozapine and found an increase in GLY levels after clozapine treatment42. The benefit of
1

H-MRS compared to plasma and serum studies is the localization of the voxels to

specific brain regions, while plasma and serum studies are not specific to any brain
region.

6.2.3

1

H-fMRS

This 1H-fMRS study of the SZ and MDD groups is likely the first study of many that will
utilize 1H-fMRS with a behavioural task to study a neurological condition. As this was
the first study of its kind, it certainly raises follow-up questions for future work. Some
suggestions for future studies and ways in which the current studies could be improved
are mentioned below.
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The GLU concentration reduction in the second run of the task needs to be further
understood. This is not the first study to demonstrate a reduction in a neurotransmitter
following a 1H-fMRS behavioural task. Michels et al43 similarly found an initial increase
in GABA concentrations followed by multiple reductions in each subsequent run of a
working memory task. A 1H-fMRS study with a Stroop paradigm should examine
metabolite concentrations in multiple groups of healthy controls, each with a different
recovery time between blocks of activation, to characterize the reduced GLU response.
An additional third block of Stroop stimuli could be added as well to see if GLU
concentrations would continue the same pattern of successive reductions in concentration
with each block of activation.
It may be useful to know when GLU levels start to decrease after the start of the Stroop
stimuli block. If it is during the Stroop stimuli block, this would reduce the average GLU
level observed. The rate and timing of GLU increases and decreases can similarly provide
valuable information towards to the health of GLU dynamics in SZ. In addition, if the
reduction in GLU concentrations is due to insufficient recovery times between blocks,
then it may be feasible to perform fMRI guidance of the fMRS voxel with a sufficiently
long recovery time between the sequences. It is possible that some people activate the
ACC in a slightly different location than others when performing the Stroop. fMRI
guidance would address this limitation of the results.
As mentioned for the static metabolite measurements from the ACC and thalamus, the
1

H-fMRS study would benefit from the additional SNR from the SPECIAL sequence.

The improved SNR may lead to improved temporal resolution to track the GLU
concentrations while the subjects are performing the tasks.
Of course, more cognitive tasks should also be explored using 1H-fMRS in the ACC and
in other regions as well. It would be of interest to utilize a cognitive task that can vary in
level of difficulty, such as the Sternberg Memory Task44, and see if GLU concentration
changes correlate with the level of difficulty. The Stroop Task and/or the Sternberg
Memory Task should be tested using an event-related 1H-MRS design to assess any
immediate GLU changes that occur when the area is stimulated. In addition, future
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studies should aim to correlate the BOLD fMRI response to the behavioural response
times and to the GLU changes. This would require identical BOLD fMRI and GLU
fMRS paradigms.
It would also be of great interest to perform the 1H-fMRS study after administration of an
NMDA antagonist, such as ketamine. This would help to further clarify whether these
results are indicative of NMDA hypofunction in SZ.

6.3 Closing remarks
Each of the chapters in this thesis contributes to the overall agenda to study the health of
GLU neurotransmission in SZ. Using the state-of-the-art 7 T MRI, it was possible to
acquire high quality 1H-MRS data and then to evolve the existing 1H-MRS methodology
into a technique that reliably measures dynamic concentrations of metabolites, 1H-fMRS.
The in vivo work presented in this thesis include the first study to measure GLY
concentrations in the ACC and thalamus using 1H-MRS, the first study to measure GLU
changes using a Stroop cognitive 1H-fMRS paradigm, and, finally, the first study to
measure GLU changes dynamically in a psychiatric population.
A consistent theme throughout this thesis is NMDA hypofunction in SZ, and the results
certainly provide strong support for such a theory. However, simply knowing that there
is NMDA hypofunction in SZ will not be enough. The studies in this thesis have laid the
ground work for monitoring of GLU dynamics during rest and activation. This tool can
be used to examine disease-related abnormalities in GLU dynamics and the effect of
GLU-modulating treatments. There is still much work that needs to be done. With each
new study, a new building block is laid and our understanding of GLU abnormalities in
SZ progresses towards one day having effective treatments for the full range of
symptoms of SZ.
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